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Abstract 
 
The work presented in this thesis describes the development of methods for the analysis of 
cannabinoids in post-mortem blood samples and hair specimens from cannabis users. It investigates 
the value of measuring post-mortem blood cannabinoid concentrations and potential value of 
analysis for cannabinoids in hair for post-mortem toxicology. 
The development and validation of a method for analysis of cannabinioids in post-mortem blood is 
described. The method involved liquid-liquid extraction (LLE) of the cannabinoids 9-
tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN) and metabolites 11-hydroxy-

9
-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-tetrahydrocannabinol-9-carboxylic acid 
(THC-COOH) from post-mortem blood followed by analysis by two dimensional gas 
chromatography-mass spectrometry (2D GC-MS). The developed method was applied to post-
mortem blood samples submitted by Her Majesty’s (HM) Coroners from fatal road traffic collisions 
(RTCs) and other routine case types (control group).  
The prevalence of cannabinoids in the RTC and control group was similar (21% of the RTC group 
and 26% of the control group were positive for at least one cannabinoid), however, 90% of the 
cannabinoid positive RTCs had detectable THC (the psychoactive component of cannabis), 
compared to 60% of the cannabinoid positive control cases. It was demonstrated that it is feasible to 
indicate possible impairment due to cannabis use in fatal RTCs when the concentration of THC 
detected is higher than those usually observed in other routine HM Coroners’ cases. 
A method was developed for analysis of THC, CBD, CBN and THC-COOH from hair. The method 
involved LLE combined with solid phase extraction (SPE) from hair followed by analysis by 2D 
GC-MS and standard GC-MS.  
The developed method was applied to 31 authentic hair specimens from regular cannabis users. The 
method was suitable for detecting exposure (by detection of THC, CBD and CBN) in weekly users 
but may only prove ingestion in daily users (by detection of THC-COOH). 
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CHAPTER 1: INTRODUCTION 
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1.1 Forensic Toxicology 
The field of forensic toxicology encompasses analysis of biological specimens for alcohol, drugs, 
poisons and any substances that are related to a medico-legal investigation. This includes the 
analysis of biological specimens for drugs, poisons or substances that contribute to the sudden, 
unnatural or violent death of an individual and/or in relation to committing an offence – for example 
driving under the influence of alcohol (1).  
Analysis of this kind is dependent on sound analytical techniques and robust evidence to support the 
interpretation of the results produced by these analyses. 
With the rapid advancement of technology in the past 50 years, the analysis of biological specimens 
for drugs has become easier, faster, more sensitive, more selective and more accurate. However, 
while research into the interpretation of the results of these analyses has also made significant 
contributions to forensic toxicology, the answers to many important questions in the field are still 
unclear. 
The analysis and subsequent interpretation of the data generated for a number of substances relevant 
to forensic toxicology is very well understood and characterised. For example, the analysis and 
interpretation of ethanol concentrations in blood are well defined and their utility has been 
demonstrated across the world, particularly for instances of driving under the influence of alcohol 
(2). However, there are some specific substances that present great difficulties to toxicologists, 
these include the cannabinoids. This is due to the chemical nature of these compounds, the way in 
which the human body processes them following ingestion, and the way in which the compounds 
behave during experimental analysis. 
This aim of the work presented in this thesis was to address specific methodological problems 
associated with the analysis of cannabinoids in biological specimens and some of the interpretative 
challenges associated with data regarding cannabinoids in biological specimens. 
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1.2 Post-mortem toxicology for HM Coroners 
A major area of forensic toxicology is the work that is conducted on behalf of Her Majesty’s (HM) 
Coroners in England and Wales. The purpose of HM Coroners is to investigate deaths that may be 
sudden, unexplained or unnatural. It is their role to establish who has died, and where, when and 
how they have died.  
HM Coroners are assisted by pathologists who conduct post-mortems on the deceased to determine 
the cause of death. During the post-mortem, biological samples maybe taken for toxicological 
analysis if it is thought they may assist in determining the cause of death of an individual. 
Biological samples taken commonly include blood, urine, stomach contents, vitreous humor and 
hair. Less frequently bile, liver, muscle and nails may also be collected.  
The types of cases likely to involve toxicology include deaths where there is a direct link with 
alcohol or drugs. These include suicides where intentional drug overdoses have been taken and the 
deaths of drug addicts where unintentional drug overdoses have been taken (e.g. heroin). Other case 
types include suicides, where the mode of death is not directly related to alcohol or drugs (e.g. 
hanging or drowning) but the deceased may have ingested substances prior to taking their life. 
Deaths that may be indirectly caused by drugs and alcohol will also be submitted for analysis. 
These include accidental deaths like falls and road traffic collisions. HM Coroners may also require 
toxicological analysis to determine chronic drug history in some deaths, which can include 
investigating compliance with antipsychotic, antidepressant or anticonvulsant medication and 
whether a person had a history of illicit drug use. 
 
1.3 Interpretation of post-mortem toxicology 
The most challenging aspect of post-mortem toxicology is the interpretation of the results from 
analysis of post-mortem specimens. The newest analytical methods may provide the most sensitive 
and accurate measurement of drugs, but this data is not meaningful unless the results can be 
interpreted. 
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Interpretation of post-mortem toxicology results is not as straightforward as interpretation of 
clinical toxicology results. There are more factors to take into consideration when looking at post-
mortem results, mostly due to the changes that occur in the body following death.  
 
1.3.1 Post-mortem Changes 
Within minutes of death occurring, autolysis, i.e. - breakdown of cells and tissues begins to take 
place. The consequent breakdown of cell membranes allows small molecules to diffuse into the 
blood vessels from tissues. This causes the movement of drugs from sites of higher concentration, 
e.g. organs and tissues into blood vessels (3). This means that the concentration of drugs in the 
blood at post-mortem will not necessarily reflect the concentration of the drugs in the blood at the 
time of death. This phenomenon is known as post-mortem redistribution (PMR) and is dependent 
on the time between death and the post-mortem. The longer this time is, the greater the increase in 
blood concentration. PMR is related to the volume of distribution (Vd) of a drug which provides an 
indication of whether a drug will be retained within the blood (Vd < 1.0 L/kg) or distributed into 
tissues (Vd > 1.0L/kg). Drugs with high volumes of distribution are therefore more likely to have 
falsely elevated blood concentrations at the time of sampling compared to the time of death.  
Unabsorbed drugs within the stomach contents may also diffuse into the blood vessels, again 
leading to falsely elevated blood concentrations. For this reason, blood should be sampled from a 
peripheral site (normally the femoral vein) away from organs such as the heart where there may be 
higher concentrations of drugs (4).  
 
1.3.2 Other factors that affect interpretation 
Post-mortem blood can vary considerably in its composition. It is generally haemolysed (unlike 
ante-mortem (AM) blood, serum cannot usually not be obtained), can be clotted and putrefactive 
changes can have occurred (5). Some drugs are unstable in post-mortem blood and may be broken 
down, leading to lower concentrations than at the time of death. Such effects can be minimised by 
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storing blood specimens in appropriate preservatives (e.g sodium fluoride, potassium oxalate tubes), 
and by refrigerating or freezing samples.  
Individuals can react differently to drugs (inter-individual variation) whereby one person may 
require a higher or lower dose of a drug in order to achieve the same therapeutic response as another 
person. Individuals can develop tolerance to some drugs (e.g. opioid analgesics). This is when a 
person is taking a drug chronically and can tolerate higher doses and blood concentrations. Such a 
person repeatedly requires higher doses to achieve the same analgesic effect. If natural disease is 
present this can also affect the way in which an individual responds to and metabolises drugs, e.g. if 
the deceased had liver or kidney disease. The case history should also be taken into consideration. 
For example, what initially may appear to be an overdose of medication from the toxicology 
findings may in fact be due to an accumulation of drug within the body due to a person’s inability to 
metabolise or clear the drug effectively because of liver or kidney failure. These facts are not often 
available at the initial stages of analysis, and may only come to light at the inquest.  
 
1.3.3 The use of published therapeutic, toxic and fatal ranges of drugs 
Published tables of therapeutic, toxic and fatal ranges for drugs are available and can provide some 
guidance, but need to be used with caution when used to interpret post-mortem blood 
concentrations.  
Firstly, most published clinical ranges refer to plasma/serum concentrations rather than to whole 
blood concentrations. It is therefore important to take into consideration the blood: plasma ratio of a 
drug because many drugs are not evenly distributed between plasma and red blood cells. Reference 
ranges do not take into consideration PMR effects, and for many drugs the interpretation of a blood 
concentration will depend on whether the person has been taking the drug chronically or if the 
person has taken a one off acute dose. In these cases, measurement of metabolite concentrations can 
be very important. 
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For post-mortem blood concentrations, a more appropriate and useful method of interpretation is for 
a laboratory to build up its own database of measured post-mortem drug concentrations which are 
linked to case histories.  
 
1.3.4 Analysis of hair 
The most effective way to establish a person’s long-term drug history is to analyse hair. Drugs 
circulating around the body in the blood become incorporated into hair at the growing point. The 
drugs diffuse from the blood circulating the base of the hair root and become fixed into the new hair 
growth. Drugs can also diffuse into the hair from sweat or sebum surrounding the hair and drugs 
coating the external surface of the hair can also be incorporated into the hair matrix. Once the drug 
is incorporated into the hair it is fixed, and stays in the hair as it grows (6). This produces a “tape-
recording” of drug use over time and can reveal a person’s long-term drug history. Recent advances 
in technology have allowed analysis of hair to be included as a routine procedure. Hair analysis is 
used across the world for a variety of applications, including workplace drug testing, child custody 
cases and reinstatement of driving licences to prove abstinence from drug(s). In addition, hair 
analysis has become useful in forensic toxicology for the use of spiked drink cases and proof of 
previous drug use. It is being used increasingly in HM Coroners’ toxicology where it can be useful 
in aiding the pathologist in determining the cause of death and the Coroner in reaching a verdict in 
as it contributes information regarding a person’s chronic drug history (7).  
 
1.3.5 Pharmacology of drugs 
The effect drugs have on the body (pharmacokinetics) and the way in which the body processes 
drugs (pharmacodynamics) forms the basis for any toxicological interpretation. The four basic 
principles of pharmacology are absorption, distribution, metabolism and excretion (ADME).  
Absorption can occur through different sites in the body depending on the route of administration. 
These include oral administration, whereby drugs will be absorbed mostly through the small 
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intestine (and less commonly from other parts of the gastrointestinal tract). Drugs that are inhaled or 
smoked are absorbed into the bloodstream through the lungs. The route of administration of a drug 
can change the effect it has on the body by altering the effectiveness of the absorption and the way 
in which the drug is metabolised.  
When drugs are administered orally they can undergo “first-pass metabolism” which is when drugs 
are transported to the liver by the hepatic portal vein after absorption from the gastrointestinal tract. 
The drugs are then metabolised prior to being absorbed into the systemic circulation. This results in 
lower bioavailability of some drugs and produces different systemic effects and metabolic profile 
compared to when a drug is taken by a route of administration other than via the gastrointestinal 
tract. 
Following absorption, drugs will be distributed into body fat and tissues to varying degrees 
dependent on several factors, including the lipophilicity of the drugs, how much the drug will bind 
to proteins, and the size of the drug. Drugs which are more likely to be distributed widely into body 
fat or tissues will have a higher volume of distribution.  
The main purpose of metabolism is to prepare the drugs for excretion from the body, usually by 
making the drug more polar. In some cases, metabolism will result in some additional 
pharmacological activity, or will be responsible for producing all the pharmacological activity 
following ingestion of a pro-drug. Metabolism occurs mainly in the liver but can also occur at other 
sites including the kidneys.  
Elimination is the process by which drugs are removed from the body. This occurs mainly by 
excretion through the kidneys, but some drugs may be eliminated in the bile, or via the lungs (e.g 
volatile substances). The rate at which drugs are excreted from the kidneys will vary dependent on 
the drugs properties, e.g. whether it is acidic (low pH) or basic (high pH), and on the pH of the 
urine.  
All aspects of the pharmacology of drugs should be taken into consideration when interpreting 
toxicological data (8). 
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1.4 Cannabis 
For over 5000 years cannabis has been used for its euphoric effects and medicinal purposes. Its 
euphoric effects promote a sense of wellbeing and relaxation. It is known to have several medicinal 
purposes which include alleviating pain and reducing spasticity in multiple sclerosis sufferers. In 
the 19th century it was brought to North America by immigrants and was made illegal in the 1930’s. 
Since the 1960’s its use has dramatically increased to the extent that it is now the most widely used 
illicit drug in the world. Herbal cannabis (referred to as marijuana) and resin (referred to as hashish) 
is obtained from the hemp plant, Cannabis Sativa. Marijuana can be found in the flowering tops and 
leaves of the plant and hashish is made from the resinous parts of the plant and compressed into 
blocks (9;10). 
 
1.4.1 Components of cannabis 
The individual compounds that are present in the cannabis plant are collectively known as 
cannabinoids and represent C21 terpenophenolic compounds. Over 60 cannabinoids have been 
identified to date. The major cannabinoids (most abundant) include the primary psychoactive 
compound 9-tetrahydrocannabinol (THC), cannabinol (CBN), which is a degradative product of 
the cannabis plant, and cannabidiol (CBD) (11). The main pharmacological activity of these 
compounds and other less abundant cannabinoids are shown in table 1.01. 
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Table 1.01 Pharmacological actions of the main cannabinoids found in the cannabis plant  (11) 
 
 
 
The cannabis plant can be cultivated to provide different strains, and each strain will contain 
different amounts of each cannabinoid. Some compounds will be absent from some strains (12).   
 
1.4.2 Modes of ingestion of cannabis 
Cannabis can be used in the form of the herbal plant material, dried resin, oil and as a powder. Most 
commonly, the herbal plant material and resin are smoked in combination with tobacco (as joints) 
or are vaporised with water in pipes or bongs. Cannabis can also be consumed orally (e.g. in 
cookies or tea) after being sufficiently heated to breakdown the tetrahydrocannabinolic acid to the 
psychoactive THC (12). 
 
 
 
 
 
 
 
Cannabinoid
Delta-9-tetrahydrocannabinol
Cannabidiol 
Cannabinol 
Delta-8-tetrahydrocannabinol 
Cannabigerolic acid
Cannabigerol
Cannabichromene
Cannabidioloic acid
Delta-9-tetrahydrocannabivarin
Analgesic, anti-inflammatory, antibiotic, antifungal
Analgesic, anti-inflammatory, antibiotic, antifungal
Antibiotic
Some psychoactive effects, analgesic
Main pharmacological actions
Primary psychoactive effects
Anxiolytic, anti-psychotic, analgesic, anti-inflammatory,     
anti-oxidant, anti-spasmodic
Anti-inflammatory, sedative, antibiotic, anticonvulsant
Some psychoactive effects
Antibiotic
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1.4.3 Pharmacology of cannabis 
Smoking cannabis provides the quickest absorption into the systemic circulation via the lungs. 
When cannabis is smoked, the bioavailability of THC can be up to 50%. After the onset of smoking, 
the concentration of THC peaks in the plasma within the first 10 minutes. After oral ingestion, the 
bioavailability is only about 6%. This is due to degradation by gastric contents and first pass 
metabolism of THC. Peak plasma concentrations are not reached until 1 to 2 hours later (13).  
THC is highly lipophillic and therefore has a high affinity to bind to adipose tissue. Following 
absorption it is rapidly distributed to adipose tissue, the liver, lungs and spleen, accompanied by a 
consequent rapid decrease in plasma concentrations. A further gradual decrease in plasma 
concentrations is seen with a secondary distribution phase whereby THC accumulates in poorly 
perfused tissues. It is then slowly released back into the blood and metabolised. The immediate 
distribution half life of THC is short (less than 1 hour). However, the slow elimination leads to a 
longer terminal half life of 1 to 4 days. THC undergoes hepatic enzymatic biotransformation to 
yield multiple metabolites, with over 20 identified to date (12). The two major metabolites are 
formed by hydroxylation to 11-hydroxy-9-tetrahydrocannabinol (11-OH-THC) followed by further 
oxidation to 11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH). 11-OH-THC has 
some psychoactive activity whilst THC-COOH is inactive. THC is excreted in the faeces and urine. 
Excretion in the faeces is mainly as the hydroxylated metabolite 11-OH-THC and in the urine as the 
glucuronide acid conjugate of THC-COOH (13). 
Within minutes of the start of smoking cannabis, metabolism to the active (11-OH-THC) and 
inactive (THC-COOH) metabolites begins. As the concentration of THC falls, small amounts of 
11–OH-THC are produced, resulting in concentrations less than 10% of the THC concentrations 
(14). Significantly higher 11-OH-THC concentrations are produced (can be equivalent to THC 
concentrations) following oral ingestion. This is due to the first pass metabolism that takes place in 
the liver prior to THC being absorbed into the systemic circulation. Further oxidation leads to the 
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concentration of THC-COOH increasing, with this compound thus persisting in the body for much 
longer than THC or 11-OH-THC (15).  
 
1.4.4 The effects of cannabis 
The psychoactive and physiological effects of cannabis result from THC acting at the two 
cannabinoid receptors: CB1R and CB2R. The CB1R is mainly expressed in the brain and is 
responsible for the “high” experienced by cannabis users (15) and for the ability of cannabis use to 
cause memory impairment, cognitive and motor disturbances. Within the brain, these receptors are 
most abundant in the cerebral cortex, hippocampus, cerebellum, substantia nigra and the 
mesolimbic dopamine pathways responsible for mediating reward (9;16).  
The binding of THC to CB1R in the cortex is responsible for the cognitive impairment associated 
with cannabis use: impaired perception and attention and behavioural effects. The binding of THC 
to CB1R in the basal ganglia and cerebellum give rise to the effects on movement and on the 
regulation of muscular contractions. Ingestion of cannabis causes a reduction in driving skills, 
including reducing reaction times, road-tracking performance, performance in divided attention 
tasks, and hand-eye co-ordination. Users will often slow their speed and take fewer risks. This may 
be due to the driver over-compensating because of their perceived impairment (12). 
THC also binds to peripheral CB1R sites resulting in increased heart rate, blood pressure and body 
temperature following acute ingestion.  
The CB2R is located in the peripheral nervous system, mainly in the lymphoid system. This is 
thought to account for inhibitory effects of cannabis on immune function. Both CB1 and CB2 
receptors are also involved in mediating pain (9;16).  
Regular use of cannabis can lead to long-term impairment of memory and learning ability (17). 
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1.4.5 Concentrations of cannabinoids in blood 
To investigate the complex pharmacokinetics and time course of plasma concentrations of THC and 
metabolites, studies have been conducted that have measured the concentrations of cannabinoids 
and metabolites in ante-mortem whole blood or plasma following controlled administration of a 
known amount of THC via cigarettes, capsules or intravenous infusion (14;18-24).  
After the start of smoking, the plasma concentrations of THC rapidly increase and peak within the 
first 10 minutes of smoking. A sharp decline follows as the THC is distributed into tissues and body 
fat.  A long terminal elimination phase then occurs as THC is released back into the blood from 
tissues and body fat. 
There are several factors which affect the concentrations of cannabinoids detected in the plasma, 
including the route of administration (i.e. smoking vs. oral), the strength of the cannabis ingested 
and an individual’s method of smoking (e.g. number of puffs, time between puffs and length of 
inhalation) (18).  
Variations in plasma concentrations will also be seen between frequent and infrequent users of 
cannabis.  
One study of note measured THC, 11-OH-THC and THC-COOH concentrations in subjects 
following smoking of a single marijuana cigarette containing a known amount of THC (either a 
placebo cigarette or a cigarette containing 1.75% or 3.75% THC). Blood samples were taken prior 
to smoking and at 1 minute intervals from the start of smoking. Samples continued to be taken at 
gradually increasing time intervals over a period of 7 days. This allowed the change in plasma 
concentrations of THC, 11-OH-THC and THC-COOH to be recorded over time. Peak plasma 
concentrations of THC were recorded between 50 – 267 ng/mL within 10.2 minutes of the start of 
smoking and fell below 5 ng/mL within 3 hours and below 1 ng/mL within 6 hours. Peak plasma 
concentrations of 11-OH-THC were noted up to 22.8 minutes after the start of smoking and ranged 
from 3.3 to 16 ng/mL. There was gradual decline in levels of this metabolite and in most cases it 
was undetectable before THC became undetectable. Concentrations of THC-COOH, the inactive 
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metabolite, did not peak until later, between 32 and 240 minutes after the start of smoking (25), and 
ranged from 15 to 101 ng/mL. However, detection times for THC-COOH were much longer, 
extending up to 168 hours after the start of smoking (14).  
These data are widely reflective of the pharmacological profile in both infrequent and frequent users 
of cannabis. However, concentrations in frequent users will persist above 1 ng/mL for longer (up to 
24 hours) due to the slower elimination of stored THC in the body tissues. THC-COOH can be 
detected in plasma for up to 7 days following smoking of a single cannabis cigarette by an 
infrequent user (13). However, concentrations of THC-COOH are much higher and have been 
reported to remain at levels over 20 ng/mL in plasma for up to 72 hours following cannabis use in 
frequent users (25). 
Mathematical models were devised from the data generated by Huestis et al.(14) to estimate the 
time of last use of cannabis based on the THC and THC-COOH plasma concentrations. Two models 
were devised, Model I was based solely on the THC concentration, whereas Model II was based on 
the ratio of THC: THC-COOH concentration. Overall, both models accurately predicted time since 
last use. Model I tended to underestimate the time since last ingestion. Model II proved more 
accurate for oral users of cannabis and tended to overestimate (rather than underestimate) the time 
of use for frequent users. Overestimation is preferable for forensic cases as it gives the benefit of the 
doubt to the user (26).  
From a forensic point of view, the difficulty with cannabis ingestion is that if a person is a chronic 
user of cannabis, detectable concentrations of residual THC and metabolites will be detected for 
hours and even days after last use. This makes it very difficult to assess whether a person was 
impaired by cannabis use at the time of an incident in question (e.g. drivers apprehended for 
suspected driving under the influence of drugs) or indeed at their time of death.  
A particularly useful study measured the levels of cannabinoids in 25 chronic users daily during one 
week of monitored abstinence. Throughout the 7 days of abstinence 175 blood specimens were 
analysed (7 for each subject). No THC was detected in 100 out of the 175 samples, THC was 
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detectable at concentrations < 1 ng/mL in 55 specimens and at concentrations  1 ng/mL in 20 
specimens. These 20 specimens all came from the same three subjects.  
For 7 days of monitored abstinence, nine of the twenty five subjects had no measureable THC on 
any day. This study found that five subjects had detectable THC on each of the 7 days, with one 
other subject with detectable THC on six of the seven days. All six subjects had detectable THC on 
the final day.  
Few samples were positive for 11-OH-THC, with average values less than or equal to 0.5 ng/mL at 
all times. The highest concentration measured was 6.3 ng/mL, and was recorded on day 1. 
THC-COOH concentrations were detected in all subjects above the limit of detection (0.25 ng/mL) 
throughout the study period and ranged from 2.8 to 91.7 ng/mL on day 1 and from 0.4 to 36.5 
ng/mL on day 7. 
This study shows that extreme care must be taken when judging a chronic cannabis user for 
impairment as, even if they have significant detectable levels of THC in their blood, it may have 
been some time since they last used cannabis (15). 
 
1.4.6 Concentrations of cannabinoids in post-mortem blood 
Due to the difficulty in determining what concentrations of cannabinoids in blood actually mean in 
terms of chronic use and acute impairment, and the relatively low toxicity of cannabis in 
comparison to other drugs of abuse, little importance is often placed on measuring blood 
cannabinoid concentrations in post-mortem cases. As a result there is very little literature on the 
range of concentrations of cannabinoids measured in post-mortem cases. Five studies have reported 
post-mortem blood concentrations of cannabinoids since 2010 (27-31) . Prior to this, only two 
studies from 1983 and 2001 had reported post-mortem blood concentrations (32;33). The range of 
concentrations detected in each of these studies is shown in table 1.02.  
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Table 1.02 Post-mortem blood* concentrations of 9- tetrahydrocannabinol (THC), 11-hydroxy-9-tetrahydrocannabinol (11-OH-THC) and 11-nor-

9
-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) (ng/mL) reported in the literature  
 
  
Author(s) 
 
 
  
Canfield et al. 
2010 (27) 
Lemos & Ingle 
2011 (28) 
Holland et al. 
2011 (29) 
Gronewold & 
Skopp 2011 (30) 
Simoes et al. 
2011 (31) 
Foltz et al. 
1983 (32) 
Giroud et al. 
2001 (33)  
 
  
 
 
THC 
 
        
  
LOD1 1 Not stated 0.25 Not stated 0.2 Not stated 0.5-1.0 
 
 
 
LOQ2 1 1 0.5 0.58 0.5 0.2 0.8-2.0 
 
 
 
Mean 5.5 16.1 7.6 3 3.9 1.7 4.9 
 
 
 
Median 1.5 11.5 3.2 2.5 2.8 0.7 4.7 
 
 
 
Range 1.0-68.0 1.0-97.0 1-47.1 0.7-5.8 0.6-12 0.4-4 2.2-8.2 
 
 
 
No. samples 
positive 88/2769 30/30 10/19 3/5 14/15 3/3 6/6  
 
11-OH-THC 
 
       
 
  
LOD 
 
Not stated 0.25 Not stated 0.5 Not stated 0.5-1.0 
 
 
 
LOQ Not Analysed 5 0.5 0.47 0.5 0.5 0.8-2.0 
 
 
 
Mean 
 
11.3 2.3 1.7 1.7 n/a 1.6 
 
 
 
Median 
 
9.5 1.4 1.7 1.4 n/a 1.2 
 
 
 
Range 
 
5.0-21 0.5-11.1 1.7 0.6-6.7 n/a 0.9-3.2 
 
 
 
No. samples 
positive  6/30 10/19 2/5 11/15 0/2 4/6  
 
THC-COOH 
 
       
 
  
LOD 1 Not stated 0.25 Not stated 0.5 Not stated 0.5-1.0 
 
 
 
LOQ 1 5 0.5 5.06 0.5 0.1 0.8-2.0 
 
 
 
Mean 17.5 61.2 17.3 84.2 15.1 26 18.2 
 
 
 
Median 8.5 32 8.4 18 9 26 9.9 
 
 
 
Range 1.0-179.0 8-330 0.5-107.6 13.7-221.0 3.0-77.0 12-40 3.3-60.9 
 
 
 
No. samples 
positive 88/2769 30/30 19/19 3/5 15/15 2/2 6/6  
 
         
 
 
*If the study does not state the site of blood sampling, assumed femoral vein, measurements from other sites excluded, 1LOD - Limit of  detection, 2LOQ – Limit of quantitation 
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Out of the seven studies, only one measured CBD and CBN, and in this study the limit of 
quantitation (lowest concentration that could be accurately and precisely measured) for these 
compounds was high (4.4 and 6.7 ng/ml), and the data therefore of limited usefulness. Two studies 
did not analyse for the active metabolite 11-OH-THC. One of the studies by Lemos et al. (28), 
provided detailed information regarding a review of 30 routine post-mortem cases that were 
cannabinoid positive and attempted to establish a link between peripheral blood: cardiac blood 
ratios in order to determine any relationship between post-mortem interval and these ratios. 
Although the study examined THC, THC-COOH and 11-OH-THC concentrations, the cases were 
initially screened by immunoassay on cardiac blood and urine with cut-off values of 5 ng/mL and 
50 ng/mL respectively. Thus, cases where concentrations were below these values would have been 
missed. Cases that screened positive were subject to confirmatory analysis by GC-MS. For the 
confirmatory analysis, the limit of detection for 11-OH-THC was too high (5 ng/ml). As 11-OH-
THC concentrations are generally lower than this, it is likely that this compound would be present 
but not detected in many of these individuals; only 6 out of 30 cases had detectable 11-OH-THC. 
Another significant recent paper by Holland et al. (29) examined PMR of THC, 11-OH-THC and 
THC-COOH. The researchers expected the THC would show more PMR than the metabolites, but 
found that PMR was similar for all analytes, and was much more modest than expected.  
Interestingly, the three cases which had both ante-mortem and post-mortem blood specimens had 
been analysed demonstrated higher concentrations in the ante-mortem specimens compared to the 
post-mortem specimens. This may have significant implications, as it suggests that the assumption 
that post-mortem concentrations are higher due to PMR is incorrect, and that in fact it may be 
possible to judge impairment based on post-mortem blood concentrations. With further work, the 
models used to estimate time of last use may therefore be applicable in post-mortem cases (29). 
In summary, there is only limited information in the literature on post-mortem blood cannabinoid 
concentrations, and until more data is published, it will remain difficult to understand the extent to 
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which PMR affects blood levels of cannabinoids, and thus to understand the relationship between 
these concentrations and the role of cannabis in deaths. 
 
1.4.7 Concentrations of cannabinoids in hair 
A major factor in understanding and interpreting cannabinoid concentrations in blood is knowing 
whether a person is a frequent or non-frequent user of cannabis. Detectable concentrations can be 
present in the blood for several days or even weeks following chronic use. There may also be 
detrimental effects on the mental abilities for long periods after chronic use (15). 
Analysis of hair provides a timeline of drug use and is therefore useful for establishing a person’s 
chronic drug history. The incorporation of a particular drug into the hair matrix is dependent on its 
physicochemical properties. Although not fully understood, binding to melanin is thought to be a 
major mechanism of incorporation (6). The neutral and lipophilic nature of THC means it is not 
highly bound to melanin. It is known that cationic drugs like amphetamines, cocaine and opiates are 
more readily incorporated into hair than anionic drugs like THC-COOH. THC and THC-COOH are 
known to have a very low incorporation rate (ICR) into hair, with a 3600 fold difference in the ICR 
compared to that of cocaine. This results in the presence of much lower concentrations of THC and 
THC-COOH in the hair compared to other drugs (13).  
As cannabis is smoked, external contamination must be considered when analysing hair for 
cannabinoids. THC, CBD and CBN are present in the smoke produced and as hair is porous, they 
can be incorporated into the hair from the outside. In order to prove cannabis consumption (i.e. that 
a person has ingested cannabis through smoking or orally rather than only being exposed to the 
smoke from cannabis), the metabolite THC-COOH must be detected in the hair. This presents 
analytical difficulties due to the extremely low concentrations of THC-COOH present in the matrix. 
In general, concentrations of THC are in the high picogram to low nanogram per milligram of hair 
range. The cut-off concentration recommended by the Society of Hair Testing (SOHT) for THC is  
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0.1 ng/mg (34). THC-COOH is present in hair in concentrations approximately a 1000 fold lower 
than THC. The SOHT recommend a cut-off concentration of  0.2 pg/mg (34).  
There have been several studies investigating the concentrations of different cannabinoids in hair 
(35-57). The compounds detected in each study vary. Some have focussed on measuring only THC-
COOH, as this proves ingestion (47-51;55;56), whilst others have only analysed for THC, CBD and 
CBN (43-46;54), which can only confirm exposure. Only two studies have determined 
concentrations for all four compounds (35;36) and one determined THC concentrations only (57). 
The range of concentrations detected in these studies is shown in tables 1.03-1.07. 
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Table 1.03 Concentrations* of cannabinoids in head hair where 9-tetrahydrocannabinol (THC), 
11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH), cannadidiol (CBD) and 
cannabinol (CBN) were analysed 
 
Author(s) 
  
  Baptista et al. 2002 (35) Villamor et al. 2004 (36) 
THC   
  
 
Weight hair (mg) 50 50 
 
LOD1 0.02 0.017 
 
LOQ2 0.1 0.057 
 
Mean 0.2 2.93 
 
Range 0.03-0.28 0.04-9.29 
 
No. samples positive 8/87 33/35 
    
    
THC-COOH       
 
Weight hair (mg) 50 50 
 
LOD 5 15 
 
LOQ 10 51 
 
Mean 28 440 
 
Range 10-90 50-800 
 
No. samples positive 18/87 24/35 
    
    
CBD       
 
Weight hair (mg) 50 50 
 
LOD 0.02 0.012 
 
LOQ 0.10 0.04 
 
Mean 0.16 4.19 
 
Range 0.04-0.47 0.01-15.26 
 
No. samples positive 20/87 34/35 
    CBN       
 
Weight hair (mg) 50 50 
 
LOD 0.05 0.024 
 
LOQ 0.1 0.08 
 
Mean 0.3 1.63 
 
Range 0.21-0.38 0.03-0.66 
 
No. samples positive 3/87 35/35 
    * All concentrations are ng/mg except THC-COOH which are pg/mg 
1LOD - Limit of detection, 2LOQ – Limit of quantitation
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Table 1.04 Concentrations* of cannabinoids in head hair where 9-tetrahydrocannabinol (THC) and 11-nor-9-tetrahydrocannabinol-9-carboxylic acid 
(THC-COOH) were analysed 
 
 Author(s) 
  
Minoli et al.  
2012 (37) 
Han et al. 2011 
(38) 
Huestis et al.  2007 
(39) 
Jurado et al. 
1996 A (40), 1995 (41)4 
Jurado et al. 
1996 B (40)4 
THC 
 
    
 
 
Weight hair (mg) 20-50 20 20 50 50 
 
LOD1 Not stated 2.5 Not stated 0.014 0.01 
 
LOQ2 Not stated 7.5 0.001 0.05 0.1 
 
Mean 0.29 22.79 0.0413 0.97 0.63 
 
Range 0.02-2.62 7.52-60.41 0.0034->0.1 0.06-7.63 0.02-2.17 
 
No. samples 
positive 120/120 18/54 20/53 49/70 54/98 
  
    
 
THC-COOH 
 
    
 
 
Weight hair (mg) 20-50 20 20 50 50 
 
LOD 0.01 0.025 Not stated 10 5 
 
LOQ 0.04 0.05 0.01 40 50 
 
Mean 1.41 2.27 0.89 500 100 
 
Range 0.04-49.74 0.10-11.68 0.1-7.3 50-3870 50-390 
 
No. samples 
positive 107/120 36/54 32/53 45/70 33/98 
       
 
* All concentrations are ng/mg except THC-COOH which are pg/mg 
1LOD - Limit of detection, 2LOQ -Limit of quantitation, 3Excluding one result reported > 0.1ng/mg, 4Jurado et al. 1996A and B (40) are two sets of 
data described in one publication, Jurado et al. 1995 contains the same data as 1996A. 
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Table 1.04 Continued Concentrations* of cannabinoids in head hair where 9-tetrahydrocannabinol (THC) and 11-nor-9-tetrahydrocannabinol-9-
carboxylic acid (THC-COOH) were analysed 
  
Author(s) 
  
Cirimele et al. 
 1995 (42) 
Mieczkowski 
 1995 (52) 
Wilkins et al. 
 1995 (53) 
THC 
 
   
 
Weight hair (mg) 100 Not stated 20 
 
LOD1 0.1 0.00002 0.01 
 
LOQ2 0.1 0.00005 0.05 
 
Mean 0.74 0.431 0.177 
 
Range 0.26-2.17 0.003-0.438 0.019-0.552 
 
No. samples positive 15/43 85/93 8/8 
  
   
THC-COOH 
 
   
 
Weight hair (mg) 100 Not stated 20 
 
LOD 100 0.02 10 
 
LOQ 100 0.05 50 
 
Mean 160 0.322 n/a 
 
Range 70-330 0.03-1.53 n/a 
 
No. samples positive 6/43 65/93 0/8 
  
    
 
* All concentrations are ng/mg except THC-COOH which are pg/mg 
1LOD - Limit of detection, 2LOQ -Limit of quantitation,  
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Table 1.05 Concentrations (ng/mg) of cannabinoids in head hair where 9-tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN) 
were analysed 
 
  
Author(s) 
  
Nadulski & 
Pragst 2007 (43) 
Skopp et al.    
2007 (44) 
Kim et al.    
2005 (45) 
Cirimele et al.    
1996 (46) 
Strano-Rossi & Chiarotti 
1999 (54) 
THC 
 
    
 
 
Weight hair (mg) 15-30 50 50 50 50 
 
LOD1 0.012 0.025 0.006 0.1 0.1 
 
LOQ2 0.037 0.025 0.05 0.1 Not stated 
 
Mean 0.49 0.34 0.14 0.15 Not stated 
 
Range 0.12-4.2 0.09-0.72 0.06-0.27 0.1-0.29 0.1-0.7 
 
No. Samples positive 77/250 12/12 4/22 5/30 11/20 
CBD 
 
     
 
Weight hair (mg) 15-30 50 50 50 50 
 
LOD 0.9948 0.025 0.005 0.02 0.2 
 
LOQ 0.04 0.06 0.05 0.02 Not stated 
 
Mean 0.37 0.23 0.04 0.44 Not stated 
 
Range 0.013-12.1 0.06-0.57 0.02-0.05 0.02-0.05 0.7-14.7 
 
No. Samples positive 69/250 8/12 6/22 23/30 20/20 
CBN 
 
     
 
Weight hair (mg) 15-30 50 50 50 50 
 
LOD 0.991 0.025 0.002 0.01 0.1 
 
LOQ 0.048 0.1 0.05 0.1 Not stated 
 
Mean 0.12 0.14 0.36 0.13 Not stated 
 
Range 0.016-0.85 0.05-0.34 0.05-1.38 0.01-1.07 0.4-0.7 
 
No. Samples positive 77/250 10/12 14/22 22/30 20/20 
       1LOD - Limit of detection, 2LOQ - Limit of quantitation
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Table 1.06 Concentrations (pg/mg) of cannabinoids in head hair where 11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) only was 
analysed 
  
Author(s) 
  
Han et al. 2011 
A (48)3 
Han et al. 2011 B 
(48)3 
Mieczkowski 
2003 (49) 
Moore et al. 2001 
(50) 
Kintz et al. 1995 
(51)  
THC-COOH 
 
      
 
Weight hair (mg) 20 20 40 20 100 
 
 
LOD1 0.025 0.025 Not stated 0.5 5 
 
 
LOQ2 0.05 0.05 Not stated 0.5 Not stated 
 
 
Mean 2.96 1.35 0.72 3.26 120 
 
 
Range 0.06-33.44 0.05-7.24 Not stated 0.6-12.9 20-390 
 
 
No. samples positive 153/164 78/248 3678/89775 5/6 17/30 
 
        
        
  
Author(s) 
  
Kim & Kyo 
2007 (55) 
Moore et al. 2006 
(56) 
Han et al. 
2011 C (47)4 
Han et al. 2011 D 
(47)4 
Han et al. 
2011 E (47)4 
THC-COOH 
 
 
    
 
Weight hair (mg) 25 20 20 20 20 
 
LOD 0.02 Not stated 0.025 0.025 0.025 
 
LOQ 0.05 0.05 0.05 0.05 0.05 
 
Mean 0.35 0.92 2.54 2.62 1.84 
 
Range 0.14-0.85 0.09-1.94 0.14-9.01 0.19-13.82 0.1-9.01 
 
No. samples positive 12/Not Stated 13/13 8/18 16/16 22/22 
 
     
 1LOD - Limit of detection, 2LOQ - Limit of quantitation, 3Han et al. 2011 A and B are two sets of data from the same publication, 4Han et al. 2011 C, 
D and E are three sets of data from the same publication.
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Table 1.07 Concentrations (ng/mg) of cannabinoids in head hair where 9-tetrahydrocannabinol 
(THC) only was analysed 
 
  
Author(s) 
  
Kauert & Rohrich 1996 (57) 
THC   
 
 
Weight hair (mg) 50-200 
 
LOD1 0.1 
 
LOQ2 0.1 
 
Mean 1.501 
 
Range 0.009-16.7 
 
No. samples positive 104/850 
 
1LOD - Limit of detection, 2LOQ - Limit of quantitation 
 
1.5 Fatal Road Traffic Collisions (RTCs) 
There were 1901 fatalities on Great Britain’s roads in 2011 (58). The number of fatalities has 
slowly declined since the 1980s despite an increase in vehicle miles of approximately 50% (303.8 
billion vehicle miles in 2011 compared to 200 billion vehicle miles in 1985 (59). It is not known 
how many fatal RTCs in Great Britain involve someone under the influence of drugs (58). The 
Report of the Review of Drink and Drug Driving Law by Sir Peter North commissioned by the 
Government was published in June 2010. It concluded that there was a significant drug driving 
problem in Great Britain that was not reflected by the figures on fatal and serious accidents reported 
by the police in 2008. It recommended that more research be carried out to investigate the 
prevalence of drug driving in Great Britain (60). Following this the United Kingdom (UK) 
government recently announced that they are to introduce new drug driving legislation. It will 
become an automatic offence for people to drive a vehicle if they have certain controlled drugs in 
their body at concentrations over specified limits. A review into driving under the influence of 
drugs by an expert panel commissioned by of the Department of Transport recommended a 
threshold of 5 ng/mL for THC in whole blood or 3 ng/mL when in the presence of alcohol at 
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concentrations greater than 20 mg/100mL (61). These recommendations only apply to living 
persons who are suspected of driving under the influence of drugs. 
  
1.5.1 The Role of Cannabis in Fatal RTCs 
In the UK, cannabis remains the most prevalent drug used across the population. Statistics from the 
British Crime Survey (BCS) state that 6.8% of 16-59 year olds (around 2.2 million people) had used 
cannabis in 2010-11. This figure increases to 17.1% of 16-24 year olds (around 1.1 million people). 
The second and third most prevalent drugs used were cocaine (2.1%) and ecstasy (1.4%) (62). A 
separate report by the NHS, “Smoking, drinking and drug use among young people in England in 
2010”, states that cannabis was the most widely used drug (8.2%) in 11-15 year olds surveyed (63). 
Two surveys investigated the prevalence of illicit drug use in the over 65 years age group and found 
it to be relatively low, with only 0.4% reporting cannabis use in England and 1.1% reporting 
cannabis use in Inner London (64). 
Cannabis is known to impair psychomotor performance, as demonstrated by studies conducted both 
under laboratory conditions with driving simulator assessments and under actual driving conditions 
(65-71). Although cannabis has been reported to be present in post-mortem blood samples from 
road fatalities, assigning fault or risk due to cannabis use has not been so easy. 
 
1.5.2 Current evidence regarding cannabis use in fatal RTCs 
1.5.2.1 Studies conducted on fatal RTCs in the UK 
Cannabis is commonly the most frequent drug (after alcohol) detected in participants in fatal and 
non-fatal road traffic collisions both in the UK and abroad, yet the published data from these studies 
is limited. 
In the UK only four studies have reported on the incidence of cannabis in fatal RTCs, and only one 
reports any concentrations of the different cannabinoids detected.  
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The only study to report cannabinoid concentrations was conducted in Scotland by Seymour et al. 
(72), and examined the incidence of drugs and alcohol in the blood in 151 fatally injured drivers. 
The incidence of illicit drugs was low, with only five cases positive for drugs other than those given 
during emergency medical treatment. Whilst THC concentrations were reported, only two cases 
were positive (the THC concentrations detected were 8 and 33 ng/mL), so little inference can be 
drawn from these isolated cases. 
The largest study was conducted in 1996-97 by Tunbridge et al., and was prepared for the Road 
Safety Division, Department of the Environment, Transport and the Regions (73). This study 
compared data from 1184 fatally injured road traffic casualties to data from a similar study 
conducted by the same group in 1985-87. This study found that cannabis was the most frequently 
detected drug after alcohol and that its frequency in post-mortem samples had increased from 2.6% 
to 11.9% since the previous study. A positive cannabis result was reported if an immunoassay 
screen in urine for cannabis was positive. Only the first 301 samples out of 1184 that were screened 
positive by immunoassay for any drug were confirmed by gas chromatography-mass spectrometry 
(GC-MS) in either blood or urine. There was no data on the concentrations of the different 
cannabinoids in the blood or even on the prevalence in the blood. No contributory role could be 
attributed to the presence of cannabis in body fluids with the reason given that cannabinoids can 
remain in the system for up to four weeks after being taken by regular users. Even if cannabis did 
not remain in the system for this long, the only conclusion that could be made from a positive 
immunoassay screen in urine was “unconfirmed previous use of cannabis”(73). 
A study published more recently by Elliott et al. (74) reported cannabinoids and alcohol as the most 
common substances detected in victims of fatal RTCs. However, this was based on detection of the 
inactive metabolite THC-COOH, and no distinction was made between blood and urine results.  
The most recent publication that included information regarding alcohol and drugs in fatal road 
traffic accidents in the UK by Clarke et al. (75) also concluded that cannabis was the most common 
drug detected (present in 4% of 1185 fatally injured vehicle occupants). No toxicological data 
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regarding the concentrations of cannabinoids, and no data on whether the compounds were analysed 
in blood or urine samples were provided. 
 
1.5.2.2 Studies conducted on fatal RTCs outside of the UK 
A number of studies have been conducted investigating cannabinoids in fatal RTC victims outside 
of the UK (76-85). For the majority of these, only the prevalence of cannabis is reported (76-78;80-
85), with one study reporting THC concentrations (0.3 – 0.5 ng/mL) in three cases (79). The 
cannabinoids that have been screened for are often not described (77;80;81;83;84). Five studies do 
specify the compound detected, with three reporting the prevalence of THC (76;78;79) and two 
studies reporting only the inactive metabolite THC-COOH (82;85).  
The most useful studies conducted include two studies by Drummer et al. (86;87) and Laumon et al. 
(88). Drummer et al. examined the involvement of alcohol and drugs on 3398 fatally injured 
drivers. For the earlier study (86) some information on the concentrations of THC detected in the 
blood samples was provided. THC concentrations ranged from 0.1 to 228 ng/mL. The median value 
was 9 ng/mL.  It was concluded that drivers with THC in their blood were significantly more likely 
to be responsible for the crash, even more so when the concentrations were  5 ng/mL. THC-COOH 
was also screened for, but no information on concentrations of this or other cannabinoids was 
reported. For the subsequent study (87) they categorised the THC data as blood concentrations < 5 
ng/mL or  5 ng/mL.  
Laumon et al. investigated cannabis intoxication and fatal road crashes in France, and also 
concluded that there was an increased risk of responsibility in participants in which cannabis was 
detected. There was also an increased likelihood of being responsible for the crash with increasing 
blood concentrations of THC. This likelihood more than doubled when THC was detected at 
concentrations over 5 ng/mL compared to concentrations less than 1 ng/mL. THC concentrations 
were reported as < 1ng/mL, 1 to 2 ng/mL, 3 to 4 ng/mL and  5 ng/mL. No information on other 
cannabinoid concentrations was given (88). 
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Other relevant studies include that by Terhune et al. (89) which reported cannabis concentrations in 
1882 fatally injured drivers between 1990 and 1991 in the United States (US). Although this was 
one of the few studies to report actual cannabis concentrations, these were only categorised into 
trace, low and high concentration ranges. As cannabis was rarely detected alone (in the absence of 
alcohol or other drugs), only limited conclusions could be drawn regarding responsibility and 
impairment effects of cannabis when detected alone. 
A Norwegian study categorised THC concentrations into ranges according to a proposed legal limit 
(> 1.3 ng/mL), a low impairment level (> 3 ng/mL) and a high impairment level (> 9 ng/mL) in 196 
blood samples from fatally injured drivers. These concentrations were chosen based on evidence 
that equated the level of resulting impairment to the impairment from resulting from blood alcohol 
concentrations of 20, 50 and 120 mg/100mL respectively. Only half of the samples were post-
mortem samples (90). 
A recent article in the British Medical Journal systematically reviewed published observational 
studies to assess if acute cannabis consumption increased the risk of motor vehicle collision. It 
concluded that the risk of a driver being involved in a serious or fatal motor vehicle collision nearly 
doubled following acute cannabis consumption (91). Out of the 2975 studies that were found, only 
nine studies were chosen for review. This was because it is was only those nine studies that tested 
for the presence of the primary psychoactive compound (THC) in blood. All other studies either 
tested for the presence of the inactive metabolite (THC-COOH) or blood and urine results could not 
be separated. Out of these nine studies, only three studies (as described above) (87-89) provided any 
information regarding concentrations of any cannabinoids in blood. None of these studies were 
conducted in the UK. Studies conducted to date do not provide sufficient evidence to establish the 
role that cannabis plays in fatal road traffic collisions in the UK.  
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1.6 Experimental methods for the analysis of cannabinoids 
The analysis of cannabinoids in biological matrices involves extracting the cannabinoids from the 
chosen matrix and eliminating unwanted endogenous compounds. 
 
1.6.1 Extraction of drugs from biological matrices 
Extraction is a necessary process required in order to separate the target drugs or compounds from 
interfering compounds within the matrix. Analysis in the post-mortem setting can be complicated 
by post-mortem changes including matrix interferences from endogenous lipophillic compounds 
and proteins, drug degradation/formation and production of artefacts (5;29;92).   
The most common methods of extraction are liquid-liquid extraction (LLE) and solid phase 
extraction (SPE). For LLE, the analytes are extracted into a carefully selected solvent which is 
determined by the chemical properties of the analytes. SPE utilises a cartridge containing a solid 
stationary phase for the analytes to adsorb to. There are many different types of cartridges 
commercially available. The most common types include C8 or C18 phases combined with a cation 
or anion exchanger. These cartridges are known as mixed mode cartridges and have the ability to 
retain acidic, neutral and basic analytes. The analytes are eluted from the cartridges using similar 
solvent mixtures that would be used for LLE. SPE has generally become the method of choice as it 
provides more specificity towards the chosen analytes and provides high reproducibility and cleaner 
final extracts than LLE. SPE can be easily automated and minimises the use of solvents compared 
to LLE. However, LLE is cheaper and quick to carry out and may produce higher recovery rates of 
analytes from the sample matrix. The method of choice will depend on the level of sensitivity 
required (i.e. the % of recovery of the analytes required from the matrix) and how clean the final 
extracts are required to be. 
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1.6.2 Extraction methods for cannabinoids from blood 
Methods for the analysis of cannabinoids in biological fluids are continually being developed. The 
majority are developed for use on clinical samples, namely ante-mortem whole 
blood/plasma/serum, urine or oral fluid (93-108). The methods that are described for the extraction 
of cannabinoids from blood include SPE and LLE. LLE is often more favourable for post-mortem 
blood due to the nature of the sample matrix (109). Non-polar compounds like THC will 
preferentially extract into non-polar solvents such as hexane, and THC-COOH which is polar will 
extract into more polar solvents such as ethyl acetate. A mixture of hexane and ethyl acetate can 
thus be used for the extraction of cannabis using LLE (92). 
Very few methods have been applied to post-mortem blood specimens (30-33;110). Of those that 
have, three used SPE and two used LLE to extract the cannabinoids. Four extracted THC, 11-OH-
THC and THC-COOH (31-33;110). Only one report detailed the use of LLE to extract THC, CBD, 
CBN, 11-OH-THC and THC-COOH (30).  
 
1.6.3 Preparation and extraction of drugs from hair 
The analysis of hair for drugs is a more time consuming and lengthy process than the analysis of 
other biological matrices like blood. Hair samples require more sample preparation before 
extraction of the drugs can be carried out.  
Each hair sample must be examined. Its appearance, length and any contamination from blood or 
dirt should be noted. If the hair sample is to be segmented to represent a period of time, it is 
necessary to know which end of the hair sample is the cut end (i.e. closest to the root), and this must 
be adequately held together to prevent movement of the hair. Samples can then be cut into the 
necessary segments, for example, segmenting into 1 cm sections will provide approximately one 
month’s drug history. The 1 cm closest to the cut end will give the information on the most recent 
month’s use. 
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After the samples are segmented and before drugs can be removed from the hair, it is necessary to 
decontaminate the hair with solvent and/or detergent (shampoo) washing. This is to remove any 
drug that is present on the hair externally and to remove unwanted dirt and grease present on the 
hair. For the case of post-mortem hair specimens it is especially important to use shampoo washing 
prior to solvent washes as post-mortem hairs tend to be dirtier and may also be contaminated with 
blood or other body fluids. 
Common solvents used for decontamination washes include methanol (MeOH), isopropanol (IPA) 
and dichloromethane (DCM). The choice of solvent washes varies widely across the range of hair 
analysis studies and may also depend on the type of drugs that are being targeted for analysis. 
After decontamination washes have been carried out each, each hair segment is cut into 1-2 mm 
pieces and weighed out. 
As any drugs present will be incorporated within the hair, it is necessary to cleave the drugs from 
the hair. This can be done with either acid or alkaline hydrolysis, enzymatic digestion or by 
treatment with solvents or buffers. The choice of preparation is dependent on the drugs of interest. 
For example, benzodiazepines are unstable under alkaline conditions (111). 
Following hydrolysis, samples can undergo either SPE or LLE in a similar manner to other 
biological matrices. 
 
1.6.4 Extraction of cannabinoids from hair 
The methods of extraction vary and depend on which cannabinoids are of interest. Many methods 
analyse for only the inactive metabolite THC-COOH, as detection of this cannabinoid is required to 
prove ingestion (37;47-51;55;56;112-115). A few focus on extracting THC, CBD and CBN. 
However, detecting or measuring these compounds can only prove exposure rather than ingestion, 
as these compounds are present in cannabis smoke and can be absorbed onto the hair externally (43-
46;54). Several methods have been reported that analyse for a combination of THC and the 
metabolite THC-COOH (37-42;52;53), with some also including the cannabinoids CBD and CBN 
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(35;36). However most of these methods either do not achieve the necessary limit of detection for 
THC-COOH (which is present in concentrations 1000 fold less than the other cannabinoids), or else 
they involve laborious extraction procedures that may require two aliquots of hair sample. 
The choice of decontamination procedure varies greatly between methods, but DCM is commonly 
employed and has been shown to successfully remove external contamination (92). A final rinse 
with acetone helps dry the hair ready for cutting. Shampoo washing can also be included prior to the 
solvent washes to remove unwanted dirt, grease or blood if necessary. 
Cannabinoids are most commonly cleaved from the hair by incubating in alkaline solutions, usually 
1M sodium hydroxide at a high temperature (70-95°C) for a set length of time (10-60 minutes). 
Using alkaline hydrolysis completely dissolves the hair. 
After hydrolysis, the hair samples are neutralised and then subjected to either SPE or LLE.  
 
1.6.5 Derivatisation 
Derivatisation is used to make polar drugs and metabolites less polar and thermally stable for GC-
MS analysis. The addition of a derivatising reagent may also produce more characteristic mass 
spectra for a compound than if it was analysed in the underivatised form. 
The choice of derivatising reagent depends largely on the functional groups that are present on the 
compound of interest. Different derivatising reagents will attach to different functional groups. 
Common derivatising reagents used include silylation, acylation and alkylation reagents. Cyclic and 
chiral derivatisation can also be performed. The chosen reagents should be capable of forming 
stable derivatives and should not produce artifacts. 
Derivatisation can be performed during extraction of the drugs, on the final dry extract or during 
injection onto the GC-MS. In general, most derivatisation is carried out on the final dry extracts 
prior to injection onto the GC-MS. 
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1.6.6 Derivatisation of cannabinoids 
One of the most common derivatising reagents used for the analysis of cannabinoids is the silyation 
reagent N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA). MSTFA attaches to the hydroxyl 
groups on THC, CBD, CBN and 11-OH-THC molecules and to both the hydroxyl group and 
carboxyl groups on THC-COOH to form trimethylsilyl derivatives (TMS). This form of 
derivatisation is suitable for GC-MS analysis operated in electron impact (EI) mode. 
For the purposes of negative chemical ionisation (NCI), derivatising reagents containing halogen 
atoms that have high electron affinity (e.g. fluorine) can improve the detectability of a compound by 
making it more electronegative (116). To make analytes suitable for NCI, derivatisation is carried 
out using perfluorinated anhydrides such as trifluoracetic anhydride (TFAA) mixed with 
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP). This combination of derivatising reagents is used to 
maximise sensitivity. The TFAA attaches to the hydroxyl group and HFIP selectively attaches to 
the carboxyl group. Adding these reagents onto the THC-COOH makes the molecule very suitable 
for NCI as it adds a total of nine fluorine atoms onto the molecule. This increases the sensitivity of 
THC-COOH analysis by approximately 1000 fold over EI mode. The resultant derivative for THC-
COOH has a high molecular weight which also provides greater selectivity. 
 
1.7 Instrumentation for the analysis of cannabinoids 
Chromatographic techniques are the methods of choice for forensic toxicology analyses. 
Hyphenated techniques such as GC-MS and liquid chromatography-mass spectrometry (LC-MS) 
are now available in the form of benchtop instruments making these techniques readily available to 
most forensic laboratories. As technology has advanced, so have the development of sensitive and 
selective methods for analysis of drugs and poisons. Analysis of cannabinoids has commonly 
employed the use of GC-MS (92). 
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1.7.1 Standard GC-MS Instrumentation 
A standard benchtop GC-MS consists of a gas chromatograph (GC) oven attached to a mass 
selective detector (MSD). The GC oven is equipped with a capillary column chosen based on the 
chemistry of the analytes of interest. The choice of capillary column and adjustment of the GC oven 
temperature programme optimises chromatographic separation for the compounds of interest. The 
most common approach to GC-MS analysis operates the MSD in EI mode. The analytes of interest 
are bombarded with high energy electrons which causes extensive fragmentation of the analytes. 
This form of ionisation is suitable for most analytes and gives a unique fragmentation pattern for 
each analyte. The other form of ionisation is chemical ionisation (CI) which can be further split into 
two categories: positive chemical ionisation (PCI) and NCI. CI involves the introduction of a 
reagent gas (e.g. methane or ammonia) which collides with high energy electrons. This causes the 
reagent gas to ionise. In the case of PCI, the reagent ions can transfer a proton to the analyte or 
combine with it to produce adduct ions. This is most useful when structural information about the 
analyte is required. NCI is often used when higher sensitivity is required. It is most suitable for 
analytes that have high electron affinity, such as molecules containing halogens (e.g. fluorine). 
Under NCI conditions, the electronegative analytes capture the low energy electrons produced by 
the collision between the high energy electrons and the reagent gas (117) . 
The MSD can monitor the mass ions (mass to charge ratio (m/z)) produced in three ways. It can 
operate in full scan mode whereby it scans an ion range, e.g. from 50-750 atomic mass units (amu). 
This will give a complete fragmentation profile of the analyte. For further selectivity and sensitivity, 
the MSD can be operated in selected ion monitoring mode (SIM), whereby only a few selected ions 
(usually three) from the known spectrum of an analyte are scanned for. The more recently 
developed third option is to operate the MSD in simultaneous SIM/SCAN mode, which enables the 
MSD to perform full scan functions at the same time as performing SIM operations. This function 
provides additional sensitivity over full scan mode but not as much as SIM operated alone. Further 
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developments of GC-MS for the analysis of cannabis include tandem mass spectrometry which 
involves two or three MSD coupled together in series to provide further selective fragmentation. 
 
1.7.2 Two dimensional GC-MS Instrumentation 
A newer technique which has recently become available and which is used in the US is two 
dimensional GC-MS (2D GC-MS). This can be operated either in EI or CI.  This technique was 
developed to improve sensitivity and selectivity on a standard GC-MS instrument without the need 
for more complicated mass spectrometry methods such as tandem mass spectrometry or use of the 
more expensive LC-MS techniques. The increases in sensitivity and selectivity are achieved by 
using a novel “heart-cutting” technique enabled by equipping the GC with a micro fluidic plate and 
a Dean’s switch that couples two analytical GC columns together (a primary and secondary column) 
and a flame ionisation detector (FID). The analytical columns chosen have different retention 
properties – typically a non-polar and a polar column are used. The analytes of interest are 
separated on the primary column. The initial direction of flow is towards the FID. Flow is directed 
towards the FID for the majority of the analysis time. The Deans switch is programmed to switch 
the direction of flow from towards the FID to the secondary column at set time intervals to “heart-
cut” only the analytes of interest from the primary column onto the secondary column. After the 
analytes of interest have been “cut”, flow is directed back towards the FID. The transfer of analytes 
from the primary to the secondary column is aided by the use of an air-cooled cryofocusing trap 
which is attached at the front of the secondary column and is used to “trap” the analytes of interest 
at the front of the column by holding a temperature of 100°C whilst the analytes are being “cut” 
onto the secondary column. The trap focuses the analytes which prevents peak broadening and 
ensures good peak shape. When the last analyte of interest has been “cut”, the temperature of the 
trap is rapidly increased to 280°C to thermally desorb the analytes onto the secondary column for 
further chromatographic separation from unwanted matrix components before they are detected by 
the MSD. Only the secondary column is connected to the MSD. This results in only a small fraction 
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of the complete analysis time directed towards the secondary column and the MSD (e.g. for one 
analyte, only 0.2 – 0.3 minutes of a 20 minute analysis time would be separated on the secondary 
column). A schematic representation of the 2D GC-MS setup is shown below in figure 1.01 (118). 
 
Figure 1.01 Schematic representation of an Agilent two dimensional 6890N gas chromatograph 
(GC) coupled with a 5975B mass selective detector (MSD), flame ionization detector (FID) and 
7683 autosampler (118). 
 
The additional sensitivity is achieved because the analytes are separated from unwanted matrix 
compounds firstly on the primary column. As the secondary column has different retention 
properties to the primary column, the analytes are then further separated from other matrix 
compounds in a manner not achievable on the primary column. Improved selectivity is achieved 
compared to standard GC-MS techniques because only a very small part of the sample components 
are directed to the MSD. Further sensitivity and selectivity can be achieved by operating the MSD 
in NCI mode with SIM. 
57 
 
1.8 Summary of methods for analysis of cannabinoids in blood and 
hair 
The instrumental method of choice for cannabinoids is GC-MS. Adapting GC-MS to 2D GC-MS 
has improved detection limits and has lead to recent publications detailing the use of 2D GC-MS for 
the analysis of cannabinoids (25;56;96;97;118-120). Other publications report the use of LC-MS 
(30;95;104;121-129).  
The range of cannabinoids analysed varies. The most common, and those of highest biological 
importance, are THC, 11-OH-THC and THC-COOH. The minor cannabinoids CBD and CBN are 
often omitted from analysis. However, a recent report in which the pharmacokinetics of 
cannabinoids after smoking were determined suggested that CBD and CBN may be potential 
markers for recent cannabis use (24).  
Analysis for cannabinoids in hair is still preferentially carried out using GC-MS. There has been a 
move towards using tandem GC-MS which is often used to achieve the sensitivity necessary for 
THC-COOH. Only one method for the analysis of hair for THC-COOH using 2D GC-MS has been 
reported. One of the analytical challenges of analysis of hair for cannabinoids is achieving a method 
that can simultaneously detect THC, CBD, CBN and THC-COOH together. There is only one 
published method validated for the analysis of 11-OH-THC in hair (53). 
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1.9 Hypotheses 
The hypotheses for this project were: 
1. The use of LLE followed by analysis with 2D GC-MS in EI mode will provide a sensitive 
and selective method of extraction and analysis for the cannabinoids THC, CBD, CBN and 
metabolites, 11-OH-THC and THC-COOH from post-mortem blood. 
2. Analysis of post-mortem blood samples from routine HM Coroners’ cases for cannabinoids 
will allow a range of concentrations to be determined for cannabinoids that are routinely 
seen in post-mortem cases. 
3. Analysis of post-mortem blood samples from fatal RTCs for cannabinoids will show 
cannabis to be the most prevalent drug detected in victims from fatal RTCs. It will allow for 
the range of concentrations to be determined for cannabinoids observed in victims from fatal 
RTCs. 
4. Comparison of the concentrations detected in control cases and fatal RTC cases will show 
that it is useful to measure the concentrations of cannabinoids in post-mortem blood samples 
by establishing the baseline concentration and range of concentrations of THC in post-
mortem blood that may be associated with impairment in fatal RTCs. 
5. The use of LLE followed by 2D GC-MS in NCI mode will provide a sensitive and selective 
method for extraction and analysis for the cannabinoids THC, CBD, CBN and metabolites, 
11-OH-THC and THC-COOH from authentic hair specimens. 
6. Analysis of authentic hair specimens and comparison of the results to self-reported data will 
show a positive correlation between the amount of cannabis used and the concentrations of 
each cannabinoid detected in the hair. Analysis of authentic hair specimens will show the 
potential use of hair analysis for cannabinoids for HM Coroners’ fatal RTC cases. 
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1.10 Aims 
The main aim of this project was to develop a method for the analysis of the cannabinoids THC, 
CBD and CBN, and the metabolites THC-COOH and 11-OH-THC in hair and post-mortem blood. 
The method developed for blood was used to analyse post-mortem blood samples to establish the 
prevalence of cannabis in fatal road traffic collision victims. The method developed for hair was 
used to analyse hair samples from regular cannabis users. 
 
1.10.1 Method development for analysis of cannabinoids in blood 
There are many methods for the analysis of cannabinoids in blood, but there are very few methods 
that have been applied to post-mortem blood specimens (28-33;110). Only one 2D GC-MS method 
has been applied to post-mortem specimens and this did not include CBD and CBN in the analysis 
(29;110). Only one method has analysed for CBD and CBN in post-mortem specimens in addition 
to THC, 11-OH-THC and THC-COOH and this was carried out on LC-MS-MS (30).  
A method was required that provided the acceptable selectivity and sensitivity for all the chosen 
analytes. It needed to be relatively quick to enable efficient throughput in the laboratory.  
- LLE provides a quick and simple method for the extraction of cannabinoids from post-
mortem blood. 
- 2D GC-MS is an ideal instrumental technique for cannabinoids and post-mortem specimens 
as it provides the required sensitivity (low ng/mL concentration range) and selectivity by 
eliminating unwanted background matrix interferences that are common in post-mortem 
blood specimens.  
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1.10.2 Application of method to blood samples from non-RTC cases 
There is limited data available for concentrations of cannabinoid detected in post-mortem blood and 
no data available on concentrations observed in routine HM Coroners’ cases.   
- In addition to specimens from fatal RTC victims, the method was applied to cases submitted 
to the laboratory from HM Coroners that were not RTCs. This included a cross-section of 
cases that were representative of the cases normally received for toxicology analysis. 
Analysis for cannabinoids was carried out as part of the investigation into the cause of death. 
These cases were defined as the “control group”.  
- Analysis of these cases was conducted to compare the results with the cannabinoid positive 
cases from RTC cases. 
 
1.10.3 Application of method to blood samples from fatal road traffic collision 
victims 
There is little data available on the extent to which cannabis is involved in fatal road traffic 
collisions in the UK. From the limited data available, it is known that cannabis is the most frequent 
drug detected after alcohol, but it is not known at what concentrations the cannabinoids are 
detected.  
- The method developed for blood was applied to post-mortem (and some ante-mortem where 
available) blood samples from victims of fatal road traffic collisions that were submitted to 
the laboratory by HM Coroners.  
- The prevalence of cannabis was compared to the prevalence of alcohol and other drugs 
present in the samples from the fatal RTC victims. 
- The cannabinoid positive cases were interrogated to establish if any conclusions could be 
drawn from the concentrations of each cannabinoid detected. 
 
61 
 
1.10.4 Interpretation and usefulness of measuring cannabinoids in post-mortem 
blood samples 
As cannabis is rarely implicated in death, and due to the difficulties in determining the relevance of 
cannabinoid concentrations, little work has been done to establish how useful it is to measure 
cannabinoids in post-mortem samples.  
- The range of cannabinoid concentrations detected in both fatal RTCs and non-RTCs was 
investigated to establish if there were any differences in the concentrations detected in the two 
case types. The usefulness of measuring cannabinoids in both case types was assessed. 
- A group in the US have published mathematical models based on ante-mortem samples to 
estimate the time of last use of cannabis (26). This is to aid in the interpretation of whether a 
person was impaired or not due to cannabis use. It was investigated if these models could be 
applied to the post-mortem blood samples. 
 
1.10.5 Method development for analysis of cannabinoids in hair 
A method was required that could simultaneously extract and detect the cannabinoids THC, CBD 
and CBN and the metabolites 11-OH-THC and THC-COOH in hair samples. Methods already 
published vary in which cannabinoids are analysed for. 2D GC-MS operated in NCI mode has been 
shown to provide the sensitivity required to detect THC-COOH at the low pg/mg concentrations 
that are present in hair (56). It has not been used to simultaneously detect THC, CBD, CBN and 11-
OH-THC in addition to THC-COOH. 
-  Initially, the aim was to develop a 2D GC-MS method that could simultaneously detect all 
five compounds at the required sensitivity. However, analytical challenges with the 
derivatisation of all five compounds made this impossible.  
- It was therefore investigated if dual derivatisation or dual extraction techniques could be used 
for simultaneous detection of THC, CBD, CBN, 11-OH-THC and THC-COOH. 
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- The developed method was applied to authentic hair specimens from self-reported regular 
cannabis users.  
 
1.10.6 Interpretation and usefulness of measuring cannabinoids in authentic hair 
specimens 
Each of the cannabis users had already been assigned a cannabis consumption score which had been 
calculated from the self-report data of how much cannabis they used and how often they used it. 
The cannabis consumption score was expressed as the “number of joints smoked”.  
- It was investigated whether the detected concentrations of cannabinoids in the authentic hair 
specimens correlated with the cannabis consumption score.   
- It was investigated what types of cannabis users had detectable concentrations of 
cannabinoids. 
 
1.11 Ethics Approval 
Blood samples (ante-mortem and post-mortem) were collected by pathologists and submitted for 
toxicological analysis at the request of HM Coroners. Ethics approval for the use of the data 
generated from this analysis was granted by South West London Research Ethics Committee 1 
(REC reference 11/LO/0033). 
Authentic hair specimens were analysed at the request of Professor Matthew Hickman from 
University of Bristol on behalf of the Avon Longitudinal Study of Parents and Children. The use of 
the data generated from this analysis was granted by Professor Matthew Hickman. 
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CHAPTER 2: DEVELOPMENT OF METHOD FOR 
THE ANALYSIS OF CANNABINOIDS IN BLOOD 
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2.1 Introduction 
This chapter describes the development of a method for the analysis of the cannabinoids THC, 
CBD, CBN and the metabolites 11-OH-THC and THC-COOH in post-mortem blood. Initially this 
involved determining the most suitable 2D GC-MS parameters by analysing unextracted methanolic 
standards of each compound. This was to ensure that the appropriate sensitivity and selectivity 
could be achieved before development of the extraction from blood was conducted. Once the basic 
method was developed, full validation of the method was carried out to ensure the method was 
robust for identification and quantification of each analyte. 
 
2.2 Initial development of 2D GC-MS method parameters 
In order to establish the optimal 2D GC-MS parameters for the detection of each analyte, I aimed 
to: 
- Establish the full scan spectrum for THC, CBD, CBN, 11-OH-THC, THC-COOH, and         
internal standards, deuterated 9-tetrahydrocannabinol (THC-d3) and deuterated 11-nor-9- 
tetrahydrocannabinol-9-carboxylic acid (THC-COOH-d3) using standard GC-MS  
instrumentation.  
- Identify the correct ions to monitor using SIM 
- Establish the approximate retention times (RT) on the primary column of the 2D GC-MS  
  using the FID for each analyte. 
- Determine the appropriate cut times for each analyte from the established retention times on  
the primary column. 
- Establish the GC oven and cryotrap settings  
- Establish the retention times and SIM windows on the secondary column 
- Prepare an unextracted calibration line with methanolic standards to ensure appropriate  
sensitivity could be achieved. 
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2.2.1 Standard GC-MS Parameters 
For the initial development, an Agilent 5973B MSD was coupled with a 6890N GC fitted with a 
spilt/splitless injector and a 7683B automatic liquid sampler (Agilent, UK). The analytical column 
was a Restek RTX-5MS (30 m x 0.25 mm i.d. x 0.25 µm d.f.) fitted with a retention gap of 
uncoated deactivated silica (1 m x 0.25 mm i.d.). The GC temperature conditions were programmed 
as follows : an initial temperature of 80°C held for 1 minute increased to 300°C at 10°C/min, held 
for 6 minutes (total run time 29 minutes). The carrier gas (helium) was operated in constant flow 
mode at 1 mL/min. The injector was maintained at 280°C. The GC-MS was programmed to 
perform a 1 µL splitless injection. The MSD was operated in EI and simultaneous full scan mode 
(50-750 amu) with SIM. The software used for data acquisition and manipulation was Enhanced 
MSD Chemstation version D.03.00.611.  
 
2.2.2 Preparation of unextracted standards 
Separate methanolic stock solutions (100 µg/mL) of THC, CBD, CBN, 11-OH-THC, THC-COOH 
and the deuterated internal standards THC-d3 and THC-COOH-d3 were prepared from purchased 
stock solutions (LGC Standards, UK) and stored at -20°C.  For analysis, separate aliquots of 
approximately 500 ng of each standard were evaporated to dryness. Each analyte was derivatised by 
the addition of 50 µL of MSTFA. The standards were heated at 70°C for 30 minutes. One µL of 
each derivatised standard was injected onto the GC-MS under the conditions described above. 
 
2.2.3 Ions chosen for SIM 
The full scan spectrum for each analyte was determined and the most appropriate ions chosen for 
the SIM. Ions were chosen that were significant on the full scan spectrum and that would be the 
most unique ions for each analyte (i.e. ions that would be less likely to be observed as background 
ions). The ions chosen for each cannabinoid and internal standard are listed in table 2.01 and the 
full scan spectrum for each compound shown in figure 2.01.  
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Table 2.01 Ions monitored for trimethylsilyl derivatives (TMS) of cannabidiol (CBD), 9-
tetrahydrocannabinol (THC), deuterated THC (THC-d3), cannabinol (CBN), 11-hydroxy-9-
tetrahydrocannabinol (11-OH-THC), 11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-
COOH), and deuterated THC-COOH (THC-COOH-d3). Quantitation ions are underlined 
 
Cannabinoid Ions monitored (m/z) 
CBD  390 319 458 
THC 371 386 303 
THC-d3* 374 389 306 
CBN 367 368 382 
11-OH-THC 371 459 474 
THC-COOH 371 473 488 
THC-COOH-d3* 374 476 491 
 
*internal standard 
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Figure 2.01 Full scan electron impact (EI) mass spectra of trimethylsilyl derivatives of (a) cannabidiol (CBD), (b) 9-tetrahydrocannabinol (THC),  (c) 
deuterated THC (THC-d3) and (d) cannabinol (CBN) 
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Figure 2.01 continued Full scan electron impact (EI) mass spectra of trimethylsilyl derivatives of (e) 11-hydroxy-9-tetrahydrocannabinol              
(11-OH-THC), (f) 11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) and (g) deuterated THC-COOH (THC-COOH-d3) 
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2.2.4 2D GC-MS Parameters 
The initial parameters for 2D GC-MS were setup based on a method for the analysis of THC-
COOH in hair developed and reported by Moore et al. (56). 
An Agilent 6890 GC was equipped with a 7683B automatic liquid sampler, microfluidic Deans 
switch, FID and interfaced with an Agilent 5975C inert XL EI/CI MSD with triple axis detector. 
The primary column was a HP-5MS (30 m x 0.25 mm i.d, 0.25 µm d.f.). Uncoated deactivated 
silica retention gap was connected from the Deans switch to the FID. The carrier gas flow (helium) 
was operated in constant pressure mode at 25.43 psi. The injector was maintained at 250°C and 
programmed to perform a pulsed splitless injection. The injection volume was 2 µL. The GC was 
equipped with an air-cooled cryofocusing trap. Compressed air was delivered to the trap at 40 psi 
via a Jun-Air compressor. The MSD was operated in EI mode with SIM, monitoring the ions stated 
in table 2.01. The software used for data acquisition and manipulation was Enhanced MSD 
Chemstation version E.02.00.493. 
 
2.2.5 Determination of Dean’s switch cut times 
In order to determine the appropriate cut times for each analyte, the approximate retention times on 
the primary column had to be established. A high concentration of an unextracted standard (1 
ng/µL) for each analyte was prepared and derivatised as described in section 2.2.2.  The GC oven 
parameters were programmed to direct all flow towards the FID. As there is deactivated retention 
column from the microfluidic plate to the FID, analytes are not retained between the microfluidic 
plate and the FID, so effectively the detection time of each peak on the FID represents the 
approximate retention time on the primary column. The GC oven and FID settings are shown in 
table 2.02. Once the approximate retention times were established the Deans Switch cut times could 
be determined. The primary column retention times and chosen cut times are shown in table 2.03. 
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Table 2.02 GC (gas chromatograph) oven and FID (flame ionization detector) parameters for determining retention times on primary column 
 
Oven Temp (°C) Hold time (min) Deans switch flow Time (min) 
Initial oven temp 150 1 Directed to FID 0.0 – 33.40 
Ramp #1 : 50°C/min 220 0 
  
Ramp #2 : 10°C/min 280 25 
  (Total run time 33.40 min) 
    
     
Cryotrap 
    
Initial temp Held at 280°C for length of run 
  
Cooling OFF 
   
 
    
FID Parameters 
    
Temperature 300°C 
 
Flame On 
Hydrogen flow 45 mL/min 
 
Electrometer On 
Air flow 450 mL/min 
 
Lit offset 0.5 
Mode Constant column + makeup flow 
  
Make up flow Nitrogen (ON) 
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Table 2.03 Retention times and cut times for cannabidiol (CBD), 9-tetrahydrocannabinol (THC),  
cannabinol (CBN), 11-hydroxy-9-tetrahydrocannabinol (11-OH-THC), 11-nor-9-
tetrahydrocannabinol-9-carboxylic acid (THC-COOH), and internal standards, deuterated THC 
(THC-d3), and deuterated THC-COOH (THC-COOH-d3) 
 
 
Compound 
Approximate retention time 
on primary column (mins) 
Deans switch cuts 
(mins) 
CBD  7.80 7.70 - 7.90 
THC and THC-d3 8.70 8.60 - 8.85 
CBN  9.45 9.35 – 9.60 
11-OH-THC  10.95 10.80 - 11.10 
THC-COOH and THC-COOH-d3 12.65 12.45 - 12.85 
 
 
2.2.6 GC oven and cryotrap settings 
The initial GC oven temperature settings were designed to allow separation on the primary column. 
Once the final cut had taken place for the last analyte that eluted on the primary column, it was 
necessary to rapidly cool the oven temperature to 185°C in order to allow a second temperature 
ramp to be programmed to allow for further separation of the analytes on the secondary column. 
Whilst this is happening it is important to hold (trap) the analytes at the head of the secondary 
column. If this was not performed, poor peak shape and sensitivity would occur. In order to achieve 
this, the cryotrap which is attached at the start of the secondary column was programmed to cool to 
100°C prior to the start of the first cut. The time taken for the cryotrap to cool to 100°C from 250°C 
was approximately 0.8 minutes. It remained at 100°C for the duration of all the cuts and until the 
GC oven had cooled back down to 185°C. The cryotrap was programmed to be rapidly heated to 
280°C to coincide with the GC oven reaching 185°C. The analytes were thermally desorbed onto 
the secondary column which effectively simulated an injection. Once this had taken place, the 
second oven temperature ramp could take place allowing separation on the secondary column. The 
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final programmed settings for the GC oven, inlet, cryotrap and Dean’s switch are shown in table 
2.04. A schematic representation of the GC oven and cryotrap settings are shown in figure 2.02. 
An unextracted 1 ng/µL standard containing all analytes was analysed using the final parameters 
described in table 2.04. The retention times that were determined from this were used to adjust the 
SIM windows in the final method. SIM only mode was used to maximize sensitivity. The FID trace 
and total ion chromatogram for a low unextracted standard containing 10 pg/µL of each analyte 
(excluding internal standards) is shown in figure 2.03.  
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Table 2.04 Two-dimensional gas chromatography parameters for cannabidiol (CBD), 9-tetrahydrocannabinol (THC), deuterated THC (THC-d3) and 
cannabinol (CBN), 11-hydroxy-9-tetrahydrocannabinol (11-OH-THC), 11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) and 
deuterated THC-COOH (THC-COOH-d3) 
 
Front inlet 
 
Back inlet (cryotrap) 
 
Temp (°C) Hold time (mins) 
Flow Mode Constant pressure  Initial temp    280°C 6.10 min 
Injection mode Pulsed splitless   Ramp #1 (cooling) 800°C/min 100°C 6.10 min 
Inlet temp 250°C   Ramp #2 (heating)   800°C/min 280°C 0.00 min 
Pressure 25.43 psi   Pressure 7.24 psi     
Pulsed pressure 45.0 psi           
Pulse time 0.80 min           
Purge flow 50 ml/min           
Purge time 1 min     
      
Total flow 54.9 ml/min           
              
Oven Temp (°C) Hold time (mins)  Deans switch cuts  Time (mins) 
Initial oven temp 150 1  CBD   7.70 - 7.90 
Ramp #1 :  50°C/min 220 0  THC and THC-d3  8.60 - 8.85 
Ramp #2 :  10°C/min 280 3.45  CBN   9.35 – 9.60 
Ramp #3 : 120°C/min 185 0  11-OH-THC   10.80 - 11.10 
Ramp #4 :  10°C/min 280 10  THC-COOH and THC-COOH-d3  12.45 - 12.85 
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Figure 2.02 Screenshot from Agilent Chemstation Software illustrating the GC oven (Oven temp) and 
cryotrap (Bk Inl Temp) settings for duration of the analysis time 
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Figure 2.03 FID trace (top) and total ion chromatogram (bottom) of an unextracted 10 pg/µL standard of the trimethylsilyl derivatives of cannabidiol 
(CBD), 9-tetrahydrocannabinol (THC), cannabinol (CBN), 11-hydroxy-9-tetrahydrocannabinol (11-OH-THC), 11-nor-9-tetrahydrocannabinol-9-
carboxylic acid (THC-COOH) using the final 2D GC-MS parameters 
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2.3 Development of liquid-liquid extraction method 
Liquid-liquid extraction is routinely used in the laboratory for preparation of post-mortem blood 
samples for analysis. The steps involved in LLE included preparing calibration standards in drug-
free blood to matrix match to samples, choosing an appropriate buffer to adjust the pH to ensure the 
analytes were all extracted, and choosing an extracting solvent mixture that all analytes would be 
extracted into. The final stage included evaporating the extract at an appropriate temperature in 
order to derivatise the extracts with a suitably chosen derivatising reagent. 
The use of a previously published method (105) for the extraction of THC and THC-COOH was 
considered. This method had not previously included CBD, CBN and 11-OH-THC in the analysis. 
The method combines the use of LLE with SPE. The previously published method conducted the 
analysis using standard GC-MS instrumentation. Modification of the LLE part of the method 
combined with the analysis by 2D GC-MS was investigated. 
 
2.3.1 Preparation of calibrations standards 
The normal protocol within the laboratory for preparing standards in blood to matrix match the 
samples involves preparation of a working solution of drugs in deionised water (dH2O). In this case, 
it was found that the results for the control standards were not consistent when prepared in this way 
(discussed in section 2.4.3). It was decided to prepare all calibration standards, internal standards 
and control standards in a working solution of MeOH that would then be added to the drug-free 
blood. This required the working solutions to be at a high concentration to minimise the volume of 
MeOH added to the blood. A volume of 50 µL of MeOH could be added to the blood without 
resulting in coagulation.  
An intermediate 10 µg/mL methanolic solution containing THC, CBD, CBN, 11-OH-THC and 
THC-COOH was prepared from purchased stock solutions. From this three working solutions of 10, 
100 and 1000 ng/mL were prepared in methanol. Stock and working solutions were stored at -20 
°C. Calibrators of 0.25, 0.5, 1.0, 2.5, 5.0, 10.0, 25.0 and 50.0 ng/mL were freshly prepared for each 
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analysis from these working calibrant solutions by adding the appropriate volume to 1 mL of drug-
free blood in a glass extraction tube. The calibration procedure is shown in figure 2.04. 
 
2.3.2 Preparation of internal standard solution 
A working solution of 0.5 µg/mL THC-d3 and THC-COOH-d3 was prepared in methanol from 
purchased stock solutions of 0.1 mg/mL THC-d3 and 1 mg/mL THC-COOH-d3. Stock and working 
solutions were stored at -20 °C.  THC-d3 was chosen to monitor the neutral cannabinoids THC, 
CBD and CBN. THC-COOH-d3 was chosen to monitor the acidic 11-OH-THC and THC-COOH. 
 
2.3.3 Preparation of quality control standards 
Quality control standards (QCs) were prepared and analysed in addition to calibration standards and 
specimens to ensure that accurate results were being obtained for the specimens. A 10 µg/mL 
methanolic solution containing THC, CBD, CBN, 11-OH-THC and THC-COOH was prepared 
from purchased stock solutions separately from the calibration standards. Working control solutions 
of 50, 250 and 1000 ng/mL were prepared in methanol from this. Stock and working solutions were 
stored at -20 °C. A low, medium and high control standard (0.75, 7.5 and 30 ng/mL) were freshly 
prepared for each analysis from these working control solutions by adding the appropriate volume 
to 1 mL of drug-free blood in a glass extraction tube. The preparation of control standards is shown 
in figure 2.05.  
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Figure 2.04 Schematic diagram representing the preparation of calibration standards prepared in methanol (MeOH) containing 9-
tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), 11-hydroxy-9-tetrahydrocannabinol (11-OH-THC), 11-nor-9-
tetrahydrocannabinol-9-carboxylic acid (THC-COOH). 
THC/CBD/CBN/THC-COOH 
1 mg/ml (1 µg/µL) Purchased  
Stock in MeOH 
11-OH-THC 
100 ug/mL (0.1 µg/µL) 
Purchased Stock in MeOH 
Prepared in silanised 1.5 mL vial 
100 µL 10 µL 
10 ug/mL (10 ng/µL) 
Intermediate in MeOH 
(1mL) 
Prepared in silanised volumetric 
500 µL 100 µL 10 µL 
100 ng/mL (0.1ng/µL) 
in MeOH (10 mLs) 
10 ng/mL (0.01 ng/µL) 
in MeOH (10 mLs) 
 
1000 ng/mL (1ng/µL) 
in MeOH (5 mLs) 
25 µL 50 µL 10 µL 50 µL 25 µL 50 µL 25 µL 10 µL 
0.25 ng/mL 0.5 ng/mL 1 ng/mL 5 ng/mL 2.5 ng/mL 50 ng/mL 25 ng/mL 10 ng/mL 
FINAL CONCENTRATION IN 1 ML OF DRUG FREE BLOOD IN SILANISED SCREW CAP EXTRACTION TUBE 
ALL SOLUTIONS 
STORED AT          
-20°C 
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Figure 2.05 Schematic diagram representing the preparation of quality control standards in methanol (MeOH) containing 9-tetrahydrocannabinol 
(THC), cannabidiol (CBD), cannabinol (CBN), 11-hydroxy-9-tetrahydrocannabinol (11-OH-THC), 11-nor-9-tetrahydrocannabinol-9-carboxylic acid 
(THC-COOH). 
THC/CBD/CBN/THC-COOH 
1 mg/mL (1 µg/µL) Purchased  
Stock in MeOH 
11-OH-THC 
100 µg/mL (0.1 µg/uL) 
Purchased Stock in MeOH 
10 µg/mL (10 ng/µL) 
Intermediate in MeOH 
(1 mL) 
50 ng/mL (0.05 ng/µL) 
in MeOH (10 mLs) 
 
250 ng/mL (0.25 ng/µL) 
in MeOH (10 mLs) 
1000 ng/mL (1 ng/µL) 
in MeOH (5 mLs) 
7.5 ng/mL 0.75 ng/mL 30 ng/mL 
10 µL 100 µL 
50 µL 250 µL 500 µL 
15 µL 30 µL 30 µL 
FINAL CONCENTRATION IN 1 ML OF DRUG FREE BLOOD IN SILANISED SCREW CAP EXTRACTION TUBE 
Prepared in silanised volumetric 
Prepared in silanised 1.5 mL vial 
ALL SOLUTIONS 
STORED AT          
-20°C 
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2.3.4 Preparation of phosphate buffer 
Addition of an acidic buffer was required in order to extract the THC-COOH from the matrix. 
Potassium dihydrogen orthophosphate is routinely used in the laboratory for preparation of 
phosphate buffers. A 1 M solution of phosphate buffer was prepared by dissolving 136.1 g of 
potassium dihydrogen orthophosphate in approximately 800 mL of dH2O. The pH was adjusted to 4 
± 0.5 with 1 M postassium hydroxide (KOH) or 1 M hydrochloric acid (HCl) and the solution was 
made up to 1 L in a volumetric flask with dH2O. It was stored at 5°C. 
 
2.3.5 Preparation of drug-free blood 
It is routine to matrix match calibration standards and QCs to the type of specimens that are being 
analysed. Drug-free blood was prepared by mixing 1 unit of red blood cells with 1 unit of plasma. 
Sodium azide (0.1 g/100 mL drug-free blood) was added as a preservative. It was stored at 5 °C. 
The normal procedure in the laboratory is to prepare drug-free blood and use it within a month. For 
this analysis it was found that chromatographic interference would occur as the drug-free blood 
aged (discussed in section 2.4.1). It was therefore decided to freshly prepare drug-free blood prior to 
each analysis. 
 
2.3.6 Preparation of extracting solvent 
A mix of hexane and ethyl acetate was used as the extracting solvent. A ratio of 5:1 (hexane:ethyl 
acetate) was used. The volume of extracting solvent was prepared dependent on the number of 
samples to be extracted during each analysis.  
 
2.3.7 Preparation of post-mortem blood specimens 
Initially, each post-mortem blood sample was analysed in duplicate undiluted. One mL of post-
mortem blood was pipetted into a glass extraction tube and 50 µL of methanol added. After the 
initial analyses, it was decided to analyse all post-mortem blood diluted by a factor of 2 with drug-
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free blood (1 in 2 dilution).  To prepare a 1 in 2 dilution, 0.5 mL of post-mortem blood was pipetted 
into a glass extraction tube and 0.5 mL of drug-free blood added. This was done in duplicate. This 
was done to match the matrix of the calibrators with the post-mortem blood samples as closely as 
possible without over diluting the post-mortem blood. Matching the matrix of the post-mortem 
bloods as closely as possible to the drug-free blood minimized the possibility of retention time shift 
occurring on the primary column which could cause the analytes to miss the timed cut from the 
primary column onto the secondary column (discussed further in section 2.4.2). The dilution factor 
was taken into consideration when calculating the results. 
 
2.3.8 Liquid-Liquid Extraction (LLE) 
To each calibration standard except the blank, and to the control and post-mortem blood samples, 
I.S (25 µL) was added and 25 µL of MeOH was added to the blank. All tubes were vortex mixed 
and 1 mL of phosphate buffer (pH 4, 1 M) added to each. All tubes were vortex mixed again and 5 
mL of hexane:ethyl acetate (5:1) added to each. The tubes were then shaken on a rotary mixer for 
10 minutes and centrifuged at 2500 rpm for 10 minutes. The organic layer was transferred to clean 
tubes. A second aliquot of 5 mL of hexane:ethyl acetate (5:1) was added to the remaining aqueous 
layer and the process repeated to maximize recovery.  The final solvent extracts were evaporated to 
approximately 1 mL under nitrogen (N2) at 50 °C and transferred to microvials. The remaining 
solvent in the microvial was evaporated to dryness under N2 at 50°C. 
 
2.3.9 Derivatisation 
The use of the derivatising reagent MSTFA is common for the analysis of cannabinoids when the 
GC-MS is operated in EI mode and is readily available in the laboratory. The dried solvent extracts 
were derivatised by the addition of 25 µL of MSTFA to the microvials. The samples were heated 
for 1 hour at 70°C to ensure complete derivatisation.  
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2.4 Initial testing of the method 
Before full validation of the method was conducted, the method was tested with full calibration 
lines and quality control standards. The initial results of extracting blood using the method 
described above were promising. The linearity was acceptable (r2 > 0.99) and the limit of detection 
(LOD) was within the expected range (0.25 – 0.5 ng/mL). There were three major issues from this 
initial testing that were subsequently overcome : - 
- Co-eluting background interferences 
- Retention time shifts with extracted samples  
- Inconsistent results for low, medium and high QC standards 
 
2.4.1 Co-eluting background interferences 
There was co-eluting background interference present on the THC and THC-d3 peaks. This included 
m/z 374 interference on the THC-d3 peak, and m/z 303 interference on the THC peak. These 
interferences affected the ratios of the quantitation and qualifier ions. The interferences were 
observed on the calibration standards. The sources of the background interferences were 
investigated and it was determined that the background interferences originated from the CBN cut. 
It was established that the interferences were dependent on the age of the drug-free blood, and that 
they became more marked with the increasing age of the drug-free blood. To rectify this, m/z 389 
was used as the quantitation ion instead of m/z 374 for THC-d3 and drug-free blood was freshly 
prepared prior to analysis. The background interferences are demonstrated in figures 2.06a and 
2.06b. The extracted ion chromatograms for an extracted blank and 50 ng/mL standard using old 
drug-free blood are shown in figure 2.06a. The extracted ion chromatograms for an extracted blank 
and 50 ng/mL standard using freshly prepared drug-free blood are shown in figure 2.06b. 
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Figure 2.06a Extracted ion chromatograms for (a) 9-tetrahydrocannabinol-d3 (THC-d3) [m/z 374, 
389, 306] and (b) 9-tetrahydrocannabinol (THC) [m/z 371, 386, 303] from an extracted blank with 
old drug-free blood showing the presence of co-eluting background. A 50 ng/mL extracted standard 
for (c) THC-d3 and (d) THC has been shown for comparison. Quantitation ions are underlined. 
 
 
 
(a) (b)
(c) (d)
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Figure 2.06b Extracted ion chromatograms for (a) 9-tetrahydrocannabinol-d3 (THC-d3) [m/z 374, 
389, 306] and (b) 9-tetrahydrocannabinol (THC) [m/z 371, 386, 303] from an extracted blank with 
freshly prepared drug-free blood. A 50 ng/mL extracted standard for (c) THC-d3 and (d) THC has 
been shown for comparison. Quantitation ions are underlined. 
 
 
 
 
 
 
 
(a) (b)
(c) (d)
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2.4.2 Retention time shifts with extracted samples 
The initial cut times were established using unextracted methanolic standards. The cut times were 
between 0.2 and 0.4 minutes long. Once the matrix was introduced into the analysis, it became 
apparent that retention times on the primary column were shifting in comparison to the retention 
times of the unextracted methanolic standards. This resulted in the compounds not being completely 
transferred across from the primary column to the secondary column during each cut time. In order 
to ensure that the cut times were accurate, a high concentration extracted standard (in blood) was 
run prior to each analysis to check the cut times. To determine the correct cut times, the FID trace 
for the high concentration standard and the FID trace for the extracted blank from the calibration 
line were overlaid and the peaks for each compound identified. It was necessary to use a high 
concentration (equivalent to 500 ng/mL in blood) in order to get identifiable peaks (that were 
distinguishable from the background peaks) on the FID trace. The overlaid traces are shown in 
figure 2.07. Once the correct retention times on the primary column for the compounds extracted 
from matrix were established, the cut times could be adjusted as necessary. This was only as little as 
an adjustment of 0.05 – 0.1 minutes for each cut, but without this adjustment, it was possible that 
the whole of the peaks on the primary column would not be transferred across onto the secondary 
column. As discussed in section 2.3.7, dilution of the post-mortem blood by a factor of two with 
drug-free blood also minimized the risk of analytes not being transferred across. This was routinely 
carried out with each batch of samples. 
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Figure 2.07 Flame ionization detector (FID) trace of a high concentration (500 ng/mL) extracted standard in blood (upper trace in red) overlaid with 
FID trace of an extracted blank standard in blood (lower trace in black), used to establish the correct retention times for 9-tetrahydrocannabinol 
(THC), cannabidiol (CBD), cannabinol (CBN), 11-hydroxy-9-tetrahydrocannabinol (11-OH-THC), 11-nor-9-tetrahydrocannabinol-9-carboxylic acid 
(THC-COOH), and internal standards, deuterated THC (THC-d3), and deuterated THC-COOH (THC-COOH-d3)  on the primary column with FID 
detection by comparing the two traces.  
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2.4.3 Inconsistent results for low, medium and high QCs 
From the initial testing of the method, linearity was acceptable with all compounds producing linear 
calibration lines with r2  0.99. However, accuracy at the lower end of the calibration line (0.25-1 
ng/mL) was not as good as at the higher end and the quantitative results for the low (0.75 ng/mL), 
medium (7.5 ng/mL) and high (30 ng/mL) QCs were not reproducible. It was necessary to achieve 
QC results within 15% of the target values (20% for the lower QC) in order to show the method was 
accurate and robust. The QC values were variable and were frequently outside the ± 20 % margins. 
It was thought that the QCs were inconsistent due to the method of preparation of either the 
calibration standards or the QCs. 
Initially the calibration standards were prepared in a working solution of dH2O as per laboratory 
protocol. The QCs were initially prepared by adding a small volume of drug in methanol to a stock 
(10 mL) of blood. This was separated into aliquots that could be pipetted out with the calibration 
standards (i.e. mimicking a case sample).  The values for the QCs were inaccurate. It was decided to 
prepare the QCs in a similar fashion to the calibration standards by preparing a working solution in 
dH2O. However, accuracy was still unacceptable. Finally, after further literature review, it was 
decided to prepare calibration standards and QCs in methanol in a manner similar to that previously 
described by Lowe et al. (120). Working solutions were also prepared in methanol. To prepare the 
calibration standards, the appropriate volume of methanol was added directly to blood. The same 
process was used to prepare the QCs, although the QCs would be prepared from a separate stock of 
drug from the calibration standards. When the calibration standards and QCs were prepared in this 
way, acceptable accuracy and precision was observed. It is not known why this preparation of the 
standards and QCs in MeOH improved accuracy. It may be that the cannabinoids were unstable 
when prepared in blood or dH2O in advance.  
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2.5 Method validation parameters 
Once it was established that the method was producing acceptable results for both the calibration 
standards and QCs, full method validation was carried out to show that the method was robust 
enough for identification and quantification of the cannabinoids on a routine basis. 
The procedure for validation was carried out based on guidelines widely accepted within the 
forensic toxicology community. This includes the United Kingdom and Ireland Association of 
Forensic Toxicologists (UKIAFT) guidelines which are based on the Society of Forensic 
Toxicologists/American Academy of Forensic Sciences (SOFT/AAFS) guidelines (130). 
The following method validation parameters were determined – selectivity, LOD, the lower and 
upper limits of quantification (LLOQ and ULOQ), linearity, inter-day precision and accuracy, intra-
day precision and accuracy and extraction efficiency.  
 
2.5.1 Selectivity 
To evaluate selectivity, at least 6 drug-free blood sources were analysed for interfering signals on 
the target ions of interest at the appropriate retention times for each analyte and the internal 
standards. To ensure that there was no interference on the target ions from compounds commonly 
encountered in the routine screening of post-mortem samples, 61 compounds including opiates, 
cocaine, amphetamines, prescription and over-the-counter medications were analysed using the 
analytical method at a concentration of 10 µg/mL. As deuterated internal standards were used, zero 
samples (drug-free blood + internal standard) were analysed to determine whether the internal 
standards caused any notable interference on the ions of interest on the non-deuterated compounds. 
 
2.5.2 Limits of detection and quantification 
The LOD, LLOQ and ULOQ were assessed on 3 separate days in duplicate (n=6). The LOD was 
the lowest concentration that could be detected with a signal to noise (SN) > 3 for all analytes. The 
LLOQ was the lowest calibrator that could be accurately and precisely determined (within ±20 % of 
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the target concentration and with a maximum of 20 % CV (relative standard deviation). The ULOQ 
was defined as the highest calibrator. 
 
2.5.3 Linearity 
Linearity was assessed (n=6) over the concentration range 0.25 – 50 ng/mL with 8 matrix matched 
calibrators evenly spaced over the concentration range. Calibrators were required to be within  ± 15 
% of the target value for all calibrators except at the LLOQ which was required to be within ± 20%. 
 
2.5.4 Accuracy and Precision 
Inter-day and intra-day accuracy and precision were determined using three QC samples: low (0.75 
ng/mL), medium (7.5 ng/mL) and high (30 ng/mL) controls. Inter-day accuracy and intra-day 
accuracy were expressed as the % bias from the expected target concentration and were required to 
be within ± 15% of the target concentration or ± 20% at the LLOQ. Intra-day precision is a measure 
of the repeatability of the assay and was expressed as the % CV. Inter-day precision is a measure of 
the repeatability of the assay between days, and was expressed as the % CV. 
 
2.5.5 Extraction efficiency 
Extraction efficiency was determined by comparing extracted analytes to unextracted analytes (n=4) 
at three control concentrations (0.75, 7.5 and 30 ng/mL). Analytes were extracted according to the 
described method. For unextracted analytes, drug-free blood was extracted and then spiked with the 
analytes at each concentration prior to evaporation under N2 and derivatisation stage.  
The LLE extraction involved extracting from the blood into solvent twice. It was investigated 
whether a single LLE into solvent was sufficient with the lowest calibrator (0.25 ng/mL) and 
highest calibrator (50 ng/mL). 
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2.6 Method validation results 
2.6.1 Selectivity 
None of the 61 commonly encountered compounds caused interference to signals for the ions 
monitored for any of the target analytes or internal standards. There were no significant 
interferences observed from the drug-free blood sources when it was prepared fresh prior to 
analysis. The 61 compounds are listed in appendix II. 
 
2.6.2 Limits of detection and quantification 
The LOD was determined as 0.25 ng/mL for all analytes. At this concentration, all analytes 
produced a signal to noise ratio (SN) > 3. The ion ratios and chromatography were satisfactory at 
this concentration. The LLOQ was determined as 0.25 ng/mL for THC, CBN and 11-OH-THC. The 
LLOQ for THC-COOH and CBD was 0.5 ng/mL as these compounds did not show acceptable 
accuracy and precision at 0.25 ng/mL. The ULOQ was determined as 50 ng/mL for all analytes. 
Extracted ion chromatograms for an extracted blank blood matrix and for each analyte extracted 
from the matrix at the LLOQ are shown in figure 2.08. 
 
2.6.3 Linearity 
A linear regression model of least squares (y = mx + c) was applied to the data. The eight 
calibrators were analysed in duplicate on three separate days. Low and high calibration curves were 
constructed using peak area ratios with the internal standard. THC-d3 was used as the internal 
standard for THC, CBD and CBN. THC-COOH-d3 was used as the internal standard for 11-OH-
THC and THC-COOH. It was necessary to construct a low and a high calibration curve to ensure 
accuracy throughout the calibration range. The low calibration range was from 0.25 (0.5 for CBD) 
and THC-COOH) to 10 ng/mL and the high calibration range was from 2.5 to 50 ng/mL for all 
analytes. The correlation coefficient r2 was  0.992 for all analytes. All points on the calibration 
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curve were within ± 15 % of the target value or ± 20 % at the LLOQ. The mean % of the target 
concentration (n=6) for each calibration point for all analytes is shown in table 2.05. 
 
2.6.4 Accuracy and precision 
Inter-day and intra-day accuracy and precision were determined by analyzing three control 
standards (0.75, 7.50 and 30.0 ng/mL) and are shown in table 2.06. Inter-day accuracy and precision 
were determined by analysis of duplicates at each concentration on 5 separate days. Intra-day 
accuracy and precision were determined by analysis of six replicates of each concentration on the 
same day. Acceptable inter-day and intra-day accuracy was seen for all analytes and was within ± 
10% of the target concentration for all analytes with the exception of 0.75 ng/mL for THC-COOH, 
which was within ± 15%. The % CV (relative standard deviation) for inter-day and intra-day 
precision were  12% for all analytes.   
 
2.6.5 Extraction efficiency 
The extraction efficiency was > 73% for all analytes. The values for all analytes are presented in 
table 2.07. In addition to determining the extraction efficiencies for each compound, it was found 
that there was no difference in the extraction efficiency between a single LLE and a double LLE for 
the lowest standard (0.25 ng/mL), but there was approximately a 10% improvement in the 
extraction efficiency for a double LLE compared to a single LLE for the highest standard (50 
ng/mL). 
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Figure 2.08 Extracted ion chromatograms for cannabidiol (CBD), 9-tetrahydrocannabinol (THC), and cannabinol (CBN) for (a) an extracted blank 
blood matrix and (b) an extracted standard at the limit of quantitation - 0.25 ng/mL for THC, CBN and 0.5 ng/mL for CBD. Quantitation ions are 
underlined. 
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Figure 2.08 Continued Extracted ion chromatograms for 11-hydroxy-9-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-tetrahydrocannabinol-9-
carboxylic acid (THC-COOH) for (a) an extracted blank blood matrix and (b) an extracted standard at the limit of quantitation - 0.25 ng/mL for 11-
OH-THC and 0.5 ng/mL for THC-COOH. Quantitation ions are underlined. 
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Table 2.05 Accuracy of each calibration point for cannabidiol (CBD), 9-tetrahydrocannabinol (THC) and cannabinol (CBN), 11-hydroxy-9-
tetrahydrocannabinol (11-OH-THC) and 11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) across the concentration range expressed as 
mean %  of target concentration (n=6). Calibrators were required to be ±15% of target concentration (±20% at the limit of quantitation). 
 
Calibrator concentration (ng/mL) Mean % of target concentration for each analyte 
    THC CBD CBN 11-OH-THC THC-COOH 
Low curve 0.25 107.8 n/a 113.6 106.5 n/a 
  0.5 103.3 103.2 104.3 101.1 106 
  1 101.3 97.7 101.2 98.6 94.6 
  
2.5 97.9 97.3 98.6 98.9 97.0 
  
5 100 102.4 101.9 100.3 100.4 
  
10 100.1 99.6 100.0 100.0 100.1 
  
  
     
High curve 2.5 101.1 100.7 98.4 103.4 106.7 
  
5 101.7 101.1 102.3 102.2 102.7 
  
10 101.1 103.4 102.8 102.2 98.8 
  
25 98.5 97.3 97.7 97.2 98.6 
  
50 100.3 100.5 100.4 100.7 100.4 
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Table 2.06 Inter-day and intra-day accuracy and precision for cannabidiol (CBD), 9-tetrahydrocannabinol (THC) and cannabinol (CBN), 11-hydroxy-

9
-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) 
 
Analyte Target concentration Inter-day (n = 10) Intra-day (n = 6) 
    (ng/mL) Accuracy (%) Precision (%CV) Accuracy (%) Precision (%CV) 
THC             
  Low curve 0.75 98.5 7.8 98.9 1.84 
    7.5 98.8 3.4 91.6 4.8 
  High curve 7.5 99.8 3.3 100.7 4.7 
  
  30 99 5.0 102.7 0.8 
11-OH-THC             
  Low curve 0.75 101.9 6.7 95.8 6.3 
    7.5 97.5 5.6 94.9 2.4 
  High curve 7.5 99.8 4.7 95.3 2.5 
    30 97.6 6.5 106.5 1.1 
THC-COOH             
  Low curve 0.75 101.7 7.4 89.3 12.0 
    7.5 96.5 2.9 106.6 2.7 
  High curve 7.5 95.5 2.6 104.1 2.5 
    30 96.7 4.3 100.5 0.8 
CBD             
  Low curve 0.75 98.2 7.6 101.4 3.8 
    7.5 102.3 5.4 90.5 5.3 
  High curve 7.5 102.1 3.9 90.8 5.1 
    30 100.5 6.7 100.6 0.5 
CBN             
  Low curve 0.75 98.1 7.1 94.9 2.7 
    7.5 99.6 5.5 94.1 8.4 
  High curve 7.5 100.5 5.3 96.3 11.0 
    30 98.4 6.2 100.8 1.3 
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Table 2.07 Mean Extraction efficiency (n=4) for cannabidiol (CBD), 9-tetrahydrocannabinol 
(THC), cannabinol (CBN), 11-hydroxy-9-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-
tetrahydrocannabinol-9-carboxylic acid (THC-COOH) 
 
QC concentration (ng/mL) Extraction efficiency (% absolute abundances) 
THC CBD CBN 11-OH-THC THC-COOH 
0.75 97.4 91.2 94.4 104.3 96.3 
7.5 84.0 85.9 85 91.1 83.8 
30 78.7 80.6 80.5 85.2 73.7 
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2.7 General discussion and conclusions 
The developed method was robust, quick and simple to conduct, and could be integrated into the 
routine work conducted in the laboratory for HM Coroners. The method employed a simple LLE 
followed by analysis by 2D GC-MS. The method was validated for the concentration range 0.25 – 
50 ng/mL, which covers the range necessary for post-mortem blood samples. The method has 
similar LOD and LLOQ to other methods that have previously been used to analyse post-mortem 
blood (28-31;33;110). The method reported by Foltz et al. (32) used GC-MS with negative chemical 
ionization and does result in a lower LOQ for THC and THC-COOH. However, this method 
required two separate extracts: one for the analysis of THC and 11-OH-THC, and one for the 
analysis of THC-COOH. It also employs trifluoroacetic anhydride as the derivatising reagent, which 
is not an ideal reagent to use for derivatization of THC, as CBD is derivatised to produce the same 
retention time and mass spectrum as THC. This is further discussed in chapter 4.  
The developed method also allows for the analysis of CBD and CBN, which has not been reported 
previously in post-mortem blood using GC-MS methods. One LC/MS/MS method has included the 
analysis of CBD and CBN but the LLOQs for THC, CBN, 11-OH-THC and THC-COOH were 
higher than the LLOQs of this method (30).  
The developed method was subsequently used in a study involving the post-mortem blood 
specimens submitted by HM Coroners as part of the investigation into the cause of death if analysis 
of cannabinoids was requested or deemed significant to the case. This included analysis of samples 
from fatal RTC victims submitted to the laboratory and other routine case types. The results from 
these analyses are reported and discussed in the next chapter.  
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CHAPTER 3: APPLICATION OF BLOOD 
CANNABIOID ANALYSIS METHOD TO FATAL 
ROAD TRAFFIC COLLISION VICTIMS AND 
OTHER ROUTINE CASE TYPES 
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3.1 Introduction 
The method described in Chapter 2 was applied to blood specimens received by the laboratory from 
HM Coroners for routine toxicology testing.  The study was undertaken to investigate the 
prevalence of cannabis in blood samples from victims of fatal RTCs submitted to the laboratory by 
HM Coroners from various jurisdictions in London and the South of England. In addition to the 
prevalence of cannabis, the study also looked at the detection and contribution of alcohol, 
prescription drugs, over the counter drugs and other illicit drugs. The study also investigated the 
prevalence of cannabis in other routine case types submitted to the laboratory. This included cases 
representative of those normally received for toxicology analysis. Analysis for cannabinoids was 
carried out as part of the investigation into the cause of death. Analysis of these cases was carried 
out to act as a control group in order to compare the results of cannabinoid positive cases from fatal 
RTCs with non-RTC cases. 
 
3.2 Aims 
The aims of the study were to  
- Establish the prevalence of cannabis use in the control group. 
- Establish the prevalence of cannabis use in fatal RTC victims.  
- Compare the prevalence of cannabis use to the prevalence of other drugs and alcohol 
detected in fatal RTC victims. 
- Compare the prevalence of cannabis use in the control group and RTC group. 
- Compare the concentrations of cannabinoids in the control and fatal RTC blood samples 
which prove positive for cannabinoids. 
- Determine if baseline concentrations of cannabinoids in post-mortem blood can be 
established. 
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3.3 Cases submitted for analysis 
Between February 2011 and June 2012, a total of 141 cases from fatal RTCs were received into the 
laboratory representing approximately 10% of all HM Coroners’ cases analysed by the laboratory 
during this time period. These cases comprised of 114 post-mortem blood samples and 27 ante-
mortem samples.   
Routine non-RTC cases received into the laboratory that required analysis for cannabinoids (control 
group) were analysed between October 2012 and March 2013. A total of 114 cases representing 
approximately 15% of all HM Coroners’ cases analysed by the laboratory during this time period 
were analysed for cannabinoids. These cases comprised of 110 post-mortem blood samples and 6 
ante-mortem samples.  
All samples were stored at 5°C prior to analysis. 
 
3.4 Choice of analysis 
The analyses carried out were determined on a case by case basis. The analyses specifically 
requested by HM Coroner for each case were taken into account. The age of the victim and the 
types of samples submitted were also considered. The analyses included measurement of alcohol, a 
general screen and quantitation of chemically basic drugs including unknowns, licit and illict drugs, 
and specific screens for morphine and cannabinoids. The methods of analysis routinely carried out 
in the laboratory are summarised in appendix III. 
 
3.4.1 Control cases selected for analysis for cannabinoids 
It was only possible to carry out analysis of samples from HM Coroners’ cases if it was thought the 
analysis was deemed necessary to aid HM Coroner in reaching a verdict and/or to assist in 
establishing the cause of death. This made establishing a suitable control group difficult. It was only 
possible to conduct analysis for cannabinoids if requested upon receipt of the samples (via the 
101 
sample request form), if the case history indicated use of cannabis or if other analysis conducted in 
the laboratory (i.e analysis of urine for drugs of abuse) indicated the presence of cannabinoids in the 
samples. 
In summary, a total of 116 samples from 114 non-RTC cases were analysed for cannabinoids to 
provide a control group. 
3.4.2 Fatal RTCs selected for analysis for cannabinoids 
Cases were subjected to analysis for cannabinoids if the victim was under the age of 70. Of the 141 
case submitted to the laboratory, 112 victims were under the age of 70.  It was not possible to 
conduct analysis for cannabinoids on some of these cases (11 out of 112) due to no blood or 
insufficient blood sample being submitted for the case. 
As discussed in the Introduction (section 1.5.1), the incidence of illicit drug use in the over 70s age 
group is relatively low and, taking into consideration the types of analysis requested by HM 
Coroners for this age group, cannabinoid analysis was not conducted on the 29 cases received 
where the victim was over 70 years of age. 
In summary, a total of 101 samples from victims of fatal RTCs were analysed for cannabinoids. 
3.4.3 Statistical Analysis 
Statistical analysis was performed using IBM SPSS Statistics Version 20. 
In sections 3.7.2 – 3.7.4, statistical analysis was performed on the concentrations of THC, 11-OH-
THC and THC-COOH detected in each group. The distribution of the concentrations of each 
analyte was assessed and found not to follow a normal distribution, therefore the non-parametric 
Mann Whitney U Test was used to test for significant differences between the RTC and control 
group for the distribution of THC, 11-OH-THC and THC-COOH concentrations. A p value < 0.05 
was considered significant. 
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In section 3.8, statistical analysis was performed on the estimated times of last ingestion as 
calculated by Model I and Model II. The data was found to follow a normal distribution, therefore 
the paired t test was used to assess if there was any significant difference between result calculated 
by Model I and Model II. A p value < 0.05 was considered significant. 
The independent t test was used to assess if there was any significant difference between the 
estimated times calculated for either Model between the RTC and control group, and between cases 
where THC concentrations were below 5 ng/mL and above 5 ng/mL. 
In section 3.9, the Spearman’s Rank Correlation Test (2-tailed) was used to assess the correlation 
between the concentrations of THC, 11-OH-THC and THC-COOH as the data was non-parametric. 
A p value < 0.01 was considered significant. 
 
3.5 Results - Demographics 
3.5.1 Age and sex 
The 114 control cases analysed for cannabinoids were predominantly male (77%) as were the 101 
RTC victims (87%). The frequency of control cases was spread across the age range 16 to 68 years 
old, with 50% of cases between the ages of 25 to 55 years old.  The frequency of RTCs was similar 
across all age ranges from 12 to 69 years with the exception of the 56 to 70 year old group which 
demonstrated approximately 50% lower incidence than the other age groups. The frequency and 
distribution for each group of cases is shown in figure 3.01 and 3.02. 
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Figure 3.01 Number of fatal road traffic collisions (RTCs) and control cases included in analysis 
classified by age range 
 
 
 
Figure 3.02 The distribution of age of control cases and fatal road traffic collision victims (RTC). 
The boxplot diagrams represent the median and interquartile range for the age for each group of 
cases. The control group had a median age of 40 years (range 16 – 68 years). The RTC group had a 
median age of 35 years (range 12 – 69 years). 
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3.5.2 Classification of control group cases 
The control group cases were classified according to the case history received when the samples 
were submitted. The classification is shown in figure 3.03. 
 
 
 
 
Figure 3.03 Classification of control case types analysed for cannabinoids based on the case history 
(n=114). The number in brackets indicates the number of cases.  
*Other included died in hospital (2), multiple injuries, light aircraft crash, jumped from height (2), carbon monoxide 
poisoning (2) and set themselves on fire. 
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3.5.3 Classification of RTC victims analysed for cannabinoids 
Victims were classified into the following groups: motorcyclists, pedestrians, car drivers, car 
passengers, pedal cyclists, drivers of other types of vehicles and a pillion passenger. The 
motorcyclists, pedestrians and car drivers made up 76 % of the cases. The breakdown of the 
classification is shown in figure 3.04. 
 
 
 
 
Figure 3.04 Classification of types of fatal road traffic collision victims (RTC) for which samples 
were analysed for cannabinoids (n=101). The number in brackets indicates the number of cases.  
*Driver other : driver lorry, driver van, driver quad bike, driver car being towed, driver mobility scooter. 
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3.6 Results - Cannabinoid positive cases 
3.6.1 Control Cases 
Analysis of post-mortem blood was carried out for THC, 11-OH-THC, THC-COOH, CBD and 
CBN on 114 cases. Two cases had AM specimens (one AM serum and one AM blood) analysed in 
addition to post-mortem blood. With the exception of one case for which only heart blood was 
available for analysis, all samples were assumed to be femoral vein blood. Analysis for THC-
COOH in the urine was conducted if a screen for drugs of abuse in urine was carried out. 
Out of 116 control samples analysed for cannabinoids, 30 were positive for at least one 
cannabinoid.  One of the cases that had AM and post-mortem blood was positive in both sample 
types. 
The cases that were positive for cannabinoids were predominantly male (23 cases, 26% of males 
tested) with six cases for female victims (28% of females tested).  The positive cases were 
distributed across the age range 18 to 60 years old, with 83% of cases falling between the age range 
25 to 54 years old. Only one case was positive over the age of 55 (a 60 year old) and four cases 
positive below the age of 24 years old. 
The most common case type that was positive for cannabinoids (15 cases, 52%) was “found dead – 
drug/alcohol related”. The next most common case type positive for cannabinoids was “hanging” 
(six cases, 21 %). The breakdown of the types of control cases that were positive and negative for 
cannabinoids in the blood is shown in figure 3.05. 
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Figure 3.05 Breakdown of control cases (n=114) positive and negative for cannabinoids in blood 
by case type 
1Other - died in hospital (2), multiple injuries, light aircraft crash, jumped from height (2), carbon monoxide poisoning 
(2), set themselves on fire 
 
The prevalence of other drugs present in the blood was examined for the cannabinoid positive cases. 
There were 12 control cases where no other drugs were detected in addition to the cannabinoids. 
The remaining 17 cases had a combination of illicit drugs and licit drugs present also. Illicit drugs 
detected included cocaine, heroin (confirmed by the presence of morphine, codeine, 6-
monoacetylmorphine (6-MAM) and contaminants of street heroin), amphetamine and ketamine. 
Licit drugs included methadone, propranolol, paracetamol, opioid analgesics, benzodiazepines, anti-
depressants, anti-psychotics and drugs given during emergency treatment. All the cases defined as 
“found dead – drug/alcohol related” that were positive for cannabinoids had other drugs present in 
the blood, as did the six cases of hanging. 
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Twenty four of the cannabinoid positive cases were either negative for alcohol in the blood (less 
than 10 mg/100mL) or had levels of alcohol in the blood lower than 50 mg/100mL. The remaining 
five cases had alcohol concentrations that ranged from 86 to 250 mg/100mL. 
Urine was screened for drugs of abuse in 17 of the 29 cannabinoid positive cases. Urine was not 
available for analysis for the remaining 12 cases. THC-COOH is detected in the drugs of abuse 
screen in urine. Of the 17 cannabinoid positive cases that were screened, THC-COOH was detected 
in 13 of them, three were negative and one urine sample was unsuitable for detection of THC-
COOH. 
The primary psychoactive component of cannabis, THC, was detected in 18 samples (60 %). The 
active metabolite 11-OH-THC was detected in 21 samples (70%). The inactive metabolite THC-
COOH was detected in all 30 cannabinoid positive samples. The frequency of the presence of CBD 
and CBN was much lower, with only six samples positive for CBN (20%) and three samples 
positive for CBD (10%). 
In four control cases, the metabolites were detected but it was not possible to determine if THC, 
CBD or CBN were present. This was due to interfering compounds present in the samples. This 
occurred when the post-mortem samples were visually observed to be decomposed or to be of poor 
quality (i.e clotted, lumpy or oily). In these cases, only the presence of the metabolites could be 
reported.  
A summary of all the control cases that were positive for cannabinoids in the blood is shown in 
table 3.01. The table contains the concentrations measured for each cannabinoid and is ordered in 
increasing concentration of THC. 
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Table 3.01 Concentrations of cannabinoids detected in blood specimens from cannabinoid positive control cases 
CASE 
CANNABINOID CONCENTRATIONS (ng/mL) OTHER DRUGS DETECTED IN 
BLOOD 
BAC       
(mg/100mL) TYPE OF CASE   
 
THC 11-OH-THC 
THC-
COOH CBD CBN  
C1 ND ND 0.62 ND ND ILLICIT and LICIT <10 FOUND DEAD DRUG/ALC RELATED    
C2 ND ND 0.62 ND ND NDD <10 FOUND DEAD AT HOME 
   
C3 ND ND 0.88 ND ND ILLICIT and LICIT <10 FOUND DEAD DRUG/ALC RELATED    
C4 ND ND 7.3 ND ND ILLICIT 13 FOUND DEAD DRUG/ALC RELATED    
C5 ND ND 3.2 ND ND ILLICIT and LICIT 126 FOUND DEAD AT HOME 
   
C6 ND 0.41 3.7 ND ND LICIT 242 FOUND DEAD DRUG/ALC RELATED    
C7 ND 2.3 4.1 ND ND NDD <10 FOUND DEAD OTHER/UNKNOWN    
C8 ND 0.36 2.10 ND ND ILLICIT 250 FOUND DEAD DRUG/ALC RELATED    
C9  0.38 ND 0.92 ND ND ILLICIT and LICIT <10 HANGING 
   
C10AM 0.62 1 7.9 ND ND NDD <10 OTHER 
   
C10PM 3.3 1.5 3.8 ND ND NDD <10 OTHER 
   
C11 0.62 2.2 19.7 ND ND LICIT <10 HANGING 
   
C12 0.98 0.42 1.11 ND ND ILLICIT <10 FOUND DEAD DRUG/ALC RELATED    
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Table 3.01 continued Concentrations of cannabinoids detected in blood specimens from cannabinoid positive control cases 
CASE 
CANNABINOID CONCENTRATIONS (ng/mL) OTHER DRUGS DETECTED IN 
BLOOD 
BAC 
(mg/100mL) TYPE OF CASE THC 11-OH-THC 
THC-
COOH CBD CBN 
C13 1.3 0.8 12.7 ND ND ILLICIT and LICIT 20 FOUND DEAD DRUG/ALC RELATED 
C14 1.36 0.55 6.07 ND ND ILLICIT and LICIT 86 COLLAPSED DRUG/ALC RELATED 
C15 2.04 0.45 5.96 ND ND ILLICIT and LICIT <10 FOUND DEAD DRUG/ALC RELATED 
C16 2.2 2.3 15.7 0.9 0.55 NDD 177 FALL 
C17 2.5 0.47 25.6 ND ND NDD <10 HANGING 
C18 2.6 1.9 19.9 ND ND NDD <10 FOUND DEAD DRUG/ALC RELATED 
C19 2.9 1.7 25.9 ND ND ILLICIT and LICIT 26 FOUND DEAD DRUG/ALC RELATED 
C20 3.2 1 17.1 ND ND ILLICIT and LICIT <10 HANGING 
C21 4 2.8 23.7 0.8 0.6 not analysed not analysed HANGING 
C22 4.6 1 18.9 U 5.4 ILLICIT <10 FOUND DEAD DRUG/ALC RELATED 
C23 7.6 5.7 42.1 ND 0.47 ILLICIT and LICIT <10 FALL 
C24 8.5 5.36 94.8 ND  1.4 NDD <10 FOUND DEAD OTHER/UNKNOWN 
C25 U ND 1.06 U U NDD <10 HANGING 
C26 U ND 2.78 ND ND NDD 16 FOUND DEAD DRUG/ALC RELATED 
C27 U ND 5.9 ND ND NDD <10 FOUND DEAD DRUG/ALC RELATED 
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Table 3.01 continued Concentrations of cannabinoids detected in blood specimens from cannabinoid positive control cases 
CASE 
CANNABINOID CONCENTRATIONS (ng/mL) OTHER DRUGS DETECTED IN 
BLOOD 
BAC 
(mg/100mL) TYPE OF CASE THC 11-OH-THC 
THC-
COOH CBD CBN 
C28 U 1.36 45.4 U U ILLICIT and LICIT <10 FOUND DEAD DRUG/ALC RELATED 
C29* Positive Positive Positive Positive Positive NDD <10 OTHER 
THC - 9-tetrahydrocannabinol, CBD - cannabidiol, CBD - cannabidiol, 11-OH-THC - 11-hydroxy-9-tetrahydrocannabinol, THC-COOH - 11-nor-9-tetrahydrocannabinol-9-
carboxylic acid, BAC - Blood alcohol concentration , ND - Not detected (limit of detection 0.5 ng/mL), NDD - no drugs detected,  *Heart blood (therefore no interpretation of 
concentrations  possible and reported as positive only), AM – antemortem blood, PM – postmortem, U – unsuitable.
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3.6.2 Detection of alcohol and drugs in RTCs 
There were 112 RTC victims that required analysis of cannabinoids in addition to the routine 
screening for drugs and alcohol. Analysis was not possible on blood for 11 cases (10%) due to 
insufficient sample or no blood was submitted. Of the remaining 101 RTC victims, no drugs were 
detected in the blood of 63 of these cases (62%) and at least one drug was detected in 38 blood 
samples (38%).  
Out of the 101 RTC samples analysed, the most common drug detected was cannabis. There were 
21 blood samples (21%) positive for cannabinoids. This figure was greater than the number of RTC 
cases with an alcohol concentration greater than 80 mg/100mL (17 cases, 17%). Drugs associated 
with emergency treatment were detected in 7 cases (7%). Cocaine was the next most common 
finding, but was detected much less frequently than alcohol or cannabis, with detection in only 5 
cases (5%). A summary of the drugs detected in this cohort is shown in figure 3.06. 
 
Figure 3.06 Summary of drugs detected from 101 blood samples from fatal road traffic collision 
victims. 
1Blood alcohol concentration,  2Lignocaine, laudanosine, ketamine,  3Methylenedioxymethamphetamine, amphetamine, 
methamphetamine, phentermine, 4Cases with morphine, 6-monoacetylmorphine and codeine, 5Metoclopramide 
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3.6.3 Detection of cannabinoids in RTCs 
Analysis of blood was carried out for THC, 11-OH-THC, THC-COOH, CBD and CBN on 101 
cases. THC-COOH was also analysed for in the urine if a screen for drugs of abuse in urine was 
carried out. Of 101 cases that were analysed for cannabinoids, 21 were positive for at least one 
cannabinoid in the blood. There were also two cases that did not have blood available for analysis 
that were positive for THC-COOH in the urine. 
The cases that were positive for cannabinoids were predominantly male (19 cases, 22% of males 
tested) with only 2 cases for female victims (15% of females tested). Eleven (52%) of the 
cannabinoid positive cases were in the age range 16-24, with 8 cases (38%) between the age of 25 
and 44. Only 2 (10%) victims were over the age of 44, a 47 and a 57 year old. 
The incidence of cannabis detected in motorcyclists was approximately double any other group. The 
breakdown of the types of victims positive for cannabinoids in the blood is shown in figure 3.07. 
Figure 3.07 Breakdown of fatal road traffic collision victims positive for cannabinoids by victim 
type. 
Driver other - driver lorry, driver van, driver quad bike, driver car being towed, driver mobility scooter 
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There was only one case where cannabis was detected in conjunction with other drugs in the blood. 
The case was also positive for morphine and ketamine, but these drugs were likely administered 
during emergency treatment. 
Alcohol was detected in addition to cannabis in 4 cases (19%). In each of these, the concentration of 
alcohol was greater than 80 mg/100mL (range 116 to 243 mg/100mL). Three of these cases were 
car drivers and one was a pedestrian. 
All cases that were positive for at least one cannabinoid in the blood were also positive for THC-
COOH in the urine (where urine was available for analysis). The primary psychoactive component 
of cannabis, THC, was detected in 19 cases (90% of those positive for cannabinoids). The active 
metabolite 11-OH-THC was detected in 15 cases (71%). The frequency of the presence of CBD and 
CBN was much lower, with only four cases positive for CBN (19%) and three (14%) for CBD. 
All of the blood samples analysed were post-mortem samples with the exception of one which was 
AM blood. A summary of all the cases positive for cannabinoids in the blood is shown in table 3.02. 
The table contains the concentrations measured for each cannabinoid and is ordered in increasing 
concentration of THC. 
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Table 3.02 Concentrations of cannabinoids detected in blood specimens from road traffic collision (RTC) victims 
CASE 
CANNABINOID CONCENTRATIONS (ng/mL) OTHER DRUGS 
DETECTED IN 
BLOOD 
BAC       
(mg/100mL) TYPE OF RTC 
THC 11-OH-THC THC-COOH CBD CBN 
R1 ND1 ND1 2.5 ND1 ND1 NDD 145 Driver, SV, no seatbelt, driving at speed 
R2 ND2 ND2 9.79 ND2 ND2 NDD <10 Motorcyclist at speed, struck other vehicle 
R3 0.66 0.41 3.44 ND1 ND1 NDD <10 Pedestrian hit by car 
R4 1.04 ND1 1.82 ND1 ND1 NDD <10 Motorcyclist, collided with HGV 
R5 1.41 ND1 3.61 ND1 ND1 NDD <10 Motorcyclist, SV collided with CR 
R6 1.7 0.77 10.35 ND1 ND1 NDD <10 Cyclist, accidental fall onto pavement 
R7 1.8 ND1 5.8 ND1 ND1 NDD <10 Pedestrian ran in front of bus, suicide note at home 
R8 1.9 0.6 2.1 ND1 ND1 NDD <10 Driver car, head on collision with a transit 
van 
R9 2.25 0.74 16.5 ND1 ND1 NDD <10 Motorcyclist, collision with car, cannabis at 
scene 
R10 3.53 0.78 8.21 ND1 ND1 NDD <10 Motorcyclist, collision with car 
R11 3.88 ND1 10.75 0.88 0.29 NDD <10 Pedestrian hit by car whilst crossing road 
R12* 4.31 2.43 121.3 ND1 ND1 MORPHINE, KETAMINE <10 Motorcyclist joyriding, fell into canal 
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Table 3.02 continued Concentrations of cannabinoids detected in blood specimens from road traffic collision (RTC) victims 
 
CASE 
CANNABINOID CONCENTRATIONS (ng/mL) OTHER DRUGS 
DETECTED IN 
BLOOD 
BAC       
(mg/100mL) TYPE OF RTC THC 11-OH-THC THC-COOH CBD CBN 
R13 4.48 15.82 45.9 ND2 ND2 NDD 243 Pedestrian was in road, hit by car 
R14 5.4 1.2 11.9 ND1 ND1 NDD <10 Passenger rear, single vehicle 
R15 15.1 3 27.8 0.5 ND1 NDD <10 Passenger rear, single vehicle 
R16 17.6 74.3 220.5 0.64 0.47 NDD <10 Motorcyclist, head on collision with car 
R17 23.88 1.77 16.56 ND1 ND1 NDD <10 Motorcyclist, collided with another vehicle 
R18 26.54 2.19 53.54 ND1 0.81 NDD 117 Driver, collided with oncoming van 
R19 32.5 5.7 94.1 ND1 1.1 NDD <10 Motorcyclist overtaking,  hit by oncoming 
vehicle 
R20 51.4 8.7 73.4 ND1 ND1 NDD <10 Passenger rear, SV, driver collided with CR 
R21 69.5 13.8 127.5 ND2 ND2 NDD 116 Driver, SV, no seatbelt 
 
THC - 9-tetrahydrocannabinol, CBD - cannabidiol, CBD - cannabidiol, 11-OH-THC - 11-hydroxy-9-tetrahydrocannabinol, THC-COOH - 11-nor-9-tetrahydrocannabinol-9-
carboxylic  acid, BAC - Blood alcohol concentration, ND1 - Not detected (limit of detection 0.5 ng/mL), ND²- Not detected (limit of detection 2.5 ng/mL), NDD - no drugs detected, 
*Ante-mortem blood, SV - Single vehicle accident, CR - central reservation, HGV - heavy goods vehicle
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3.7 Results - Comparison of concentrations detected in control and 
RTC cases 
3.7.1 Summary of concentrations detected 
 There were similar numbers of control and RTC cases positive for any cannabinoid. Out of 116 
control samples tested (114 cases), thirty samples (26%) were positive for at least one cannabinoid. 
Out of 101 RTC samples tested, twenty-one (21%) were positive for at least one cannabinoid. In 
both groups, all positive samples were positive for THC-COOH. Ninety percent of the positive RTC 
samples had detectable THC, compared to only 59% of the positive control samples. Both groups of 
cases had a similar proportion of positive samples with detectable 11-OH-THC (70%). Detection of 
CBD and CBN was low in both groups. Only three control samples and three RTC samples were 
positive for CBD and six control samples and five RTC samples were positive for CBN. 
A summary of the concentrations detected for each group is shown in table 3.03a and 3.03b. 
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Table 3.03a Frequency, range and median value of concentrations of each cannabinoid detected in 
control cases (total number of samples analysed = 116). Values are calculated on the measured 
concentrations (excluding “not detected results”). 
 
Cannabinoid No. samples positive* Range (ng/mL) Median (ng/mL) 
THC 17 0.38 - 8.5 2.5 
11-OH-THC 20 0.36 - 5.7 1.18 
THC-COOH 29 0.62 - 94.8 6.07 
CBD 2 0.8 - 0.9 0.85 
CBN 5 0.47 - 5.4 0.6 
 
THC - 9-tetrahydrocannabinol, CBD - cannabidiol, CBD - cannabidiol, 11-OH-THC - 11-hydroxy-9-
tetrahydrocannabinol, THC-COOH - 11-nor-9-tetrahydrocannabinol-9-carboxylic  acid  
*The heart blood sample that was positive for cannabinoids was excluded from this table as no quantitation was 
conducted on the heart blood. All samples were post-mortem blood with the exception of one sample which was ante-
mortem blood. 
 
 
Table 3.03b Frequency, range and median value of concentrations of each cannabinoid detected in 
fatal RTC cases (total number of samples analysed = 101). Values are calculated on the measured 
concentrations (excluding “not detected results”). 
 
Cannabinoid No. samples positive Range (ng/mL) Median (ng/mL) 
THC 19 0.66 - 69.5 3.88 
11-OH-THC 15 0.41 - 74.3 0.78 
THC-COOH 21 1.82 - 220.5 11.9 
CBD 3 0.5 - 0.88 0.64 
CBN 5 0.29 - 1.1 0.5 
 
THC - 9-tetrahydrocannabinol, CBD - cannabidiol, CBD - cannabidiol, 11-OH-THC - 11-hydroxy-9-
tetrahydrocannabinol, THC-COOH - 11-nor-9-tetrahydrocannabinol-9-carboxylic  acid  
All samples were post-mortem blood with the exception of one sample which was ante-mortem blood. 
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3.7.2 THC concentrations in cannabinoid positive cases 
Although there were a similar number of both types of cases positive for THC, the concentrations 
detected in the fatal RTC victims spanned a greater range and the THC concentrations in fatal RTC 
victims positive for cannabinoids were significantly higher than the THC concentrations detected in 
control subjects positive for cannabinoids, as assessed by the non-parametric Mann-Whitney U Test 
(p < 0.05).  
All concentrations detected in the control group were below 10 ng/mL. Two samples (7%) were 
between 5 and 10 ng/mL and fifteen samples were less than 5 ng/mL (50%). Four of these samples 
were less than 1 ng/mL. Eight samples (27%) had no detectable THC. The remaining 16% of 
cannabinoid positive samples consisted of one heart blood sample (positive for THC but not 
quantitated) and 4 samples unsuitable for the analysis of THC. 
In the RTC group, there were seven samples (33%) that had concentrations greater than 10 ng/mL, 
(15.1 – 69.5 ng/mL). Twelve samples (57%) had concentrations less than 10 ng/mL of which eleven 
were below 5 ng/mL. One of these samples was less than 1 ng/mL. Two samples (10%) had no 
detectable THC. 
A boxplot diagram for each group of cases is shown in figure 3.08.  
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Figure 3.08 Boxplot diagram displaying the median and interquartile range of 9-
tetrahydrocannabinol (THC) concentrations detected in the cannabinoid positive control cases and 
fatal road traffic collision victims (RTC). The whiskers represent the minimum and maximum THC 
concentration (excluding outliers). The control group had a median THC concentration of 1.3 
ng/mL and a range  of 0 – 8.5 ng/mL. The RTC group had a median THC concentration of 3.88 
ng/mL and a range of 0 – 69.50 ng/mL.  The data includes outliers and cases where THC was “not 
detected”. 
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3.7.3 11-OH-THC concentrations 
The number of cases positive for 11-OH-THC was similar in each cohort of cases. According to the 
non-parametric Mann-Whitney U Test, there is no significant difference between the distributions 
of 11-OH-THC concentrations between each group (p>0.05). All concentrations measured in the 
control group (21 samples) were below 6 ng/mL. Only two samples were greater than 3 ng/mL 
(7%). Eighteen samples (60%) contained concentrations lower than 3 ng/mL, ten of which had 
concentrations of 1 ng/mL or less, and nine cannabinoid positive samples (30%) contained no 
detectable 11-OH-THC. The remaining sample was positive for 11-OH-THC in heart blood and 
therefore not quantitated. In the RTC group, there were five samples (24%) that had concentrations 
greater than 5 ng/mL (5.7 – 74.3 ng/mL). The ten remaining samples (48%) with detectable 11-OH-
THC had concentrations of 3 ng/mL or less, five of which had concentrations lower than 1 ng/mL. 
Six RTC samples (29%) had no detectable 11-OH-THC. 
Concentrations of 11-OH-THC are in general much less than the THC concentration (14). There 
were two RTC cases where the 11-OH-THC concentration was much greater than the THC 
concentration. In one case (R13), the THC and 11-OH-THC concentrations were 4.48 and 15.82 
ng/mL respectively. In the other case (R16), the THC and 11-OH-THC concentrations were 17.6 
and 74.3 ng/mL respectively. When cannabis is ingested orally, it results in 11-OH-THC 
concentrations much higher than those of THC (21), so this data suggests that these two individuals 
may have orally ingested cannabis rather than smoking it. 
A boxplot diagram for each group of cases is shown in figure 3.09. 
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Figure 3.09 Boxplot diagram displaying the median and interquartile range of 11-hydroxy-9-
tetrahydrocannabinol (11-OH-THC) concentrations detected in the cannabinoid positive control 
cases and fatal road traffic collision victims (RTC). One RTC case was excluded where the 11-OH-
THC concentration was 74.3 ng/mL to show the distribution more clearly. The whiskers represent 
the minimum and maximum 11-OH-THC concentration (excluding outliers).  The control group 
had a median 11-OH-THC concentration of 0.55 ng/mL and a range of 0 – 5.7 ng/mL. The RTC 
group had a median 11-OH-THC concentration of 0.78 ng/mL and a range of 0 – 74.30 ng/mL. The 
data includes outliers and cases where 11-OH-THC was “not detected”. 
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3.7.4 THC-COOH concentrations 
THC-COOH was the most commonly detected cannabinoid and was present in all cannabinoid 
positive cases in both cohorts. According to the non-parametric Mann-Whitney U Test, there is no 
significant difference between the distributions of THC-COOH concentrations between each group 
(p > 0.05) however the THC-COOH concentrations detected in the RTC group spanned a greater 
range than the control group. 
There was a larger spread of THC-COOH concentrations in both the control group and RTC groups 
compared to the THC and 11-OH-THC concentrations detected. However, in a similar manner to 
THC and 11-OH-THC, the highest THC-COOH concentrations were observed in the RTC group. 
All concentrations detected in the control group were lower than 50 ng/mL, with the exception of 
one case where the concentration was 94.8 ng/mL. Only five control samples (17%) were above 20 
ng/mL and 18 samples (60%) had concentrations lower than 20 ng/mL. Twelve of these were lower 
than 10 ng/mL. There were six samples (29%) in the RTC group that had concentrations greater 
than 50 ng/mL (53.5 – 220.5 ng/mL). Two RTC samples (10%) were between 20 and 50 ng/mL and 
13 RTC samples (62%) had concentrations lower than 20 ng/mL. Eight of these were lower than 10 
ng/mL. 
A boxplot diagram for each group of cases is shown in figure 3.10. 
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Figure 3.10 Boxplot diagram displaying the median and interquartile range of 11-nor-9-
tetrahydrocannabinol-9-carboxylic (THC-COOH) concentrations detected in the cannabinoid 
positive control cases and fatal road traffic collision victims (RTC). The whiskers represent the 
minimum and maximum THC-COOH concentration (excluding outliers). The control group had a 
median THC-COOH concentration of 6.07 ng/mL and a range of 0.62 – 94.8 ng/mL. The RTC 
group had a median THC-COOH concentration of 11.9 ng/mL and a range of 1.82 – 220.5 ng/mL. 
The data includes outliers and cases where THC-COOH was “not detected”. 
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3.7.5 CBD and CBN concentrations 
The detection of CBD and CBN was low in both groups of cases, with only three samples in each 
group positive for CBD, and each with concentrations lower than 1 ng/mL. There were six control 
samples and five RTC samples positive for CBN. The concentrations measured ranged from 0.29 to 
5.4 ng/mL. 
3.7.6 Summary of differences between groups 
It was shown that there was a significant difference in the distribution of concentrations between 
each group for THC but not for 11-OH-THC or THC-COOH. However, the boxplot diagrams 
showed that there was a trend towards higher concentrations of THC, 11-OH-THC and THC-
COOH being detected in the RTC group. The highest THC, 11-OH-THC and THC-COOH 
concentrations were all observed in the RTC group. Differences between the two groups for CBD 
and CBN concentrations were not tested because there were too few positive cases. 
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3.8 Results - Correlation of THC and THC-COOH concentrations 
with time of last use 
The models established by Huestis et al. (26) were applied to data from both groups that had 
calculated values for THC and THC-COOH. This was to test if the models were applicable to post-
mortem blood concentrations. Model I utilises the THC concentration only, and Model II utilises 
both THC and THC-COOH concentrations. The models and calculations are described in appendix 
IV. 
The calculated values for time of last ingestion for both Model I and Model II for each RTC and 
control sample that had measureable THC and THC-COOH are shown in table 3.04a and 3.04b. 
There was no difference between the estimated times calculated using Model I (based only on the 
THC concentration) or Model II (based on THC and THC-COOH concentrations). There was no 
significant difference in the means calculated for Model I and Model II results (p > 0.1). 
It was examined whether there was any difference in the estimated times calculated with both 
Model I and Model II between the control samples and the RTC samples.  Using the independent t-
test, there was no significant difference in the means calculated for either Model between the 
control and RTC samples (p > 0.1). 
It was examined whether there was any significant difference between samples with THC 
concentrations below 5 ng/mL and samples with THC concentrations above 5 ng/mL. There was a 
significant difference in the estimated times calculated using Model I (p < 0.05) but not using 
Model II (p > 0.1). 
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Table 3.04a Estimated time of ingestion calculated with Model I and Model II for control samples with measureable 9-tetrahydrocannabinol (THC) 
and 11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH). 
 
THC 
(ng/mL) 
THC-COOH 
(ng/mL) 
Model I : Time of last 
ingestion (hrs) 
Estimated time between 
(95% CI) 
Model II : Time of last 
ingestion (hrs) 
Estimated time between 
(95% CI) 
0.98 1.11 1.62 1.15 and 2.29 hours 0.87 0.57 and 1.32 hours 
1.3 12.7 1.49 1.06 and 2.10 hours 1.48 0.97 and 2.26 hours 
1.36 6.07 1.47 1.04 and 2.07 hours 1.22 0.80 and 1.86 hours 
2.04 5.96 1.30 0.92 and  1.83 hours 1.10 0.72 and 1.67 hours 
2.2 15.7 1.27 0.90 and 1.79 hours 1.37 0.90 and 2.09 hours 
2.5 25.6 1.22 0.87 and 1.72 hours 1.50 0.98 and 2.29 hours 
2.6 19.9 1.21 0.86 and 1.70 hours 1.40 0.92 and 2.13 hours 
2.9 25.9 1.17 0.83 and 1.64 hours 1.45 0.95 and 2.21 hours 
3.2 17.1 1.13 0.80 and 1.60 hours 1.28 0.84 and 1.94 hours 
3.3 3.8 1.12 0.80 and 1.58 hours 0.87 0.57 and 1.32 hours 
4 23.7 1.06 0.75 and 1.49 hours 1.31 0.86 and 1.99 hours 
4.6 18.9 1.01 0.72 and 1.43 hours 1.19 0.78 and 1.82 hours 
7.6 42.1 0.87 0.62 and 1.23 hours 1.29 0.85 and 1.96 hours 
8.5 94.8 0.84 0.60 and 1.19 hours 1.53 1.01 and 2.34 hours 
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Table 3.04b Estimated time of ingestion calculated with Model I and Model II for RTC samples with measureable 9-tetrahydrocannabinol (THC) and
11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH).
THC 
(ng/mL) 
THC-COOH 
(ng/mL) 
Model I : Time of last 
ingestion (hrs) 
Estimated time between 
(95% CI) 
Model II : Time of last 
ingestion (hrs) 
Estimated time between 
(95% CI) 
0.66 3.44 1.83 1.29 and 2.58 hours 1.27 0.83 and 1.93 hours 
1.04 1.82 1.59 1.13 and 2.25 hours 0.96 0.63 and 1.47 hours 
1.41 3.61 1.45 1.03 and 2.05 hours 1.06 0.70 and 1.62 hours 
1.7 10.35 1.37 0.97 and 1.93 hours 1.32 0.87 and 2.01 hours 
1.8 5.8 1.35 0.96 and 1.90 hours 1.12 0.74 and 1.71 hours 
1.9 2.1 1.33 0.94 and 1.87 hours 0.86 0.56 and 1.31 hours 
2.25 16.5 1.26 0.89 and 1.87 hours 1.38 0.91 and 2.10 hours 
3.53 8.21 1.10 0.78 and 1.55 hours 1.04 0.68 and 1.58 hours 
3.88 10.75 1.07 0.76 and 1.51 hours 1.08 0.71 and 1.65 hours 
4.31 121.3 1.03 0.73 and 1.46 hours 1.93 1.27 and 2.95 hours 
4.48 45.9 1.02 0.73 and 1.44 hours 1.50 0.99 and 2.29 hours 
5.4 11.9 0.97 0.69 and 1.36 hours 1.02 0.67 and 1.56 hours 
15.1 27.8 0.71 0.50 and 1.00 hours 0.98 0.64 and 1.49 hours 
17.6 220.5 0.68 0.48 and 0.95 hours 1.58 1.04 and 2.41 hours 
23.88 16.56 0.62 0.44 and 0.87 hours 0.77 0.50 and 1.17 hours 
26.54 53.54 0.60 0.42 and 0.84 hours 1.00 0.66 and 1.52 hours 
32.5 94.1 0.56 0.40 and 0.79 hours 1.09 0.72 and 1.67 hours 
51.4 73.4 0.49 0.35 and 0.69 hours 0.92 0.60 and 1.40 hours 
69.5 127.5 0.45 0.32 and 0.63 hours 0.98 0.64 and 1.49 hours 
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3.9 Results - Correlation of THC, 11-OH-THC and THC-COOH 
concentrations 
There was a strong positive correlation between the concentrations of THC, 11-OH-THC and THC-
COOH. The correlation was strongest between THC and THC-COOH ( = 0.814, p < 0.01) 
followed by the correlation between 11-OH-THC and THC-COOH ( = 0.810, p < 0.01), and 
finally by the correlation between THC and 11-OH-THC ( = 0.733, p < 0.01). The scatter plot 
diagrams for each correlation are shown in figure 3.11a, 3.11b, 3.12, 3.13a and 3.13b. Figure 3.11b 
and 3.13b are included to illustrate that the correlation remains when two samples with unusually 
high 11-OH-THC concentrations are excluded. 
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Figure 3.11a Scatter plot diagram showing the correlation between 9-tetrahydrocannabinol (THC) 
and 11-hydroxy-9-tetrahydrocannabinol (11-OH-THC) concentrations in all positive cannabinoid 
samples. THC concentrations correlate with 11-OH-THC concentrations, (Spearman  = 0.733, p < 
0.01). 
  
Figure 3.11b Scatter plot diagram showing the correlation between 9-tetrahydrocannabinol (THC) 
and 11-OH-THC concentrations in all positive cannabinoid samples, excluding two samples with 
unusually high 11-OH-THC: THC ratios. THC concentrations correlate with 11-OH-THC 
concentrations, (Spearman  = 0.711, p <0.01). 
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Figure 3.12 Scatter plot diagram showing the correlation between 9-tetrahydrocannabinol (THC)
and 11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) concentrations in all positive
cannabinoid samples. THC concentrations correlate with THC-COOH concentrations, (Spearman  
= 0.814, p <0.01). 
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Figure 3.13a Scatter plot diagram showing the correlation between 11-hydroxy-9-
tetrahydrocannabinol (11-OH-THC) and 11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-
COOH) concentrations in all positive cannabinoid samples. 11-OH-THC concentrations correlate 
with THC-COOH concentrations, (Spearman  = 0.810, p <0.01). 
Figure 3.13b Scatter plot diagram showing the correlation between 11-hydroxy-9-
tetrahydrocannabinol (11-OH-THC) and THC-COOH concentrations in all positive cannabinoid 
samples, excluding two samples with unusually high 11-OH-THC: THC ratios. 11-OH-THC 
concentrations correlate with THC-COOH concentrations, (Spearman  = 0.788, p <0.01). 
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3.10 Discussion of results 
The aims of this study were to establish the prevalence of cannabis use in fatal RTC victims and 
compare it to the prevalence of other drugs and alcohol detected in fatal RTC victims, establish the 
prevalence of cannabis use in the control group and compare it to the prevalence in fatal RTCs. The 
concentrations of cannabinoids detected in control and fatal RTC victims blood samples which 
proved positive for cannabinoids were compared. From this data, it was proposed that it may be 
possible to determine baseline concentrations of cannabinoids present in post-mortem blood. 
Cannabis was the most prevalent drug detected in fatal road traffic victims from 101 cases. 
Cannabis was detected in more cases than alcohol (at concentrations greater than 80 mg/100mL). 
Detection of other drugs was considerably less common than the detection of either cannabis or 
alcohol. 
Comparison with the control group showed a similar percentage of cannabinoid positive cases, but 
the concentrations detected in the control group were lower than the RTC group. In the control 
group, the cannabinoids were also detected in conjunction with other drugs, including heroin, 
cocaine, and prescription drugs. 
The primary reason for conducting toxicological analysis for HM Coroners is to aid the pathologist 
in establishing a cause of death and to aid the Coroner in reaching a verdict. As cannabis is a drug 
that is not generally implicated in causing death due to its lack of direct toxicity (in contrast to a 
drug like heroin), the main reason for analysis of cannabinoids is to either show the deceased had a 
history of cannabis use or to show that cannabis may be implicated in the death indirectly, i.e. due 
to impairment which subsequently caused an accident or fatal injury. 
The difficulty is determining whether the presence of alcohol or drugs contributed to the fatal 
accident. With alcohol there is an established dose/response relationship and there is clear evidence 
that a person’s risk factor of being involved in an accident is well correlated with higher BAC 
values. At BACs greater than 50 mg/100mL, driving ability can be impaired (131). Above 80 
mg/100mL the risk increases rapidly (132). 
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Unlike alcohol, equating impairment to blood cannabinoid concentrations is not straightforward - a 
clear dose/response relationship has not been established. The pharmacology of cannabis makes it 
difficult to interpret cannabinoid concentrations both in-life and in post-mortem blood samples. 
Firstly, in-life concentrations may not necessarily reflect recent ingestion if the person is a chronic 
user of cannabis. It has been shown that THC concentrations greater than 1 ng/mL can be detected 
in chronic cannabis users up to 7 days following monitored abstinence (15). Secondly, post-mortem 
blood concentrations will differ from those at the time of death due to post-mortem redistribution. 
As THC is stored within body tissues, after death, it will leach back out into the blood of chronic 
users – leading to elevated concentrations of THC at the time of sampling compared to at the time 
of death. Due to this, there is a trend towards only detecting the presence of cannabinoids instead of 
measuring the concentrations, as interpretation of concentrations is generally regarded as 
impossible. However, researchers have recently published preliminary data suggesting that post-
mortem redistribution is considerably lower than previously thought, and showing that in three 
deaths where both ante-mortem and post-mortem blood samples were available, concentrations of 
THC were lower in the post-mortem peripheral blood samples than the ante-mortem blood samples 
(29). Although this study is preliminary, it suggests there is merit in measuring post-mortem blood 
concentrations of cannabinoids.  
Drummer et al. assessed whether fatally injured drivers were more likely to be responsible for the 
accident if drugs and/or alcohol were detected. It concluded that fatally injured drivers with whole 
blood THC concentrations greater than 5 ng/mL were more likely to be culpable than those with 
concentrations less than 5 ng/mL. Drivers that had both THC concentrations > 5 ng/mL and a BAC 
> 50 mg/100mL were even more likely to be responsible for the crash (87). A study by Laumon et 
al. that investigated cannabis intoxication and fatal road crashes in France also concluded there was 
an increased risk of responsibility with cannabis detection. It was observed that there was an 
increase in the likelihood of being responsible for the crash with increasing blood concentration of 
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THC. This likelihood more than doubled when THC was detected at concentrations over 5 ng/mL 
compared to at concentrations less than 1 ng/mL (88).  
In an attempt to ascertain if the presence of cannabinoids played a role in the fatal accidents in this 
study, the cannabinoid positive cases described in table 3.02 were separated into distinct groups 
according to the blood THC concentration. Group 1 contains cases 1 and 2 where THC was not 
detected, and thus the deceased could not have been under the influence at the time of death. Group 
2 contains cases 3-9 which had THC concentrations lower than 3.5 ng/mL. Group 3 contains cases 
10-14 with THC concentrations between 3.5 and 5.5 ng/mL. It has been suggested that THC 
concentrations between 3.5 and 5 ng/ml are equivalent to a BAC of 50 mg/100mL (133). Therefore 
the victims placed in group 2 are unlikely to be significantly impaired by cannabis use at the time of 
death. For the cases listed in group 3, low level impairment similar to a BAC of 50 mg/100mL is 
possible, although this only represents in-life concentrations for non-frequent users of cannabis. 
Given the possibility that post-mortem concentrations may increase after death, for cases that fall 
into this category – it is unlikely that impairment due to cannabis use is a factor for cases that fall 
into this category. The final group contains cases 15-21, in whom the THC concentration ranged 
between 15 and 70 ng/mL. Even when taking into account chronic use and the possibility of post-
mortem redistribution, it is probable that the seven victims in this final group were under the 
influence of cannabis at the time of death. Out of these cases, five victims were 
drivers/motorcyclists that had concentrations of THC > 5 ng/mL (17.6 – 69.5 ng/mL). Two of these 
also had BAC > 80 mg/100mL (117 and 116 mg/100mL). This would strongly suggest that 
impairment with cannabis (plus alcohol for two cases) was a factor in the RTC based on the reports 
by Drummer et al. (87) and the study by Laumon et al. (88). 
It is possible that the presence of CBD and CBN may in the future be a useful indicator of recent 
ingestion. In a recent controlled study, CBD and CBN were not detectable two hours after smoking 
(24). In our study CBD was detectable in only three cases and CBN in four cases. All but one of 
these cases fell into the final group of cannabinoid positive cases in whom THC concentrations 
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were greater than 15 ng/mL. The prevalence of CBD and CBN was also low in the control group, 
with only three cases with detectable CBD and six cases with detectable CBN. Four of the CBN 
positive cases also had the four highest THC concentrations detected in the control group. 
This is the first report of cannabis being more prevalent than alcohol in studies conducted on RTCs 
in the UK within the last 10 years. Whilst cannabis was more prevalent than alcohol, it was not 
possible to say that its presence in all cases was a contributory factor, although in nearly a quarter of 
the cannabis positive cases, it is likely that impairment would have been a factor.  Even though this 
study has limitations as it only covers a small sample size and is geographically restricted, it 
demonstrates a significant problem with cannabis and fatal RTC’s.  
The concentrations of cannabinoids, and particularly THC detected in the control group also 
enforces the conclusions drawn from the RTC data. THC concentrations detected in the control 
group were generally not detectable or lower than 5 ng/mL (77% of cannabinoid positive control 
cases).  Only two cannabinoid positive control samples had THC concentrations greater than 5 
ng/mL (7.6 and 8.5 ng/mL).  
The review into driving under the influence of drugs conducted on behalf of the Department of 
Transport recommended that it should become an automatic offence for a person  to drive with 
concentrations greater than 5 ng/mL of THC in the blood (3 ng/mL in the presence of 
concentrations of alcohol > 20 mg/100mL) (61). This study suggests a similar agreement in post-
mortem blood samples from fatal road traffic collisions. 
Prior to this study, there had been no reports of concentrations detected in post-mortem blood 
samples from fatal RTCs and six reports of post-mortem blood concentrations in general (27-33). 
This study represents the first study that compares the concentrations of cannabinoids in post-
mortem samples from fatal RTCs and other routine HM Coroners’ cases.   
Investigation into whether the Models devised to estimate time of last use could be applied to post-
mortem samples showed that there was no significant difference between estimated times for the 
control group and the RTC group with either model. There was a significant difference between the 
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estimated times calculated for cases where the concentration of THC was less than 5 ng/mL (i.e in 
cases where it would be difficult to imply impairment) and cases where the concentration of THC 
was greater than 5 ng/mL (i.e in cases where impairment should be considered) using Model I. It is 
understandable that a significant difference was observed when Model I was utilised because this is 
only based on the THC concentration, thus as the THC concentration increased, the estimated time 
of ingestion decreased. When THC-COOH concentrations are factored in using Model II which has 
been reported to be more suitable for post-mortem blood samples (18), there was no significant 
difference in the estimated time of last ingestion between either type of case. It has been reported 
that the Models may not be suitable for post-mortem blood samples. This is because in order to 
apply the models, whole blood concentrations must be converted into plasma concentrations. In 
ante-mortem samples, the ratio is approximately 0.5, however Giroud et al. reported variable ratios 
for post-mortem samples and suggested the use of the models for post-mortem samples should not 
be advocated (33). The results reported here suggest the same. 
There were positive correlations between the concentrations of THC, 11-OH-THC and THC-
COOH, indicating that as the concentration of THC increased, as did the concentrations of 11-OH-
THC and THC-COOH. 
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CHAPTER 4: DEVELOPMENT OF METHOD FOR 
ANALYSIS OF CANNABINOIDS IN HAIR 
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4.1 Introduction 
This chapter describes the development of a method for the analysis of the cannabinoids THC, 
CBD, CBN and the metabolites 11-OH-THC and THC-COOH in hair samples. The initial aim was 
to analyse for the TFAA-HFIP derivatives of these compounds using 2D GC-MS with NCI 
detection. It was found that using TFAA-HFIP, THC and CBD had the same retention time and 
mass spectra. The procedures used to overcome this limitation are described. A method of 
extraction which includes LLE combined with SPE that produced two separate extracts from a 
single hair specimen was eventually developed. This allowed for analysis of the TMS derivatives of 
THC, CBD, CBN and 11-OH-THC on standard GC-MS and the TFAA-HFIP derivative of THC-
COOH on 2D GC-MS. 
 
4.2 Standard GC-MS parameters 
The following were established for analysis on standard GC-MS instrumentation. 
- The retention times and full scan spectrum for the TFAA-HFIP derivatives of THC, CBD,   
CBN, 11-OH-THC, THC-COOH, THC-d3 and THC-COOH-d3. 
- The retention times and full scan spectrum for the TMS derivatives of THC, CBD, CBN, 11- 
OH-THC, THC-COOH, THC-d3 and THC-COOH-d3. 
- The correct ions to monitor using SIM for both the TFAA-HFIP and TMS derivatives of  
each analyte. 
 
4.2.1 Preparation of unextracted standards (TFAA-HFIP derivatives) 
Separate methanolic stock solutions (100 µg/mL) of THC, CBD, CBN, 11-OH-THC, THC-COOH 
and the deuterated internal standards THC-d3 and THC-COOH-d3 were prepared and stored at -
20°C.  For analysis, separate aliquots of approximately 500 ng of each standard were evaporated to 
dryness. The TFAA derivatives of THC, CBD, CBN and 11-OH-THC and the TFAA-HFIP 
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derivative of THC-COOH were formed by the addition of 50 µL of TFAA-HFIP (50:30) to the 
standards. The standards were heated at 70°C for 30 minutes. The excess TFAA-HFIP was 
subsequently evaporated to dryness at 50°C under N2 and the derivatised compounds reconstituted 
in 50 µL of toluene. For each derivatised standard, 1 µL was injected onto the standard GC-MS 
under the conditions described below.  
 
4.2.2 Initial standard GC-MS Parameters 
For the initial development, standard GC-MS parameters were used as described in section 2.2.1 
 
4.2.3 Ions chosen for SIM for TFAA-HFIP derivatives 
The full scan spectrum for each analyte was determined and the most appropriate ions chosen for 
SIM. Ions were chosen that were significant on the full scan spectrum and that would be the most 
unique ions for each analyte (i.e ions that would be less likely to be observed as background ions). 
The ions chosen for each cannabinoid and internal standard are listed in table 4.01 and the full scan 
spectrum for each compound shown in figure 4.01.  
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Table 4.01 Retention times (RT) and ions monitored for the trifluoroacetic acid (TFAA) derivatives 
of cannabidiol (CBD), 9- tetrahydrocannabinol (THC), deuterated THC (THC-d3), cannabinol 
(CBN) and 11-hydroxy-9-tetrahydrocannabinol (11-OH-THC) and trifluoroacetic acid-1,1,1,3,3,3-
hexafluoro-isopropanol (TFAA-HFIP) derivatives of 11-nor-9-tetrahydrocannabinol-9-carboxylic 
acid (THC-COOH) and deuterated THC-COOH (THC-COOH)-d3. 
 
Cannabinoid RT (min) Ions monitored (m/z) 
CBD-TFAA 18.72 410 367 395 
THC-TFAA 18.72 410 367 395 
THC-d3-TFAA*  18.68 413 370 398 
CBN-TFAA 19.35 391 392 406 
11-OH-THC-2TFAA 19.95 408 365 393 
THC-COOH-TFAA-HFIP  19.54 477 590 422 
THC-COOH-d3-TFAA-HFIP* 19.52 480 593 425 
 
*internal standard 
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Figure 4.01 Full scan electron impact (EI) mass spectra of the trifluoroacetic anhydride derivatives of (a) cannabidiol, (b) 9-tetrahydrocannabinol 
(THC), (c) deuterated THC and (d) cannabinol.  
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Figure 4.01 continued Full scan electron impact (EI) mass spectra of the trifluoroacetic anhydride derivatives of (e) 11-hydroxy-9-
tetrahydrocannabinol and trifluoroacetic anhydride-1,1,1,3,3,3-hexafluoro-isopropanol derivative of (f) 11-nor-9-tetrahydrocannabinol-9-carboxylic
acid (THC-COOH), and (g) deuterated THC-COOH. 
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Unique retention times and principal ions were elucidated for CBN, 11-OH-THC, THC-COOH, 
THC-COOH-d3 and THC-d3. However, it was shown that THC and CBD have the same retention 
time and mass spectrum when derivatised with TFAA-HFIP as shown in the mass spectra (a) and 
(b) in figure 4.01. In addition to this, the derivatives did not produce a single peak, but rather one 
main peak with two additional smaller peaks for both compounds as shown in figure 4.02. As the 
initial aim was to analyse for all five compounds simultaneously, it was necessary to address this 
limitation before further refining the instrumental parameters (discussed in 4.4). 
Figure 4.02 Identical Total Ion Chromatogram for 9-tetrahydrocannabinol (THC) and cannabidiol
(CBD) derivatised with trifluoroacetic anhydride mixed with 1,1,1,3,3,3-hexafluoro-isopropanol 
(50:30) in electron impact (EI) mode. 
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4.2.4 Ions chosen for SIM for TMS derivatives 
The retention times and ions chosen for SIM for the TMS derivatives have previously been 
described in chapter 2 (2.2.2-2.2.3). 
 
4.3 2D GC-MS Parameters  
Due to the difficulties with derivatisation, the 2D GC-MS was only set up for the analysis of the 
TFAA-HFIP derivatives of THC-COOH and THC-COOH-d3. The following was established for 
analysis on 2D GC-MS instrumentation. 
- The 2D GC-MS parameters with NCI detection for the TFAA-HFIP derivatives of THC- 
COOH and THC-COOH-d3. This included establishing the approximate retention times on  
the primary column, the Dean’s switch cut time, the GC oven and cryotrap settings, the  
retention times on the secondary column and the correct ions to monitor using SIM.   
- The approximate sensitivity of the instrumentation was assessed with unextracted standards  
of the TFAA-HFIP derivative of THC-COOH.  
 
4.3.1 Initial 2D GC-MS parameters 
The initial parameters for 2D GC-MS were setup based on a method for the analysis of THC-
COOH in hair developed and reported by Moore et al. (56). 
The GC parameters have previously been described in section 2.2.4. The MSD was operated with 
NCI. Ammonia was used as the reagent gas. Initially, simultaneous full scan mode (50-750 amu) 
with SIM mode was used. This was subsequently changed to SIM only mode. The software used for 
data acquisition and manipulation was Enhanced MSD Chemstation version E.02.00.493. 
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4.3.2 2D GC Parameters 
In order to establish the 2D GC parameters, a high concentration of an unextracted standard (1 
ng/µL) of the TFAA-HFIP derivatives of THC-COOH and THC-COOH-d3 were prepared as 
described in 4.2.1. The same protocol was followed as described in chapter 2 (2.2.5-2.2.6) to 
determine the approximate retention times on the primary column, the Dean’s switch cut time, the 
GC oven and cryotrap settings and the retention times on the secondary column,  The final 
programmed settings for the GC oven, inlet, cryotrap and Dean’s switch are shown in table 4.02. 
 
4.3.3 Ions chosen for SIM in NCI mode 
Operating the MSD in NCI mode results in considerably less fragmentation than occurs when the 
MSD is operated in EI mode. The ions detected are the molecular ion (m/z 590) and one major 
fragment of the derivatised molecule (m/z 422). The deuterated internal standard THC-COOH-d3 
gives m/z 593 (molecular ion) and m/z 425 (major fragment ion). Some minor ions are produced, 
including m/z 423 (for THC-COOH) and m/z 426 (for THC-COOH-d3), but these are less abundant 
than the major ions. The derivatised structure of THC-COOH and major ions produced with NCI 
are shown in figure 4.03. 
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Table 4.02 Two-dimensional gas chromatography parameters for 11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) and 11-nor-9-
tetrahydrocannabinol-9-carboxylic acid-d3 (THC-COOH-d3) derivatised with trifluoroacetic anhydride mixed with 1,1,1,3,3,3-hexafluoro-isopropanol 
(50:30). 
Front inlet Back inlet (cryotrap) Temp (°C) Hold time (mins) 
Flow Mode Constant pressure Initial temp 280 6.6 
Injection mode Pulsed splitless Ramp #1 (cooling) 800°C/min 100 1.8 
Inlet temp 250°C Ramp #2 (heating) 800°C/min 280 0 
Pressure 25.43 psi Pressure 7.24 psi 
Pulsed pressure 45.0 psi 
Pulse time 0.80 min 
Purge flow 50 mL/min 
Purge time 1 min 
Total flow 54.9 mL/min 
Oven Temp (°C) Hold time (mins) Deans switch cut Time (mins) 
Initial oven temp 150 1 THC-COOH + THC-COOH-d3 7.40 - 7.70 
Ramp #1 :  50°C/min 220 0 
Ramp #2 :  10°C/min 275 0 
Ramp #3 : 120°C/min 185 0 
Ramp #4 :  10°C/min 280 2 
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Figure 4.03 Structure of 11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH)
derivatised with trifluoroacetic anhydride mixed with 1,1,1,3,3,3-hexafluoro-2-propanol (50:30) 
illustrating the point of fragmentation. Chemical groups added to the molecule from the derivatising 
reagent are highlighted in red. 
Fragmentation occurs here to generate 
m/z 422 
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4.3.4 Determining the approximate sensitivity 
To establish the approximate sensitivity of the instrument when operated in NCI mode, unextracted 
standards of the TFAA-HFIP derivative of THC-COOH were analysed. Sensitivity was required to 
be within the low pg/mg of hair range. The SOHT recommend a cut-off concentration of 0.2 pg/mg 
of hair. Based on a 30 mg sample of hair, this equates to 6 pg total (per 30 mg hair). It is usual for 
final derivatised extracts to have a final volume in the region of 25 µL. This final volume would 
result in a concentration of 0.24 pg/µL in the microvial. Therefore it was necessary to check if the 
sensitivity was acceptable at or near this concentration. 
4.3.4.1 Preparation of unextracted standards for sensitivity check 
An intermediate solution (0.2 µg/mL) of THC-COOH was prepared by pipetting 10 µL of THC-
COOH (1 mg/mL) to a 50 mL volumetric flask and making it up to volume with MeOH.  A 
working solution of THC-COOH was prepared by pipetting 5 µL of the intermediate solution into a 
vial and making up to 1mL with MeOH. This gave a final working concentration of 1 pg/µL THC-
COOH. Unextracted standards (0.1 pg/µL, 0.2 pg/µL and 0.5 pg/µL)  were prepared by pipetting 
the appropriate amount of the working solution into a microvial. These concentrations are 
equivalent to 0.08 pg/mg (2.5pg total), 0.16 pg/mg (5pg total) and 0.42 pg/mg (12.5 pg total) based 
on a 30 mg hair sample.  The unextracted standards were derivatised with TFAA-HFIP as 
previously described is 4.2.1. 
4.3.4.2 Results from sensitivity check 
The required sensitivity for THC-COOH concentrations that are present in hair could be achieved 
by analysing for the TFAA-HFIP derivative of THC-COOH using 2D GC-MS with NCI detection. 
The extracted ion chromatograms for 0.1 pg/µL, 0.2 pg/µL and 0.5 pg/µL are shown in figure 4.04. 
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Figure 4.04 Extracted ion chromatograms for (a) 0.1 pg/ µL, (b) 0.2 pg/µL and (c) 0.5 pg/µL of the 
11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) derivatised with trifluoroacetic
anhydride mixed with 1,1,1,3,3,3-hexafluoro-isopropanol (50:30). 
(a) (b)
(c)
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4.4 Adjustment of derivatisation 
It was known that the TMS derivatives of THC and CBD present with different retention times and 
mass spectra so it was investigated whether the derivatisation protocol could be adjusted to allow 
THC and CBD to be distinguished when derivatised with TFAA-HFIP. The following steps were 
followed :- 
- The structures of underivatised THC and CBD, and the TMS and TFAA derivatives of THC 
and CBD were examined 
- The effects of simultaneous dual derivatisation with MSTFA and TFAA-HFIP were 
investigated 
- The effects of two-step re-derivatisation with TFAA-HFIP following derivatisation with 
MSTFA were investigated 
- The effects of two-step re-derivatisation with MSTFA following derivatisation with TFAA-
HFIP were investigated 
4.4.1 Underivatised structures of THC and CBD 
THC and CBD have the same molecular weight (314.46) and the structures differ by an open or 
closed pyran ring. The pyran ring is closed on the THC structure and open on the CBD structure, in 
which a hydroxyl group is attached in place of the oxygen atom. The hydroxyl groups are the 
possible sites of derivatisation for MSTFA and TFAA. The underivatised structures of THC and 
CBD are shown in figure 4.05. 
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Figure 4.05 Underivatised structures of 9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Sites available for derivatisation are highlighted in blue. 
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4.4.2 TMS derivatives of THC and CBD 
TMS derivatives are formed by a silyl group attaching to the hydroxyl groups present on the THC 
and CBD molecules. As there are two hydroxyl groups on the CBD structure and only one hydroxyl 
group on the THC structure, different retention time and mass spectrum are elucidated to give THC-
TMS and CBD-2TMS (as shown in chapter 2, figure 2.01). The TMS derivatives of THC and CBD 
are shown in figure 4.06. 
4.4.3 TFAA derivatives of THC and CBD 
As TFAA derivatises in the same manner as MSTFA by attaching to hydroxyl groups on a 
molecule, it would be expected that THC-TFAA and CBD-2TFAA would be produced, with TFAA 
groups attaching at the same hydroxyl sites that MSTFA would attach to on the THC and CBD 
molecules. However, the resultant chromatographic and mass spectral properties for CBD observed 
in figures 4.01 and 4.02 indicated that derivatisation had only occurred at one hydroxyl site rather 
than two.  The TFAA derivative of THC and the proposed TFAA derivative of CBD are shown in 
figure 4.07. 
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Figure 4.06 Structures of trimethylsilyl (TMS) derivatives of 9-tetrahydrocannabinol (THC-TMS)
and cannabidiol (CBD-2TMS). Chemical groups added to the molecule from the derivatising 
reagent are highlighted in red. 
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Figure 4.07 Structures of trifluoroacetic anhydride (TFAA) mixed with 1,1,1,3,3,3-hexafluoro-2-
propanol (HFIP) derivatives of 9-tetrahydrocannabinol (THC-TFAA) and cannabidiol (CBD-
TFAA). Chemical groups added to the molecule from the derivatising reagent are highlighted in 
red. Sites available for derivatisation are highlighted in blue. 
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4.4.4 Dual derivatisation with MSTFA and TFAA 
At this stage it was not known why CBD would not derivatise as expected. The Toxicology Unit 
has experience with producing dual derivatives for drugs of abuse screening in urine (134). It was 
investigated whether it would be possible to manipulate the derivatisation to perform dual 
derivatisation with both TFAA and MSTFA. It was proposed that it may be possible to attach a 
TMS group to the free hydroxyl group on the CBD molecule to elucidate different retention time 
and mass spectrum from THC-TFAA. The proposed reaction is shown in figure 4.08. 
To investigate this an unextracted 100 ng/µL standard of CBD was derivatised in two ways – with 
25 µL MSTFA followed by  25 µL TFAA-HFIP (50:30) and with 25 µL TFAA:HFIP (50:30) 
followed by 25 µL MSTFA. The samples were heated at 70°C for 30 minutes with the 1st reagent,
then the 2nd reagent was added and they were heated at 70 °C for another 30 minutes. The samples
were analysed using the conditions described in 2.2.1. 
No dual derivatives were observed with either combination. For the MSTFA followed by TFAA 
derivatisation no TMS or TFAA peaks were observed. For the TFAA followed by MSTFA 
derivatisation, only the TFAA peaks were observed. Thus this method of dual derivatisation was 
shown not to be a suitable solution. 
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Figure 4.08 Possible dual derivatisation of cannabidiol (CBD) with trifluoroacetic anhydride (TFAA) and N-methyl-N-trimethylsilyl-
trifluoroacetamide (MSTFA) to produce combined TFAA-trimethylsilyl (TMS) derivative. Derivatisation with TFAA highlighted in red, derivatisation 
with MSTFA highlighted in blue. 
158 
 
4.4.5 Two-step re-derivatisation 
Derivatisation with TFAA-HFIP was necessary in order to make THC-COOH detectable using 2D 
GC-MS operated in NCI mode. This was to achieve the sensitivity required for THC-COOH 
concentrations that are present in hair. The concentrations of THC, CBD and CBN found in hair are 
detectable with standard GC-MS operated in EI mode. Derivatisation with MSFTA for THC, CBD 
and CBN to produce the TMS derivatives would achieve the necessary sensitivity for these 
compounds. It was not known at what concentrations 11-OH-THC would be detectable and this was 
not investigated at this stage.  
It was proposed that re-derivatisation with a second reagent following analysis with the first reagent 
would be a suitable method of analysis. To investigate this, two sets of unextracted 100 ng/µL 
standards were prepared each of THC, CBD, CBN and THC-COOH. The first set was derivatised 
with 50 µL of MSTFA by heating at 70°C for 1 hour. The second set was derivatised with 25 µL of 
TFAA-HFIP (50:30) by heating at 70°C for 30 minutes. The second set was dried down completely 
at 40°C under N2 and reconstituted in 50 µL of toluene. Both sets were analysed using the 
parameters described in 2.2.1. 
Following analysis, both sets of standards were dried down completely at 40°C under N2. The first 
set was re-derivatised with 25 µL of TFAA-HFIP (50:30) by heating at 70°C for 30 minutes, dried 
down completely at 40°C under N2 and reconstituted in 50 µL of toluene. The second set was re-
derivatised with 50 µL MSTFA by heating at 70°C for 1 hour. Both sets of standards were re-
analysed using the parameters described in 2.2.1.  
It was determined that it was possible to derivatise firstly with MSTFA, carry out analysis, then re-
derivatise with TFAA-HFIP for THC-COOH detection. TMS derivatives were completely replaced 
by TFAA-HFIP derivatives. It was not possible to derivatise with TFAA-HFIP for THC-COOH 
detection and then to subsequently derivatise with MSTFA and carry out a successful analysis for 
the TMS derivatives. No TMS derivatives were detected after initial derivatisation with TFAA-
HFIP. It was not possible for TMS derivatives to displace TFAA-HFIP derivatives. 
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4.4.6. Two step re-derivatisation for low level detection of THC-COOH 
 A method of derivatisation was developed that could be used firstly to analyse for the THC, CBD 
and CBN with TMS derivatives using standard GC-MS instrumentation in EI mode. The samples 
could then be dried down and re-derivatised with TFAA-HFIP for THC-COOH analysis using 2D 
GC-MS in NCI mode. This was established using high concentration standards (100 ng/µL). It was 
investigated if the same results were achievable at the concentrations that THC-COOH is present in 
hair (pg/µL range) using 2D GC-MS in NCI mode.  
To investigate this, two sets of unextracted standards of THC-COOH were prepared. These 
represented a high concentration (10 pg/µL equivalent to 250 pg total) and a low concentration (0.4 
pg/µL equivalent to 10 pg total) of THC-COOH that would be detected in a 30 mg hair sample. One 
set was derivatised with TFAA-HFIP only, the other set was derivatised with MSTFA and then re-
derivatised with TFAA-HFIP as described previously. Both standards were analysed using 2D GC-
MS with NCI under the conditions described in 4.3.1 – 4.3.3.  
There was a significant loss of sensitivity and distortion of peak shape observed with the re-
derivatised THC-COOH standards in comparison to the single derivatised standards. The difference 
is shown in figure 4.09. The loss in sensitivity coupled with the loss that occurs when drugs are 
extracted from matrix made this an unsuitable method for analysis for low concentrations of THC-
COOH. 
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Figure 4.09 Total Ion Chromatogram for 0.4 pg/µL 11-nor-9-tetrahydrocannabinol-9-carboxylic 
acid (THC-COOH) derivatised with trifluoroacetic anhydride mixed with 1,1,1,3,3,3-hexafluoro-2-
propanol (TFAA-HFIP) only and 0.4 pg/µL THC-COOH derivatised with N-methyl-N-
trimethylsilyl-trifluoroacetamide (MSTFA) followed by TFAA-HFIP. 
 
4.4.7 Summary of derivatisation problems 
For the detection of low concentrations of THC-COOH in hair (picogram range), analysis by 2D 
GC-MS in NCI mode provides a suitable instrumental method.  
Derivatisation with perfluorinated anhydrides coupled with perfluoroalchohols like TFAA-HFIP 
was required to maximize the sensitivity and selectivity that can be achieved with the MS operated 
in NCI mode. It was not possible to analyse for THC and CBD using TFAA-HFIP as the 
derivatising reagent as they have identical retention times and identical mass spectra are produced. 
The concentrations of THC, CBD and CBN present in hair are higher (nanogram range) than those 
of THC-COOH. Detection of these concentrations are achievable by derivatising with MSTFA and 
analyzing on standard GC-MS instrumentation in EI mode.  
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It was investigated whether dual derivatisation or two-step re-derivatisation using MSTFA and 
TFAA-HFIP would be a suitable solution. It was found that derivatisation with MSTFA for the 
analysis of THC, CBD and CBN followed by re-derivatisation with TFAA-HFIP for THC-COOH 
was a suitable solution only at high concentrations of THC-COOH. At the concentration range 
appropriate for hair samples there was too much loss in sensitivity for THC-COOH, meaning this 
derivatisation method was unsuitable. 
 
4.4.8 Discussion of derivatisation problems 
Since the isolation of CBD in the 1940s (135) and the discovery of the correct structure in the 1960s 
(136), it has been reported that CBD cyclizes to 8-THC and 9-THC under acidic conditions (137-
143) by means of a Lewis-acid-catalyzed process (137). The amounts of 8-THC and 9-THC 
produced are dependent on the reaction conditions (i.e strength of acid, reaction time, and 
temperature) (138-140). The perfluorinated anhydrides are highly acidic (they must be removed 
prior to analysis to prevent damage to the GC column). TFAA provides an acidic medium for the 
closure of the open ring present on the CBD structure to a closed pyran ring thus producing THC 
(see figure 4.05 for the structures of THC and CBD). 
In addition to identical retention time and mass spectra, it was also observed that multiple peaks 
were formed following derivatisation with TFAA-HFIP. This has been reported elsewhere, and 
likely represents the isomerisation of 9-THC to 8-THC with an intermediate product also formed 
to give three peaks on the chromatogram (as shown in figure 4.02). This conversion occurs more 
readily with the combined derivatisation mixture of TFAA-HFIP (84%) than with TFAA alone 
(10%) (144). This pattern has been reported with the derivatisation combination 
pentafluoropropionic anhydride and pentafluoroisopropanol (PFPA-PFPOH) (106). The addition of 
chloroform during the derivatisation process can minimise this conversion but does not eliminate it 
in the presence of a perfluoroalcohol (144). This work has shown that the same pattern is observed 
when CBD is derivatised with TFAA-HFIP due to the conversion of CBD to THC. 
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There have been numerous publications detailing the analysis of cannabinoids using perfluorinated 
anhydrides alone or coupled with perfluoroalcohols (22;32;35;38;40-42;52;53;56;57;100;105-
108;115). There are only two publications that report the production of identical retention time and 
mass spectra for CBD and THC when derivatised with PFPA-PFPOH (35;107) and none that detail 
the same reaction with TFAA-HFIP.  
This shows the unsuitability of derivatisation with TFAA-HFIP for the analysis of THC and CBD. 
Even if analysis of THC only is of interest, consideration must be given to the possibility of the 
presence of CBD in a sample when choosing the method of derivatisation and interpreting the 
results. 
 
4.5 Final developed instrumental methods 
The initial aims were to develop a method for the simultaneous analysis of THC, CBD, CBN, 11-
OH-THC and THC-COOH from hair samples using 2D GC-MS. Investigation into the 
derivatisation processes has shown that this was not possible. It was therefore necessary to develop 
a protocol that allowed for the separate instrumental methods of analysis for the TMS derivatives of 
THC, CBD and CBN and the TFAA-HFIP derivative of THC-COOH. At this stage it was not 
known what the most suitable method for 11-OH-THC would be. The addition of 11-OH-THC to 
the instrumental methods is discussed later in section 4.6.1 – 4.6.4. Two options were assessed :- 
(a) It was possible that 2D GC-MS could be used for both analysis of the TMS derivatives of 
THC, CBD and CBN and the analysis of the TFAA-HFIP derivative of THC-COOH. The 
2D GC-MS would be operated in EI mode for THC, CBD and CBN. The 2D GC-MS would 
be operated in NCI mode for the analysis of the TFAA-HFIP derivative of THC-COOH. As 
there is only one 2D GC-MS instrument available in the laboratory, this option would 
involve significant downtime of the instrument to allow for switching between EI and NCI 
mode (approximately 2 days). This would mean there would be a delay between the analysis 
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of samples containing the TMS derivatives and the samples containing the TFAA-HFIP 
derivatives. 
(b) Standard GC-MS instrumentation is readily available in the laboratory in addition to 2D 
GC-MS. Standard GC-MS instrumentation could be used for the analysis of the TMS 
derivatives of THC, CBD, CBN. 2D GC-MS operated in NCI mode could be used for the 
analysis of the TFAA-HFIP derivative of THC-COOH. This option would mean that the 
samples containing the TMS derivatives and the samples containing the TFAA-HFIP 
derivatives could be analysed simultaneously on the two instruments. There would be no 
downtime on the 2D GC-MS for switching between ionisation modes and there would be no 
delay in the analysis of any of the samples. 
Option (b) was chosen as the most suitable protocol. The TMS derivatives were analysed using the 
standard GC-MS parameters described in section 2.2.1. The TFAA-HFIP derivative of THC-COOH 
was analysed using the parameters described in section 4.3.1 – 4.3.3. 
 
4.6 Development of liquid-liquid extraction method 
The aim was to develop a method for the simultaneous analysis of THC, CBD, CBN, 11-OH-THC 
and THC-COOH. In the very early stages of development, an SPE method was used successfully to 
extract THC-COOH from hair. The aim was to include the other cannabinoids into this method. The 
problems with derivatisation meant this was not possible and the extraction method had to be 
redesigned. It was necessary to develop a method that resulted in two separate extracts for analysis. 
One extract was required for the THC, CBD and CBN for derivatisation with TMS followed by 
analysis on standard GC-MS instrumentation. The second extract was required for the THC-COOH 
for derivatisation with TFAA-HFIP and analysis on 2D GC-MS.  
It was proposed to investigate whether adaptation of the LLE extraction used for the extraction of 
cannabinoids from blood described in chapter 2 would be suitable for the extraction of cannabinoids 
from hair. 
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4.6.1 Rationale for adapting the LLE method for blood 
The LLE method for the extraction of cannabinoids from blood involved adjusting the pH of the 
blood by the addition an acidic buffer (pH 4). This allowed all five analytes (THC, CBD, CBN, 11-
OH-THC and THC-COOH) to be extracted into the organic solvent.  
In the preparation of the hair samples for analysis, the cannabinoids are released from the hair by 
the addition of 1M sodium hydroxide (NaOH). This makes the pH of the digested hair strongly 
alkaline. It was proposed that extraction of this solution directly into hexane:ethyl acetate would 
result in the THC, CBD and CBN moving from the digested hair solution into the organic solvent. 
The acidic THC-COOH and 11-OH-THC would remain in the digested hair solution. 
The first organic solvent layer would be removed, dried down and derivatised with MSTFA reagent 
for analysis on standard GC-MS instrumentation. This would be referred to as the ‘A’ extract. 
The remaining digested hair would be acidified by the addition of strong acid and again extracted 
into hexane:ethyl acetate. This would result in the THC-COOH and 11-OH-THC moving into the 
organic solvent. The second organic solvent layer would be removed, dried down and derivatised 
with TFAA-HFIP reagent for analysis on 2D GC-MS. This would be referred to as the ‘B’ extract. 
 
4.6.2 Summary of initial extraction method steps 
Initial extraction steps were based on the normal laboratory protocol for preparation of hair samples 
for analysis. In the early stages, high concentrations were used to ensure detection of the analytes 
prior to constructing full calibration lines at the appropriate concentration ranges. The concentration 
lines were constructed as total ng of drug (or pg for THC-COOH) per sample.  
 
4.6.2.1 Preparation of cannabinoid drug mix 
A working solution of THC, CBD, CBN, 11-OH-THC, THC-COOH and internal standards THC-d3 
and THC-COOH-d3 was prepared at a concentration of 7.5 ng/µL for the initial stages of testing. 
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This gave an equivalent final total concentration of 75 ng total of each analyte per sample. 
Preparation of the final calibration lines is described later in section 4.6.5.1. 
 
4.6.2.2 Preparation of chemical solutions 
A 1 M solution of NaOH was prepared by dissolving 4 g of NaOH pellets in 100 mL of dH2O. A 1 
M solution of phosphate buffer (pH 4) was prepared as described in section 2.3.4. 
 
4.6.2.3 Preparation of extracting solvent 
A mix of hexane and ethyl acetate was used as the extracting solvent. A ratio of 5:1 (hexane:ethyl 
acetate) was used. The volume of extracting solvent prepared was dependent on the number of 
samples to be extracted during each analysis. 
 
4.6.2.4 Preparation of hair standards 
Drug-free hair was provided from volunteers within the laboratory known to be drug free. Prior to 
use, the drug-free hair was shampoo and solvent washed and cut as finely as possible according to 
routine laboratory procedure. Approximately 30 mg of drug-free hair was weighed out for each 
standard required. The appropriate volume of cannabinoid drug mix was added to each hair sample. 
In the initial stages, this was 10 µL of 7.5 ng/µL cannabinoid drug mix. Where blank standards 
were required methanol was added in place of cannabinoid drug mix. 
 
4.6.2.5 Digestion of hair 
To digest (dissolve) the hair completely, 0.5 mL of 1 M NaOH was added to each hair sample and 
heated at 70°C for 30 minutes until the hair was completely dissolved. The samples were allowed to 
cool prior to the next stages. 
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4.6.3 Initial testing of the proposed method 
The initial testing was conducted on 2D GC-MS in EI mode and TMS derivatives only. This was to 
ensure the basic concept of the method worked by analysing high concentration standards. Once it 
was established that the principle was sound, the use of 2D GC-MS in NCI mode for the analysis of 
the TFAA-HFIP derivatives of THC-COOH (‘B’ extracts) was introduced. 
Three 75 ng total hair standards and 1 blank hair standard were prepared in extraction tubes as 
described in section 4.6.2. The pH of the samples was checked and found to be pH 14. Hexane:ethyl 
acetate (5:1, 3 mLs) was added to each sample. The samples were shaken on a rotary mixer for 10 
minutes and centrifuged at 2500 rpm for 10 minutes. The organic solvent layer was transferred to 
clean tubes. The tubes were labeled as ‘A’ extracts. The remaining aqueous layer was acidified to 
approximately pH 4/5 with 1 mL phosphate buffer (pH 4, 1 M) and two drops of glacial acetic acid. 
Hexane:ethyl acetate (5:1, 3 mLs) was added to each sample. The samples were shaken on a rotary 
mixer for 10 minutes and centrifuged at 2500 rpm for 10 minutes. The organic solvent layer was 
transferred to clean tubes. The tubes were labeled as ‘B’ extracts. All samples were dried down to 1 
mL under N2 and transferred to microvials. The samples were dried down completely. All samples 
were derivatised with 25 µL MSTFA as previously described (the B vials were to be derivatised 
with TFAA:HFIP eventually). All samples were analysed on 2D GC-MS in EI mode as described in 
2.2.4-2.2.6. 
 
4.6.4 Results from initial testing 
Initial testing showed that as expected the THC, CBD and CBN were detectable in the ‘A’ extracts 
and THC-COOH was detectable in the ‘B’ extracts. It was found that although 11-OH-THC was 
expected to be extracted into the ‘B’ extract due to its acidic properties, it actually extracted into the 
‘A’ extract. As analysis of 11-OH-THC was of less interest than the other cannabinoids, this was 
not investigated further. 
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It was also found that some THC, CBD, CBN and 11-OH-THC was detectable in the ‘B’ extracts 
(approximately 5% of the abundances detected in the ‘A’ extracts). This was expected as it was not 
possible to remove the organic solvent layer entirely from the aqueous layer during LLE. To 
address this, the volume of hexane:ethyl acetate added was increased from 3 mL to 4 mL to 
minimise the amount of THC, CBD, CBN and 11-OH-THC left with the aqueous layer. 
 
4.6.5 Including the derivatisation for THC-COOH  
It was established that it was possible to perform the analysis by separating the extracts into two. 
The ‘A’ extracts containing THC, CBD, CBN and 11-OH-THC and the ‘B’ extracts containing 
THC-COOH. The initial testing was conducted by derivatising with MSTFA only. It was necessary 
to repeat the process described in 4.6.3 but to derivatise the ‘B’ extracts with TFAA-HFIP and 
analyse them on 2D GC-MS in NCI mode. It was also necessary to ensure that suitable sensitivity 
was achieved for each analyte. This was tested by preparing full calibration lines at the appropriate 
concentration ranges for each analyte. Although 11-OH-THC did not extract as expected, it was 
included in the calibration lines. 
 
4.6.5.1 Preparation of calibration lines 
A calibration line ranging from 2.5 to 200 ng total was constructed for THC, CBD, CBN and 11-
OH-THC. A calibration line ranging from 5 to 400 pg total was constructed for THC-COOH. The 
preparation of the calibration standards is shown in figure 4.10.  
 
4.6.5.2 Preparation of internal standard solution 
THC-d3 was used as the internal standard for THC, CBD, CBN and 11-OH-THC. THC-COOH-d3 
was used as the internal standard for THC-COOH-d3. An intermediate solution (0.2 µg/mL) of 
THC-COOH-d3 was prepared by pipetting 10 µL of THC-COOH-d3 (1 mg/mL) into a 50 mL 
volumetric flask and making it up to volume with MeOH. A working solution containing both 
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THC-d3 and THC-COOH-d3 was prepared by pipetting 10 µL of THC-d3 (100 µg/mL) and 10 µL of 
the intermediate solution of THC-COOH-d3 (0.2 µg/mL) into a vial and making it up to 1 mL with 
MeOH. This gave a final working concentration of 1 ng/µL THC- d3 and 2 pg/µL THC-COOH-d3.  
 
4.6.5.3 Protocol for extraction of full calibration lines 
Drug-free hair was weighed out (approximately 30 mg) for each of the seven standards described in 
figure 4.10. A blank hair standard and a zero standard (blank hair with only internal standard added) 
were also included. The calibration standards were prepared as described in 4.6.5.1 and shown in 
figure 4.10. Internal standard solution was added (75 µL of 1 ng/µL THC-d3 and 2 pg/µL THC-
COOH- d3) to all standards except the blank. MeOH (75 µL) was added to the blank. 
The standards were digested as described in 4.6.2.5. The extraction was carried out as described in 
4.6.3 except for the derivatisation stage. After the ‘A’ and ‘B’ extracts had been transferred to 
microvials and dried down completely under N2, the ‘A’ extracts were derivatised with 25 µL of 
MSTFA and the ‘B’ extracts were derivatised with 25 µL of TFAA-HFIP (50:30). All samples were 
heated at 70°C for 30 minutes. The ‘B’ extracts were allowed to cool, evaporated to dryness under 
N2 at 50°C and then reconstituted in 25 µL of toluene. 
The ‘A’ extracts were analysed on standard GC-MS instrumentation in EI mode for THC, CBD, 
CBN and 11-OH-THC. The ‘B’ extracts were analysed of 2D GC-MS in NCI mode for THC-
COOH. 
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Figure 4.10 Schematic diagram representing the preparation of calibration standards containing 9-tetrahydrocannabinol (THC), cannabidiol 
(CBD), cannabinol (CBN), 11-hydroxy-9-tetrahydrocannabinol (11-OH-THC), 11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH). 
THC/CBD/CBN 
1 mg/mL (1 µg/µL) Purchased 
Stock in MeOH 
11-OH-THC 
100 µg/mL (0.1 ug/µL) 
Purchased Stock in MeOH 
0.2 µg/mL (0.2 ng/µL) 
Intermediate in 50 mL MeOH 
1ng/µL THC/CBD/CBN/11-OH-THC 
2 pg/µL THC-COOH  in 1mL MeOH 
 
25 ng total 50 ng total 10 ng total 5 ng total 2.5 ng total 100 ng total 200 ng total 
500 µL 
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volumetric 
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Stock in MeOH 
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FINAL TOTAL PG THC-COOH 
2 µg/mL (2 ng/µL) 
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10 µL 
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ALL SOLUTIONS 
STORED AT -20°C 
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4.6.6 Results from extraction of full calibration lines 
4.6.6.1 – THC/CBD/CBN/11-OH-THC (‘A’ extracts) 
The linearity was acceptable with r2 > 0.99 for all analytes. The lowest standard analysed (2.5 ng 
total) showed a SN >10 for all analytes. Ion ratios remained consistent across the calibration range 
for CBD, CBN and 11-OH-THC. There was no chromatographic interference from endogenous 
compounds present in the zero or blank standards for CBD, CBN and 11-OH-THC. The ion ratio 
was distorted on the lowest standard for THC due to a small amount of co-eluting m/z 371. The 
extracted ion chromatograms for the blank and each compound in the lowest calibration standard 
(2.5 ng total) extracted from hair are shown in figure 4.11.  
 
4.6.6.2 THC-COOH (‘B’ extracts) 
Analysis of the THC-COOH extracts was not as successful as the extracts for THC, CBD, CBN and 
11-OH-THC. There was significant background interference present for the ions that were used to 
detect each analyte (m/z 590, 422, 423 for THC-COOH and m/z 593, 425, 426 for THC-COOH-d3). 
This made it difficult to distinguish the lower concentrations (up to 50 pg total) from the 
background interferences. The extracted ion chromatograms for the blank and each of the 
calibration standards extracted from hair are shown in figure 4.12. 
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Figure 4.11 Extracted ion chromatogram of a blank (left hand traces) and 2.5 ng total standard 
(right hand traces)  of (a) cannabidiol, (b) 9-tetrahydrocannabinol, (c) cannabinol and (d) 11-
hydroxy-9-tetrahydrocannabinol extracted from 30 mg hair.  
(a) (a)
(b) (b)
(c) (c)
(d) (d)
Blank extracted 2.5 ng total extracted
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Figure 4.12 Extracted ion chromatogram of 11-nor-9-tetrahydrocannabinol-9-carboxylic acid for 
(a) blank, (b) 5 pg total, (c) 10 pg total, (d) 20 pg total (e) 50 pg total, (f) 100 pg total, (g) 200 pg 
total and (h) 400 pg total. 
(a) (b)
(c) (d)
(e) (f)
(g) (h)
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4.6.6.3 Testing ‘A’ extracts for absence of THC-COOH 
It was important to ensure that no THC-COOH was being removed from the digested hair during 
the LLE for THC, CBD, CBN and 11-OH-THC. To assess this, the extraction was carried out as 
described with a full calibration line, but the ‘A’ extracts were derivatised with TFAA-HFIP instead 
of MSTFA and analysed for THC-COOH on 2D GC-MS. It was shown that no THC-COOH was 
present in any of the ‘A’ extracts, confirming that all THC-COOH remained in the aqueous digested 
hair after LLE and that no loss in recovery was occurring due to the LLE for THC, CBD, CBN and 
11-OH-THC. 
 
4.6.7 Adjustment of extraction of THC-COOH 
It was not possible to get acceptable detection of THC-COOH by performing LLE. Too much 
background interference was present which made it difficult to distinguish the THC-COOH and 
THC-COOH-d3 peaks from the background. 
To clean up the background, it was proposed to adjust the second part of the LLE extraction (for 
THC-COOH) to SPE. The use of a strong anion exchange cartridge would hypothetically allow for 
additional clean up steps to be performed without losing the sensitivity for THC-COOH.  
 
4.7 Development of LLE followed by SPE  
4.7.1 Rationale for LLE followed by SPE 
The first LLE stage would be carried out to extract THC, CBD, CBN, 11-OH-THC as previously 
described. The remaining aqueous digested hair contains THC-COOH in the ionised form. Addition 
of the remaining aqueous digested hair to strong anion exchange cartridges (which are positively 
charged) in this state should allow the THC-COOH (which is negatively charged) to bind to the 
cartridge. Wash steps with dH2O and methanol would remove some of the unwanted matrix 
components without washing out the bound THC-COOH from the cartridges. The cartridges could 
then be acidified by the addition of an acidified elution solvent to neutralize the THC-COOH and 
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allow it to be eluted. This extract could then be dried down and derivatised as previously described 
for analysis on 2D GC-MS. 
 
4.7.2 General SPE procedure 
The general laboratory protocol followed for SPE procedures is described below. 
- The chosen SPE cartridges are attached to a vacuum manifold 
-  The SPE cartridges are conditioned with 2 mL MeOH followed by 2 mL dH2O and  
depending on the application 2 mL of buffer to adjust the pH of the cartridges. 
-  The supernatant of the prepared samples is added to the cartridges and allowed to pass  
through under atmospheric pressure. 
-  The chosen wash stages are carried out (may include a dH2O wash and/or a solvent wash). 
-  The cartridges are dried under full vacuum (length of time dependent of cartridge type). 
-  The cartridges are acidified or basified dependent on the analytes of interest 
-  An elution solvent mixture is applied to elute the analytes of interest from the cartridges (the  
    previous step may be combined with this last step).   
 
4.7.3 Protocol for extraction 
The protocol was initially tested with three sets of a blank, zero, low (10 pg total THC-COOH) and 
high (400 pg total THC-COOH) standard. The initial sample preparation steps in 4.6.2 were 
followed as described. The LLE procedure in 4.6.3 was followed to extract THC, CBD, CBN and 
11-OH-THC. These extracts were dried down and derivatised with MSTFA as described previously. 
The extraction was altered to include SPE from this point. The remaining aqueous layer (digested 
hair in 1 M NaOH containing THC-COOH and THC-COOH-d3) was diluted with 3 mLs of dH2O. 
The samples were vortexed and centrifuged for 10 minutes at 2500 rpm. The supernatant was 
applied to Bond Elut Certify II cartridges previously conditioned with 2 mL MeOH followed by 2 
mL dH2O. The supernatant was allowed to pass through the cartridges under atmospheric pressure. 
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Different wash steps were tested to identify which gave the cleanest results. The following wash 
steps were tested :- 
- 2 mLs dH2O only 
- 2 mLs dH2O followed by 1 mL MeOH 
- 2 mLs MeOH only 
The washes were allowed to pass through the cartridges under atmospheric pressure. The cartridges 
were dried under full vacuum for 5 minutes. The THC-COOH and THC-COOH-d3 was eluted from 
all samples with a mix of acidified hexane:ethyl actetate (80:20 + 1% glacial acetic acid). The 
extracts were dried down and derivatised with TFAA-HFIP as previously described. 
The final TMS derivatised extracts for THC, CBD, CBN and 11-OH-THC were analysed on 
standard GC-MS instrumentation. The final TFAA-HFIP derivatised extracts for THC-COOH were 
analysed on 2D GC-MS with NCI detection. 
An equivalent set of samples were extracted using the full LLE method at the same time in order to 
directly compare efficacy of the extraction procedures. 
 
4.7.4 Results for THC-COOH extracted by LLE followed by SPE 
The final extracts that were produced using SPE visually looked much cleaner than the extracts that 
were produced using full LLE. The SPE extracts that included a MeOH wash looked cleaner than 
the SPE extracts that were washed with dH2O only. There was no difference in appearance between 
the MeOH only wash and the dH2O followed by MeOH wash. 
Analysis of the peak abundances and background noise produced for each wash step was compared 
to that produced with the full LLE extracts. It was found that the dH2O wash did not significantly 
clean up the background, but washing with MeOH did. Washing with MeOH also reduced the peak 
sizes but the S:N was much better than that observed with full LLE extracts, or with SPE with a 
dH2O wash only. 
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It was decided to use the wash step that included MeOH only as there was no further improvement 
when a dH2O wash was included in addition to the MeOH wash. It was found that reducing the 
volume of MeOH to 0.5 mL improved the size of the peaks but still cleaned up the background as 
well as using 1 mL of MeOH. A comparison of the improvement in background observed for full 
LLE and the chosen LLE followed by SPE method is shown in figure 4.13 (for THC-COOH) and 
figure 4.14 (for THC-COOH-d3). 
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Figure 4.13 Extracted ion chromatograms for full LLE extraction (left hand traces) and LLE 
followed by SPE with 0.5 mL MeOH wash (right hand traces) for (a) blank, (b) 10 pg total, (c) 400 
pg total for the trifluoroacetic anhydride hexafluorisopropanol derivative of 11-nor-9-
tetrahydrocannabinol-9-carboxylic acid (THC-COOH). 
(a) (a)
(b) (b)
(c) (c)
LLE extraction only LLE followed by SPE with 0.5mL MeOh wash
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Figure 4.14 Extracted ion chromatograms for full LLE extraction (left hand traces) and LLE 
followed by SPE with 0.5 mL MeOH wash (right hand traces) for (a) blank and (b) internal standard 
200 pg total for the trifluoroacetic anhydride hexafluoroisopropanol derivative of 11-nor-9-
tetrahydrocannabinol-9-carboxylic acid-d3 (THC-COOH-d3). 
 
 
The method was further tested with a full calibration line.  It was not possible to establish what the 
likely LOD of the method would be for THC-COOH at this stage, so it was decided to adjust the 
lower end of the calibration line to include more points. The 10 ng total/20 pg total standard was 
removed and a 7.5 ng total/15 pg total and 15 ng total/30 pg total standard were included in the 
calibration line described in figure 4.10. The final calibration lines included the points 5, 10, 15, 30, 
50, 100, 200 and 400 pg total for THC-COOH and 2.5, 5, 7.5, 15, 25, 50, 100 and 200 ng total for 
THC, CBD, CBN and 11-OH-THC. The linearity for THC-COOH was acceptable with r2 > 0.99. 
The extracted ion chromatograms for each calibration point, including the blank are shown in figure 
4.15. 
(a) (a)
(b) (b)
LLE extraction only LLE followed by SPE with 0.5mL MeOh wash
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Figure 4.15 Full calibration line for the trifluoroacetic anhydride-1,1,1,3,3,3-hexafluorisopropanol derivative of 11-nor-9-tetrahydrocannabinol-9-
carboxylic acid (THC-COOH) with the chosen LLE followed by SPE method. Calibration points are (a) blank, (b) 5 pg total, (c) 10 pg total, (d) 15 pg total, 
(e) 30 pg total, (f) 50 pg total, (g) 100 pg total, (h) 200 pg total and (i) 400 pg total. 
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
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4.8 Summary of developed method 
The work described up to this point had demonstrated the development of a working method for the 
extraction and analysis of THC, CBD, CBN, 11-OH-THC and THC-COOH from hair samples. The 
method involved preparation of the hair samples followed by digestion with 1 M NaOH. The 
digested hair samples were subjected to LLE at pH 14 to extract THC, CBD, CBN and 11-OH-THC 
from the digested hair solution. These extracts were dried down and derivatised with MSTFA for 
analysis by standard GC-MS instrumentation. Acceptable linearity was observed from calibration 
lines between 2.5 and 200 ng total. The LOD at this point was determined as 2.5 ng total. 
The remaining digested hair solution was subsequently subjected to SPE for the extraction of THC-
COOH from the digested hair solution. SPE was carried out using Bond Elut Certify II cartridges 
and included a MeOH wash stage to clean up the background interferences observed on the 
chromatograms. The THC-COOH and THC-COOH-d3 were subsequently eluted from the 
cartridges, dried down and derivatised with TFAA-HFIP for analysis on 2D GC-MS with NCI 
detection. Acceptable linearity was observed from calibration lines between 5 – 400 pg total. It was 
not possible to determine what the LOD would be at this point, as detection at the low calibration 
points (5,10,15 and 30 pg total) was variable. 
 
4.9 General discussion of developed method 
The initial aim for the analysis of cannabinoids in hair was to develop a method that was capable of 
analysing for THC, CBD, CBN, 11-OH-THC and THC-COOH simultaneously using 2D GC-MS. 
Due to the difficulties encountered with the derivatisation this was not possible. It was necessary to 
design an extraction method that would allow for the separate derivatisation of THC, CBD, CBN 
and 11-OH-THC using MSTFA to be analysed on standard GC-MS and THC-COOH using TFAA-
HFIP to be analysed on 2D GC-MS. 
For the analysis of THC, CBD and CBN, an acceptable LOD of 2.5 ng total was observed. For a 
hair sample weighing 30 mg, this equates to 0.08 ng/mg of hair. The cut-off concentration 
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recommended by the SOHT for THC is  0.1 ng/mg (34).  The SOHT do not have a recommended 
cut-off for CBD and CBN.  Previously published methods that have analysed for THC, CBD and 
CBN have reported limits of detection ranging from 0.0002 to 2.5 ng/mg for THC, 0.005 to 0.9948 
ng/mg for CBD and 0.002 to 0.991 ng/mg for CBN (35;36;38;40-46;52;54;57). 
Although 11-OH-THC did not extract with THC-COOH as anticipated, which would allow for 
analysis by 2D GC-MS to achieve better sensitivity, an LOD of 2.5 ng total (0.08 ng/mg) was 
observed. This was better than the only reported method in the literature for the analysis of 11-OH-
THC in hair which had an LOD of 0.5 ng/mg (53). The SOHT do not have a recommended cut-off 
concentration for 11-OH-THC and to date, there have been no reports of detectable 11-OH-THC in 
hair specimens. 
Whilst to date there have only been two methods previously published that have analysed for all 
four compounds together and this study had better LOD and LOQ for THC-COOH (35;36), further 
work was required to improve the detection of THC-COOH as it was unclear what the LOD would 
be. It was anticipated that the LOD would be between 10 and 30 pg total. This would equate to 
between 0.3 pg/mg and 1 pg/mg based on a 30 mg hair sample. The SOHT recommends a cut-off 
concentration of 0.2 pg/mg. Other previously published methods that did not analyse for all four 
compounds have reported LODs for THC-COOH ranging between 0.001 and 100 pg/mg (37-
42;47;48;50-53;55;56;113).  
Further work was required to validate the method and it would be desirable to achieve a lower LOD 
for THC-COOH to fall in-line with the recommended cut-off by the SOHT. However, the method 
was in an acceptable working state that would allow for the analysis of authentic hair specimens as 
discussed in the next chapter. 
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CHAPTER 5: APPLICATION OF METHOD FOR 
ANALYSIS OF CANNABINOIDS IN HAIR TO 
AUTHENTIC HAIR SPECIMENS 
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5.1 Introduction 
Up to this stage, the method developed for the measurement of cannabinoids in hair samples had 
only been tested with hair samples spiked with methanolic drug standards. It was therefore 
necessary to investigate its utility when applied to authentic hair specimens from self-reported 
cannabis users to ensure that the method was practical and able to detect cannabinoids in actual hair 
specimens. I also investigated whether there was any correlation between the concentrations of each 
cannabinoid and the self-reported use of cannabis by the users that the specimens were obtained 
from.  
 
5.2 Authentic hair specimens 
Analysis of authentic hair specimens was requested by researchers at Bristol University as part of 
the Avon Longitudinal Study of Parents and Children. The specimens provided were from self-
reported cannabis users with a range of cannabis use. Thirty one specimens were received by post 
and had already been labelled with an anonymous unique identifier number. Upon receipt, 
specimens were stored at room temperature prior to analysis. The hair specimens were split into 
four batches for analysis. 
 
5.3 Preparation of hair specimens 
5.3.1 Condition of the hair specimens 
Each hair specimen was visually inspected and the colour, total length and condition of the hair 
noted. It was also noted if the cut end (closest to the scalp) was marked and if the hair strands were 
aligned. All hair specimens were segmented into sections and each section placed in a separate 
specimen tube. The 1st section representing the most recent growth was 3 cm for all hair specimens 
with exception of any that were less that 3 cm in total length, or were unable to be aligned properly. 
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For these specimens, the 1st segment was representative of the total length of the hair specimen. A 
summary of the properties of each hair specimen are shown in table 5.01. 
 
5.3.2 Washing the hair specimens 
After the hair specimens had been segmented, it was necessary to solvent wash them. The normal 
laboratory protocol includes shampoo washing for post-mortem hair samples, but as these were 
specimens from living people and were relatively clean, shampoo washing was not necessary. 
Solvent washes were carried out to remove any drug present on the hair surface. The solvent washes 
were kept for analysis. The washing protocol was as follows :- 
1. Three mL of DCM was added to each specimen tube containing the hair specimens 
2. The DCM was swirled around the hair specimens and left to sit for 1 – 2 minutes. 
3. The DCM was removed into a clean specimen tube and labelled as wash DCM 1. 
4. This was repeated with a second aliquot of DCM (3 mL) which was subsequently labelled as 
wash DCM 2. 
5. A final rinse of 1 mL of acetone (to help dry the hair) was added to the specimen tubes, 
swirled around the hair specimens and removed immediately. This rinse was discarded. 
6. The hair specimens were left to dry completely overnight. 
 
5.3.3 Cutting the hair specimens 
Once the hair specimens were completely dry, they were cut as finely as possible into 
approximately 1-2 mm pieces with sharp scissors in the specimen tube. It was important to cut the 
hair as finely as possible as this would aid digestion of the hair. The scissors were wiped clean with 
methanol inbetween the cutting of each hair segment. 
 
 
185 
 
5.3.4 Weighing out the hair specimens 
Each hair specimen was weighed out into a silanised 5 mL screw cap tube. Approximately 30 mg 
was weighed out for each hair specimen. The exact amount weighed out was recorded for each 
specimen. Approximately 30 mg of drug-free hair was also weighed out (9 aliquots) for each 
calibration standard. 
 
5.3.5 Preparation of calibration standards and addition of internal standards 
Once the hair was weighed out, a full calibration line was prepared to run alongside the hair 
specimens as previously described in figure 4.10 with the inclusion of two additional points as 
discussed in section 4.7.4.  Internal standard solution (75 µL) containing 1 ng/µL THC-d3 and 2 
pg/µL THC-COOH-d3 was added to each calibration standard and authentic hair specimen with the 
exception of the blank.  
 
5.3.6 Digestion and extraction 
The digestion and extraction was conducted according to the method that was developed in chapter 
4. The final protocol that was followed is shown in figure 5.01. 
 
 
 
 
 
 
 
 
 
 
186 
 
 
Table 5.01 Visual properties of hair specimens 
 
Specimen 
No. 
Visual inspection 1st 
section 
length 
(cm) 
Other comments Cut ends 
marked/aligned Colour 
Total 
Length 
(cm) 
CA1 Marked with red dot/aligned Medium brown 7.5 3  
CA2 Cut ends not aligned - 
aligned in lab Dark brown > 18 
3cm 
(approx 
20% 1 
cm) 
Long and wavy 
CA3 Marked with red dot/aligned Medium brown 7 3  
CA4 Marked with red dot/aligned 
Medium-dark 
brown 3 3  
CA5 Marked with red dot/aligned Medium brown 5 3  
S01 Marked with red dot/aligned Dark brown 14.5 3  
S02 Marked with red dot/aligned Medium brown 20.5 3  
S03 Marked with red dot/aligned Medium brown 3.5 3.5  
S04 Marked with red dot/aligned 
Medium brown, 
pink/red dye, 
grey 
35 3 
 
S05 Marked with red dot/aligned 
Light 
brown/auburn 11 3  
S06 Marked with red dot/aligned 
Dark brown/red 
hair 8 3  
S07 Marked with red dot/aligned Light brown 2-2.5 2 
3 separate 
sections in foil - 
unknown if 
continuous 
growth 
S08 Cut ends not aligned Medium brown 2.5 2.5 
 
S09 Marked with red dot/aligned Medium brown 12 3  
S10 Marked with red dot/aligned Light brown 40 3 
wavy, long, some 
dyed hair 
S11 Marked with red dot/aligned Ash 9 3  
S12 Marked with red dot/aligned Medium brown 15 3  
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Table 5.01 Continued Visual properties of hair specimens 
 
Specimen 
No. 
Visual inspection 1st 
section 
length 
(cm) 
Other comments Cut ends 
marked/aligned Colour 
Total 
Length 
(cm) 
S13 Marked with red dot/aligned White 2 2 
very fine - like 
cat hair 
S14 
Marked with red dot, not 
very well aligned - 
aligned in lab as best as 
possible 
Dark brown at 
roots, 10cm 
onwards dyed 
blonde 
30 3 
 
S15 Marked with red dot - not 
aligned 
Dark 
brown/black 1-3 3 
varying lengths - 
mostly 3 cm 
S16 Marked with red dot/aligned 
Light brown 
some grey 11 3  
S17 
Marked with red dot, not 
well aligned - aligned in 
lab as best as possible 
Medium brown 12 3 
 
S18 Marked with red dot/aligned Dark brown 2.5 2.5  
S19 
Cut end not aligned - 
aligned in lab as best as 
possible 
Dyed 
purple/plum 9 3  
S20 Marked with red dot/aligned 
Light brown and 
grey 34 3 long and tangled 
S21 Marked with red dot/aligned 
Light - medium 
brown 2.5 2.5 
varying lengths 
1-2.5cm, mostly 
2.5 cm 
S22 Marked with red dot/aligned Grey 7 3  
S23 Not aligned, unable to 
align Light brown 9 9 
hair kinked and 
not in packet 
properly 
S24 Not aligned - aligned in lab as best as possible 
Light brown/dark 
blonde ends 18 3  
S25 Not aligned - aligned in lab as best as possible Light brown 16 3  
S26 Not aligned, unable to 
align Medium brown 5 5 
hair bent in 
middle 
 
 
 
 
 
 
 
 
 
188 
 
 
Figure 5.01 Protocol for digestion and extraction of hair specimens
TO ALL CALIBRATORS AND AUTHENTIC HAIR SPECIMENS
DIGESTION
(a) 0.5 mL of 1M sodium hydroxide added
(b) Tubes capped
(c) Heated at 70°C for 30 minutes (or until completely dissolved) in a heating block
(d) Removed from heating block and left to cool
EXTRACTION
1. LLE
(a) 4 mLs of hexane: ethyl acetate (5:1) added
(b) Shaken on rotary mixer for 10 minutes
(c) Centrifuged at 2500 rpm for 10 minutes
2. Organic solvent layer contains THC, THC-d 3 , CBD, CBN and 11-OH-THC 3. SPE - Remaining aqueous layer contains THC-COOH and THC-COOH-d 3
(a) Organic solvent layer transferred to fresh screw cap tube (a) 3 mLs dH2O added
(b) Organic solvent layer dried down under N2 at 50°C to approximately 1 mL (b) Samples shaken for 10 minutes on rotary mixer
(c) Organic solvent layer (1 mL) transferred to GC vial (c) Samples centrifuged for 10 minutes at 2500 rpm
(d) Organic solvent layer dried down completely under N2 at 50°C (d) Bond Elut Certify II cartridges conditioned with 2 mL MeoH then 2 mLs dH2O
(e) GC vials capped (e) Supernatant from samples applied to cartridges
(f) 25 µL TMS added with syringe through cap septum (f) Cartridges dried on full vacuum for 30 seconds
(g) Samples heated at 70°C for 30 minutes then cooled (g) 0.5 mL MeOH applied to cartridges
(h) 1 µL injected onto standard GC-MS (h) Cartridges dried on full vacuum for 5 minutes
(i) 3 mLs hexane:ethyl acetate:glacial acetic acid (80:20:1) applied to cartridges to elute 
(j) Eluate dried down under N2 at 50°C to approxiamtely 1 mL
(k) Eluate transferred to GC vial and dried down completely under N2 at 50°C
(l) 25 µL TFAA:HFIP (50:30) added to vials
(m) GC vials capped
(n) Samples heated at 70°C for 30 minutes then cooled
(o) TFAA:HFIP evaporated to dryness under N2 at 50°C then cooled
(p) Samples reconstitued with 25 µL toluene and capped
(q) 2 µL injected onto 2D GC-MS
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5.3.7 Analysis of the solvent washes 
For each hair specimen, two solvent washes were produced during the preparation of the hair 
specimens. These were labelled DCM 1 and DCM 2. 
Prior to analysis of these hair specimens no work had been undertaken to determine the best method 
of analysis for the solvent washes.  
It is common practice to analyse the solvent washes if analysis of the hair specimen produces a 
positive result. This is to exclude the possibility of external contamination, which could be present 
either from exposure to cannabis smoke (which would give rise to the presence of THC, CBD and 
CBN on the hair surface) or from sweat or sebum surrounding the hair (which may give rise to 
THC, CBD, CBN, 11-OH-THC and THC-COOH on the hair surface). If there were cannabinoids 
present due to contamination from sweat or sebum, it would be expected that the concentration of 
the metabolites would be higher in the washes than in the hair itself. It was therefore anticipated that 
analysis by standard GC-MS for the TMS derivatives of all analytes would be sufficient to detect 
the presence of cannabinoids in the washes.  
 
5.3.7.1 Preparation of solvent washes for analysis 
When the solvent washes had evaporated to less than 1 mL in the specimen tube, the DCM was 
transferred to a microvial. The DCM was allowed to evaporate completely. The vials were capped 
and 25 µL of MSTFA reagent added. The washes were heated at 70°C for 30 minutes. The washes 
were allowed to cool and 1 µL injected onto standard GC-MS for analysis for all analytes.  
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5.4 Calculation of results from analysis of authentic hair specimens 
5.4.1 Construction of calibration lines 
Agilent Chemstation software was used to calculate the abundance (area under the chromatographic 
peak) for each analyte and internal standard. Microsoft Excel was used to calculate the % peak area 
ratios (% PAR) for each analyte (peak area for analyte/peak area for internal standard * 100) and to 
construct the calibration lines using the equation y = mx + c. 
The calibration lines for each analyte were constructed as ng total (for THC, CBD, CBN and 11-
OH-THC) and pg total (for THC-COOH) rather than as ng/mg and pg/mg. This is routine procedure 
in the laboratory as it makes the calculations simpler and allows for varying weights of hair.  
Two calibration lines were constructed for each analyte. For THC, CBD, CBN and 11-OH-THC, a 
lower calibration line had to be constructed in order to ensure accuracy at the lower end of the 
calibration range. Calibration lines were constructed for the total range (2.5 – 200 ng total) and for 
the lower range (2.5 – 50 ng total). For THC all results were calculated using the lower calibration 
line with the exception of 2 cases that were above 50 ng total where the full calibration line was 
used. For CBD and CBN the lower calibration line was used to calculate all results. THC, CBD and 
CBN that were identified qualitatively but calculated as less than 2.5 ng total were reported as 
positive (less than 2.5 ng total). 
For THC-COOH, the sensitivity was poor for the low standards, so a calibration curve starting from 
the 15 pg total standard was constructed (up to 400 pg total). Representative calibration lines for 
each analyte are shown in figure 5.02, 5.03 and 5.04. 
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Figure 5.02 Representative calibration lines for 9-tetrahydrocannabinol (THC) plotted as the total 
concentration (ng total) against the % peak area ratio (%PAR) for concentration range (a) 2.5 - 50 
ng total and (b) 2.5 - 200 ng total.  
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R² = 0.9989
0
50
100
150
200
250
300
350
400
450
0 50 100 150 200 250
%PAR
Total THC (ng)
y = 1.7215x + 4.3973
R² = 0.9996
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60
%PAR
Total THC (ng)
192 
 
 
 
Figure 5.03 - Representative full calibration lines plotted as the total concentration (ng total) 
against the % peak area ratio (%PAR) over the concentration range 2.5 – 50 ng total for (a) 
cannabidiol (CBD) and (b) cannabinol (CBN). 
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Figure 5.04 - Representative calibration lines plotted as the total concentration against the % peak 
area ratio (%PAR) for (a) concentration range 2.5 - 50 ng total (ng) 11-hydroxy-9-
tetrahydrocannabinol (11-OH-THC) and (b) concentration range 15-400 pg total (pg) 11-nor-9-
tetrahydrocannabinol-9-carboxylic acid (THC-COOH). 
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5.4.2 Qualitative identification of analytes 
5.4.2.1 THC/CBD/CBN/11-OH-THC 
Positive identification of these analytes was confirmed by the presence of the three SIM ions in the 
mass spectrum at the correct RT (± 0.15 min) and in the correct ratio (± 20% of the calibrator ion 
ratio) (145).  
 
5.4.2.2 THC-COOH 
Due to the softer ionization that occurs in NCI compared to EI, positive identification of THC-
COOH was different to the other analytes. Positive identification was based on the criteria set by 
Moore et al (50) which stated that the three SIM ions in the mass spectrum should be present within 
30% of the calibration ratio. The peak should be present at the correct retention time compared to 
the internal standard and should be compared to known controls/calibrators in the same batch. 
There should also be adequate chromatographic removal of other peaks arising from the matrix. 
 
5.4.3 Calculation of concentrations in authentic specimens 
Once an analyte had been identified as present qualitatively, the peak area of the analyte and 
internal standard was calculated by the Agilent Chemstation software. The %PAR of the analyte to 
internal standard in the hair specimen was calculated and input into the y = mx + c equation 
resulting from the calibration line previously constructed using Microsoft Excel. This gave a 
calculated value for the total concentration of drug in the whole weight of the hair sample. The 
concentration of analyte per mg of hair was then calculated. A representative calculation for the 
amount of THC calculated in the one of the specimens is shown in figure 5.05. 
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Figure 5.05 Representative calculation of the concentration of 9-tetrahydrocannabinol (THC) 
present in the specimen S01, (a) peak areas for the deuterated internal standard (THC-d3)  and THC 
are used to calculate the % peak area ratio (%PAR) in each calibration standard, (b) each calibration 
point is plotted against the %PAR to construct a calibration line in y=mx+c format, (c) %PAR is 
calculated for the hair specimen, (d) the total THC concentration (ng total) in the hair specimen is 
calculated followed by the concentration of THC (ng) per mg of hair. 
(a)
CALIBRATION STANDARDS AREA DATA FROM AGILENT CHEMSTATION
Total [THC]  THC-d3 (m/z 389) THC (m/z 371) %PAR
(ng total) Abundance Abundance
0 54496 0 0
2.5 55822 5099 9.13
5 56215 7626 13.57
7.5 54628 9407 17.22
15 55480 16355 29.48
25 62003 29013 46.79
50 63147 57435 90.95
100* 64545 118717 183.93
200* 88430 342362 387.16
*not used in calibration line
(b)
(c) Specimen S01 area data from Agilent Chemstation
THC-d3 (m/z 389) THC (m/z 371) %PAR
Abundance Abundance
70483 28127 39.91
(d)
y = 39.91
m = 1.721 x = (y - c)/m  x = 20.6 ng total THC
c = 4.397
20.6/29.93
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5.4.4 Statistical Analysis 
Statistical analysis was performed using IBM SPSS Statistics Version 20. 
Statistical analysis was performed on the concentrations of THC, CBD, CBN and THC-COOH 
detected in the hair specimens. The data was found not to follow a normal distribution. Therefore 
non-parametric tests were used. 
In section 5.5.3, the Mann Whitney U test was used to assess if there was any significant difference 
in distribution of the concentrations of THC, CBD, CBN and THC-COOH detected between weekly 
and daily users. Spearman’s Rank Correlation Test (1-tailed) was used to assess whether the 
concentrations of THC, CBD, CBN and THC-COOH correlated with the number of joints smoked 
by each user. 
A p value < 0.05 was considered significant. 
 
5.5 Results from analysis of authentic hair specimens 
For each batch of samples, the solvent washes for the authentic hair specimens were examined to 
establish the presence of any surface contamination and the concentrations of each analyte in the 
authentic hair specimens were calculated. Correlations between the concentrations detected and the 
self-report data obtained concerning the use of cannabis for each authentic specimen were 
investigated. 
 
5.5.1 Results of analysis of the washes 
Analysis of the washes was conducted on standard GC-MS instrumentation. No CBD or THC-
COOH was detected in any of the washes. THC was detected in the first wash (DCM1) for two 
cases (S06 and S09). The concentrations were in the region of or below 2.5 ng total (the lowest 
standard). CBN was detected in the region of or below 2.5 ng total in 10 out of 31 specimens. One 
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case (S13) had CBN present in both washes (DCM1 and DCM2) at a concentration greater than 2.5 
ng total.  
 
5.5.2 Concentrations detected in authentic hair specimens 
Of the 31 hair specimens analysed, only four contained no detectable cannabinoids or metabolites. 
All specimens were negative for 11-OH-THC as expected. THC, CBD and CBN were detected in 
22, 20 and 22 specimens respectively. THC-COOH was detected in 14 specimens. All four analytes 
were detected in 12 specimens.  
For the four specimens in which no analytes were detected, ingestion or exposure to cannabis could 
not be confirmed. For the 14 specimens where THC-COOH was detected, this confirmed ingestion 
of cannabis. For the remaining 13 specimens, there were four specimens that had peaks present 
indicative of THC-COOH which would establish ingestion, however, the concentrations were less 
than 30 pg total and the peaks did not meet the criteria stated for qualitative identification for THC-
COOH stated in 5.4.2.2, and thus it was not possible to confidently identify the THC-COOH. 
A summary of the range and mean concentrations detected for each analyte are shown in table 5.02. 
The concentrations of the cannabinoids detected in each hair specimen and the interpretation of the 
results summarised as ingestion, exposure or no ingestion/exposure are shown in table 5.03.  
The four specimens where ingestion was possible are written in blue. Cases that were confirmed as 
ingestion are written in green. Cases where only exposure could be confirmed are written in red. 
Where no exposure or ingestion could be confirmed, these cases are written in black.  
Figure 5.06 displays the extracted ion chromatograms for a hair specimen that was positive for 
THC, CBD, CBN and THC-COOH – confirming ingestion of cannabis. For comparison, the 
extracted blank and two lowest extracted standards for each analyte are also shown. 
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Table 5.02 Summary of the concentrations (ng/mg) detected for 9-tetrahydrocannabinol (THC), 
cannabidiol (CBD), cannabinol (CBN) and 11-nor-9-tetrahydrocannabinol-9-carboxylic acid 
(THC-COOH) in 31 authentic hair specimens from regular cannabis users.  
 
 
* When THC, CBD or CBN were qualitatively identified but calculated below the bottom standard 
 
 
 
Analyte Range Mean Median Pos < 2.5 ng total* No. Positive
THC (ng/mg) 0.15 - 2.23 0.65 0.39 2 22
CBD (ng/mg) 0.09 - 0.85 0.33 0.22 2 20
CBN (ng/mg) 0.09 - 0.34 0.16 0.15 9 22
THC-COOH (pg/mg) 1.08 - 5.04 2.30 2.08 n/a 14
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Table 5.03 Concentrations of 9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN) and 11-nor-9-tetrahydrocannabinol-9-
carboxylic acid (THC-COOH) detected in each hair specimen and summary of the interpretation of the results. Text is coloured according to the 
interpretation, black text: no exposure/ingestion, red text: exposure, green text: ingestion, blue text: possible ingestion which could not be confirmed. 
Specimen 
No. 
Section 1 
Length 
(cm) 
Weight 
(mg) 
 
Concentration (ng/mg) Concentration (pg/mg) 
 Interpretation of results 
 
THC CBD CBN THC-COOH 
 
    
     
 
CA1 3 29.69 
 
ND ND ND ND 
 
No exposure/ingestion in past 3 months 
CA2 3 29.99 
 
ND ND ND ND 
 
No exposure/ingestion in past 3 months 
CA3 3 29.50 
 
ND ND ND ND 
 
No exposure/ingestion in past 3 months 
CA4 3 29.92 
 
ND 0.22 <2.5 ng total ND 
 
Exposure in past 3 months 
CA5 3 29.08 
 
0.19 ND <2.5 ng total ND 
 
Exposure in past 3 months 
S01 3 29.93 
 
0.69 0.12 0.15 3.08 
 
Ingestion in past 3 months 
S02 3 29.07 
 
<2.5 ng total <2.5 ng total <2.5 ng total 3.23 
 
Ingestion in past 3 months 
S03 3.5 29.46 
 
0.23 0.83 <2.5 ng total 1.6 
 
Ingestion in past 3.5 months 
S04 3 29.34 
 
0.15 0.54 0.09 1.22 
 
Ingestion in past 3 months 
S05 3 31.52 
 
ND ND <2.5 ng total ND 
 
Exposure in past 3 months 
S06 3 29.61 
 
0.71 ND 0.21 ND? (0.83) 
 
Exposure/Ingestion? In past 3 months 
S07 2 29.83 
 
2.23 0.26 0.34 5.04 
 
Ingestion in past 2 months 
S08 2.5 30.00 
 
0.23 ND <2.5 ng total ND? (0.81) 
 
Exposure/Ingestion? In past 2.5 months 
S09 3 29.78 
 
0.64 <2.5 ng total 0.09 ND 
 
Exposure in past 3 months 
S10 3 29.36 
 
0.19 ND ND ND 
 
Exposure in past 3 months 
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Table 5.03 Continued Concentrations of 9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN) and 11-nor-9-tetrahydrocannabinol-
9-carboxylic acid (THC-COOH) detected in each hair specimen and summary of the interpretation of the results. Text is coloured according to the 
interpretation, black text: no exposure/ingestion, red text: exposure, green text: ingestion, blue text: possible ingestion which could not be confirmed. 
Specimen 
No. 
Section 1 
Length 
(cm) 
Weight 
(mg) 
 
Concentration (ng/mg) Concentration (pg/mg) 
 Interpretation of results 
 
THC CBD CBN THC-COOH 
 
S11 3 30.31 
 
0.24 0.36 0.2 ND? (0.54) 
 
Exposure/Ingestion? In past 3 months 
S12 3 28.76 
 
ND ND ND ND 
 
No exposure/ingestion in past 3 months 
S13 2 30.64 
 
0.24 0.18 <2.5 ng total 1.7 
 
Ingestion in past 2 months 
S14 3 31.55 
 
ND 0.17 ND ND 
 
Exposure in past 3 months 
S15 3 29.84 
 
0.54 0.16 0.10 2.85 
 
Ingestion in past 3 months 
S16 3 29.87 
 
0.34 0.16 <2.5 ng total ND? (0.78) 
 
Exposure/Ingestion? In past 3 months 
S17 3 30.99 
 
2.12 0.38 0.23 2.8 
 
Ingestion in past 3 months 
S18 2.5 30.88 
 
0.94 0.32 <2.5 ng total 1.08 
 
Ingestion in past 2.5 months 
S19 3 29.09 
 
0.71 ND 0.13 ND 
 
Exposure in past 3 months 
S20 3 29.97 
 
ND 0.14 ND 2.19 
 
Ingestion in past 3 months 
S21 2.5 29.62 
 
<2.5 ng total ND ND 1.96 
 
Ingestion in past 2.5 months 
S22 3 29.44 
 
ND 0.22 ND ND 
 
Exposure in past 3 months 
S23 9 29.05 
 
0.31 0.85 0.1 1.13 
 
Ingestion in past 9 months 
S24 3 29.69 
 
0.41 0.11 0.15 2.46 
 
Ingestion in past 3 months 
S25 3 29.02 
 
0.37 0.78 0.1 1.8 
 
Ingestion in past 3 months 
S26 5 29.28 
 
1.45 0.09 0.19 ND 
 
Exposure in past 5 months 
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Figure 5.06a Extracted ion chromatograms for 9-tetrahydrocannabinol for (a) an extracted blank 
(b) an extracted standard containing 2.5 ng total THC and (c) cannabis positive hair specimen S04 
(29.34 mg) containing 0.15 ng/mg THC. 
(a)
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Figure 5.06b Extracted ion chromatograms for cannabidiol (CBD) for (a) an extracted blank (b) an 
extracted standard containing 2.5 ng total CBD (c) cannabis positive hair specimen S04 (29.34 mg) 
containing 0.54 ng/mg CBD. 
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Figure 5.06c Extracted ion chromatograms for cannabinol (CBN) for (a) an extracted blank (b) an 
extracted standard containing 2.5 ng total CBN (c) cannabis positive hair specimen S04 (29.34 mg) 
containing 0.09 ng/mg CBN. 
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Figure 5.06d Extracted ion chromatograms for 11-nor-9-tetrahydrocannabinol-9-carboxylic acid 
(THC-COOH) for (a) an extracted blank (b) an extracted standard containing 30 pg total THC-
COOH (c) cannabis positive hair specimen S04 (29.34 mg) containing 1.22 pg/mg THC-COOH. 
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5.5.3 Correlation of results with cannabis score assigned to each hair specimen 
Analysis of the hair specimens was blinded so that it was unknown which types of cannabis users or 
non-users each hair specimen was obtained from. Information regarding the cannabis consumption 
was provided after the analysis was complete. The questionnaire that provided the information is 
detailed in appendix V. 
 
5.5.3.1 Type of user 
From the information provided on the self-report questionnaire, each user described their cannabis 
use as one of the following : 
- I only ever tried cannabis once 
- I used to sometimes take cannabis but I never do now 
- I use cannabis less than once a month 
- I use cannabis monthly 
- I use cannabis weekly 
- I use cannabis daily 
 
All users returned a result of being either a weekly or daily cannabis user. There were 13 weekly 
users and 18 daily cannabis users. It was found that there was no difference in the distribution of 
concentrations observed for both types of users for THC, CBD and CBN, but there was a difference 
in the distribution of THC-COOH concentrations between daily and weekly users (p < 0.05). The 
box-plots for each group are shown in figure 5.07a (for THC-COOH and THC) and figure 5.07b 
(for CBD and CBN). 
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Figure 5.07a Boxplot diagrams representing the median and interquartile range of concentrations detected in weekly and daily cannabis users for (a) 
11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) (pg/mg) and (b) 9-tetrahydrocannabinol (THC) (ng/mg). There was a significant 
difference in the distribution of THC-COOH concentrations (p<0.05) detected between weekly and daily users, but no difference in the distribution of 
THC concentrations (p>0.05). 
 
(a) (b) (b)
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Figure 5.07b Boxplot diagrams representing the median and interquartile range of concentrations detected in weekly and daily cannabis users for (a) 
cannabidiol (CBD) and (b) cannabinol (CBN) (ng/mg). There was no significant difference (p>0.05) in the distribution of CBD and CBN 
concentrations detected between weekly and daily users. 
(a) (b)
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5.5.3.2 Cannabis consumption score  
A cannabis consumption score was calculated based on self report information given by each user. 
The users answered multiple choice questions on their frequency of use of cannabis during the 
previous three months, with separate answers for each month.  An average monthly score was 
assigned based on how many days per week they smoked cannabis. They were also asked on a day 
in each month how many “joints/spliffs” they smoked. The two values were multiplied to provide 
the number of “joints/spliffs” smoked per month. As the samples were analysed as 3 cm segments 
representing 3 months use, the three values for each month were added together to get the number 
of “joints/spliffs” smoked per 3 months. For 2 cases where only 2 cm segments were analysed, the 
score was calculated on the previous 2 months answers only. There were 6 specimens that cannabis 
consumption scores could not be compared to the concentrations detected, because segment lengths 
greater than 3 cm were analysed (if it was not possible to segment or if the specimens were 
misaligned). 
The data was examined to determine if there was any correlation between the number of joints 
smoked and the concentrations of each cannabinoid and metabolite detected. It was expected that 
there would be an increase in concentrations as the number of joints per month increased.  
It was found that there was no correlation between the number of joints smoked per month and the 
THC, CBD, CBN and THC-COOH concentration when examined individually, however when the 
THC, CBD and CBN concentrations were combined there was some correlation ( = 0.395, p < 
0.05). If THC-COOH levels are also included, there is a weak positive correlation ( = 0.401, p < 
0.05). The scatter plot diagrams for each analyte compared to the number of joints smoked are 
shown in figure 5.08a (for THC and CBD) and 5.08b (for CBN and THC-COOH). The scatter plot 
diagrams for the cumulative concentrations compared to the number of joints smoked are shown in 
figure 5.08c. 
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Figure 5.08a Scatter plot diagrams showing no correlation between the number of joints smoked 
and the concentrations of (a) 9-tetrahydrocannabinol (THC)  (Spearman  = 0.067, p > 0.05) and 
(b) cannabidiol (CBD)  (Spearman  = 0.281, p >0.05) detected in authentic hair specimens.  
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Figure 5.08b Scatter plot diagrams showing no correlation between the number of joints smoked 
and the concentrations of (a) cannabinol (CBN) (Spearman  = 0.416, p > 0.05) and (b) 11-nor-9-
tetrahydrocannabinol-9-carboxylic acid (THC-COOH) (Spearman  = 0.176, p > 0.05) detected in 
authentic hair specimens.  
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Figure 5.08c Scatter plot diagrams showing correlation between the number of joints smoked and 
the cumulative concentrations of (a) 9-tetrahydrocannabinol (THC), cannabidiol (CBD)  and 
cannabinol (CBN)  (Spearman  = 0.395, p < 0.05) and (b) THC, CBD, CBN and 11-nor-9-
tetrahydrocannabinol-9-carboxylic acid (THC-COOH)  (Spearman  = 0.401, p < 0.05) detected in 
authentic hair specimens.  
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5.6 Discussion of results 
5.6.1 Comparison of results to other studies 
The concentrations detected for each analyte (shown in table 5.02) were compared to the 
concentrations detected in previous studies. With the exception of three studies (42;46;51), the hair 
specimens analysed were from known cannabis users. The remaining three studies analysed hair 
specimens from post-mortem cases. The number of specimens analysed in each study varied widely 
and ranged from 6 to 250 specimens. One additional study analysed 89775 specimens (49). This 
data has been described previously in chapter 1, tables 1.03 – 1.07. In the following sections 
(5.6.1.1 – 5.6.1.4), the concentrations detected in this study have been compared to those reported in 
the previous studies using diagrams illustrating the minimum, maximum and mean values reported 
for each study. There were two studies that have been excluded for comparison because in one, only 
the mean value was reported (49) and in the other, only the range was given but no mean values 
described (54). 
 
5.6.1.1 THC 
The concentrations detected in other studies varied widely. The minimum and maximum 
concentrations detected across all the studies ranged from 0.003 ng/mg and 60.41 ng/mg. There was 
a broad range of concentrations of THC detected in the different studies but the concentrations 
detected in this study were similar. The mean values reported in each study ranged from 0.04 to 
22.79 ng/mg and the mean value reported in this study was 0.65 ng/mg.  The lowest standard used 
in this study was 2.5 ng total which equated to 0.08 ng/mg based on a 30 mg hair specimen. This 
was chosen because the SOHT recommend a cut-off value of  0.1 ng/mg. In this study, there were 
four hair specimens that had possible THC peaks below 2.5 ng total, but for which qualitative 
identification could not be confirmed because the ratio of ions in the specimen did not match the ion 
ratios in the lowest standard. It is probable that the ion ratio alters at the lower concentrations. 
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Based on this and the concentrations reported in other studies a lowest standard of 1.25 ng total 
would be more appropriate.    
Of note are seven studies (38;40-42;52;53;57) that used an inappropriate derivatising reagent. Five 
of these studies had some of the highest maximum THC concentrations reported across all the 
studies (38;40-42;57). It is possible that THC levels reported in those studies were falsely elevated 
due to the conversion of CBD to THC during the derivatisation reaction as described previously in 
chapter 4. The remaining two studies (52;53) detected THC concentrations similar to the majority 
of other studies. A diagram illustrating the ranges observed for all studies is shown in figure 5.09.  
The study by Strano-Rossi and Chiarotti (54) is not shown because a mean value was not reported. 
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Figure 5.09 Diagram representing minimum, maximum and mean value for the concentrations of 9-tetrahydrocannabinol (THC) detected in each 
study. Mean values are represented by a green marker and noted by the corresponding data on the diagram. Studies are ordered in increasing mean 
THC concentration. Studies boxed in red used an inappropriate derivatising reagent in the study. The data for this study is boxed in blue.  
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5.6.1.2 CBD 
Only a few other studies have reported measured concentrations of CBD (35;36;43-46;54). These 
ranged from 0.01 to 15.26 ng/mg. The range and mean values for these studies and this study are 
shown in figure 5.10. The study by Strano-Rossi and Chiarotti (54) is not shown because a mean 
value was not reported. 
With the exception of the studies by Nadulski and Pragst (43) and Villamor et al. (36), generally the 
concentration of CBD was less than 1 ng/mg. The concentrations detected in this study were similar 
to these studies. The mean values reported across the range of studies ranged from 0.04 to 4.19 
ng/mg. The mean value reported in this study was 0.33 ng/mg. There is no recommended cut-off for 
CBD. However, as concentrations were less than 1 ng/mg, a lowest standard of 1.25 ng total would 
be more appropriate. 
 
 
Figure 5.10 Diagram representing minimum, maximum and mean value for the concentrations of 
cannabidiol (CBD) detected in each study. Mean values are represented by a green marker and 
noted by the corresponding data on the diagram. Studies are ordered in increasing mean CBD 
concentration. The data for this study is boxed in blue.  
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5.6.1.3 CBN 
There were few studies that described the range and mean CBN concentrations detected (35;36;43-
46). Across all the studies, concentrations ranged from 0.01 to 6.66 ng/mg. The range and mean 
values for CBN for each study compared to this one are shown in figure 5.11. The study by Strano-
Rossi and Chiarotti (54) is not shown because a mean value was not reported. 
There was a smaller range of concentrations detected for CBN than THC. Concentrations detected 
across all studies were less than 2 ng/mg with the exception of the study by Villamor et al. (36). 
The concentrations detected in this study were similar to the other studies. The means values across 
all studies ranged from 0.12 to 1.63 ng/mg. The mean value in this study was 0.16 ng/mg. There is 
no recommended cut-off for CBN. However, as concentrations were at the low end of the 
concentration range and in this study there were 9 specimens that had detectable CBN below 2.5 ng 
total, a lowest standard of 1.25 ng total would be more appropriate.  
 
Figure 5.11 Diagram representing minimum, maximum and mean value for the concentrations of 
cannabinol (CBN) detected in each study. Mean values are represented by a green marker and noted 
by the corresponding data on the diagram. Studies are ordered in increasing mean CBN 
concentration. The data for this study is boxed in blue.  
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5.6.1.4 THC-COOH 
There have been a greater number of studies that have focused on analysing for THC-COOH in hair 
(35-42;47-53;55;56). This is due to the detection of THC-COOH required for proof of ingestion. 
Amongst the studies that have been reported, there has been a wide range of concentrations 
reported. Concentrations detected across all the studies ranged from 0.03 pg/mg to 3870 pg/mg. The 
range and mean values for all the studies including this one are compared in figure 5.12. The study 
by Mieczkowski (49) is not shown because a range of concentrations was not reported. 
Although the range of concentrations detected was broad, when the studies that had significantly 
higher ranges were excluded, the mean values were across the range were similar. The mean values 
across all the studies ranged from 0.322 to 500 pg/mg. There were five studies which detected much 
higher concentrations and mean values than the other 12 studies (35;36;40;42;51). This was because 
the LOQ for these studies was much higher than the remaining studies and lower concentrations 
would not have been detected. When these studies were excluded, the means ranged from 0.322 to 
3.26 pg/mg. The mean concentration detected in this study was 2.3 pg/mg. The comparison shows 
that this study resulted in similar values to previous literature. There were also a significant number 
of results that were detected below the current limit of detection (1 pg/mg) for this study. It is 
necessary to improve on the LOD in order to detect less frequent users of cannabis. A limit of 
detection of 1 pg/mg is most likely only suitable for detecting heavy weekly users or daily users. 
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Figure 5.12 Diagram representing minimum, maximum and mean value for the concentrations of 
11-nor-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) detected in each study. Mean 
values are represented by a green marker and noted by the corresponding data on the diagram. 
Studies are ordered in increasing mean THC-COOH concentration. The data for this study is boxed 
in blue. The diagram in (a) represents all the studies, the diagram in (b) is exploded to highlight the 
studies with lower values. 
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5.6.1.5 Conclusions from comparison with other studies 
The current LOD/LOQ of 2.5 ng total (0.08 ng/mg based on 30 mg hair) for THC, CBD and CBN 
in this study was in line with the SOHT recommended cut-off value for THC (0.1 ng/mg). The 
current LOD/LOQ would remain acceptable for detection of weekly and daily cannabis use, but 
may not be suitable for less frequent users. If it was necessary to detect less frequent users of 
cannabis, observations made from comparing these results to other studies indicate that a lower 
limit of detection and quantitation of 1.25 ng total (0.04 ng/mg based on 30 mg hair) would be more 
acceptable. Indications from the results described are that this would be achievable based on the 
current sensitivity of the method. A good SN (>10) was observed on the 2.5 ng total standard for 
THC, CBD and CBN.  
The current LOD/LOQ for THC-COOH of 30 pg total (1 pg/mg based on 30 mg hair) was capable 
of detecting some weekly and daily cannabis users. However, not all reported weekly users had 
detectable THC-COOH. It would be necessary to improve on the LOD/LOQ in order to detect 
lower concentrations which may be associated with less frequent use. Improvement of the 
LOD/LOQ for THC-COOH would require further work to improve the cleanup of the background 
noise.  
 
5.6.2 Correlation of concentrations detected with self reported cannabis use 
This chapter has demonstrated that the method developed in chapter 4 is suitable for the analysis of 
authentic hair specimens for the detection of THC, CBD, CBN and THC-COOH. The authentic hair 
specimens were from regular users of cannabis, who had described themselves either as daily or 
weekly cannabis users.  
It was found that the method was suitable for detecting THC, CBD, CBN in both types of users as 
there was no difference in the concentrations of THC, CBD and CBN detected for weekly and daily 
users. Analysis of THC-COOH was suitable for detecting mainly daily users. There was a 
significant difference in the concentration of THC-COOH detected between weekly and daily users, 
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but this was due to THC-COOH being undetectable in 11 out of 13 weekly users. This shows that 
the current method is suitable for detecting ingestion for daily users, but may not prove ingestion 
for less frequent users.  
The cannabis users had also provided an estimate of the number of joints that they had smoked in 
the three months prior to the hair specimen being taken which was translated into a cannabis 
consumption score (no. joints smoked). There was no correlation between the concentrations of the 
individual analytes detected and number of joints smoked, but a small correlation when the 
concentrations of the analytes were added together. It has previously been reported that the 
cumulative concentrations of THC, CBD and CBN are more closely related to usage than the THC 
concentration alone (44). Better correlation may be observed with the cumulative concentration of 
THC, CBD and CBN because of the pyrolytic breakdown of THC to CBN and the possible 
cyclization of CBD to THC during smoking (54;141).  
Only 31 specimens were analysed in this study. It is possible that better correlation may be 
observed with a greater sample size but it must also be noted that self-reporting can be wholly un-
reliable, either because the user may not want to report their usage truthfully, because they may 
have a tendency to underestimate their use, and/or because it may be extremely difficult for the user 
to accurately recall on how many days per week they smoked cannabis and how many joints they 
smoked. There is also a great degree in variation of the strength and type of cannabis that is used 
and the manner in which it is ingested.   
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5.7 Conclusion 
The method described here is suitable for detecting exposure (by detection of THC, CBD and CBN) 
in weekly users but may only prove ingestion in daily users (by detection of THC-COOH). If it is 
necessary to prove ingestion in less frequent users, improvements on the LOD/LOQ for THC-
COOH are required.  
The initial aim of the project was to analyse paired blood and hair samples from victims of fatal 
road traffic collisions. This was with the aim of establishing if the deceased was a regular or in-
frequent user of cannabis. This may help in interpreting the concentrations of cannabinoids detected 
in the post-mortem blood. Knowing the chronic history of the deceased would help establish the 
likelihood of the presence of residual THC at low concentrations in the post-mortem blood of 
frequent users and would aid interpretation of the degree of post-mortem redistribution that may 
occur after death. If it could be established that the deceased was a heavy user of cannabis, then 
more caution could be given to interpretation of the blood results.     
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CHAPTER 6: GENERAL DISCUSSION 
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6.1 Development of methods 
The work presented in this thesis has described the development of two methods for the analysis of 
cannabinoids.  
Firstly, a method for the analysis of cannabinoids in post-mortem blood using LLE and 2D GC-MS 
was developed and validated. The method was suitable for analysis of the majority of post-mortem 
blood samples. There were four blood samples out of 217 that were unsuitable for analysis due to 
poor sample quality (e.g. in decomposed samples), however this is a problem that can be 
encountered in all types of analyses used for post-mortem blood and cannot be eliminated 
completely.  
Secondly, a method for the analysis of cannabinoids in hair using LLE, SPE, 2D GC-MS and 
standard GC-MS was developed. It was used to analyse hair from known cannabis users and was 
shown to be suitable for the detection of daily cannabis use. Further work is required to improve the 
assay if it is required to detect less frequent use. 
The experience gained from the development of the methods described in this thesis has also led to 
further use of 2D GC-MS within the laboratory. It has become vital in the development of assays 
that require increased sensitivity over the use of standard GC-MS. For example, 2D GC-MS 
methods have been developed for the analysis of fentanyl and buprenorphine in post-mortem blood. 
Analysis for therapeutic blood concentrations of these two drugs is not possible without the 
enhanced sensitivity achieved by the use of 2D GC-MS. 
 
6.2 Application to routine analysis in the laboratory 
6.2.1 Post-mortem blood samples 
The analysis of post-mortem blood samples for cannabinoids is now in routine use in the laboratory. 
The analysis has also been adapted into a screening protocol to decrease the length of time of 
analysis which has allowed more efficient throughput within the laboratory.  
224 
 
If analysis for cannabinoids is requested for a case and urine is received, a specific screen for drugs 
of abuse is carried out which includes analysis for THC-COOH. In this study urine was available 
for analysis in 34 of the cannabinoid positive cases. Thirty of these were positive for THC-COOH 
and one urine sample was unsuitable for the detection of THC-COOH. The three remaining cases 
that were not positive for THC-COOH in the urine had only very low concentrations of THC-
COOH in the blood (below 4.0 ng/mL) and contained no other detectable cannabinoids. This shows 
that analysis of the urine is a suitable screening tool to indicate whether it is necessary to carry out 
blood analysis. All cases positive for THC-COOH in the urine were positive for at least one 
cannabinoid in the blood.  
For the purposes of analysis for HM Coroners, if THC-COOH is detected in the urine, analysis of 
the blood for cannabinoids will be carried out if deemed necessary by the case history (e.g. a fatal 
RTC case will require blood analysis, but a heroin related death may not). If THC-COOH is not 
detected in the urine, for the majority of HM Coroners’ cases, it would be acceptable to simply 
report “no THC-COOH detected in the urine”. If no urine is submitted for a case and analysis for 
cannabinoids is requested or indicated by the case history, blood cannabinoid analysis will always 
be conducted. 
The fully developed method described in chapter 2 has been adapted into a blood screen for 
cannabinoids. It has been modified to allow for fast throughput of samples within the laboratory. 
The screening method uses the described method with three modifications. 
1. Four calibrators (0.25 ng/mL, 2.5 ng/mL, 5 ng/mL and 10 ng/mL) plus a zero and a blank 
standard rather than a full set of calibrators are used. This allows an estimate of the 
concentrations of cannabinoids present to be detected. 
2. The blood samples are not run in duplicate because an accurate concentration is not required 
for a screen result. 
3. The LLE has been adapted to only extract in hexane:ethyl acetate once (rather than twice as 
described in chapter 2) as maximum recovery is not required for a screen.  
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Any samples that screen positive for cannabinoids are treated in one of two ways.  
1. If it is thought that cannabis may have played a part in the cause of death (e.g in an RTC), 
further analysis will be conducted to accurately quantify the cannabinoids present using the 
complete validated method described in chapter 2. This will allow for interpretation of the 
concentrations detected to be provided on the final toxicology report. 
2. If cannabis is present but is unlikely to be significantly implicated in the death (e.g. in heroin 
related deaths), the presence of cannabinoids will be reported as positive (consistent with 
recreational use) on the final toxicology report. A similar approach is adopted within the 
laboratory for reporting cocaine and amphetamines. 
 
6.2.2 Analysis of hair specimens 
At the start of this project, the routine analysis of hair conducted in the laboratory did not include 
analysis for cannabinoids. Unfortunately, over the duration of this study, there has been a 
significant decline in the number of hair samples from routine HM Coroners’ cases received by this 
laboratory for analysis (107 cases were submitted in 2007 and only 34 in 2012). This is due to 
changes in presiding HM Coroners within the different jurisdictions, their preference not to conduct 
hair analysis and due to local authorities who fund the Coroners service having to significantly cut 
their costs. As a result of this, it was not possible to analyse paired blood and hair samples from 
fatal RTC victims. Despite this, a method is now in place that can be used for the detection of daily 
users of cannabis.  
 
6.3 Contribution to knowledge for hair analysis of cannabinoids 
This work has highlighted a significant problem with derivatisation of THC and CBD with TFAA-
HFIP.  This is a common derivatising mix used when detection by GC-MS in NCI mode has been 
used for the analysis of THC-COOH. This combination as well as other perfluorinated anhydrides 
alone or coupled with perfluoroalchohols have also been used for the analysis of other cannabinoids 
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including THC (22;32;35;38;40-42;52;53;56;57;100;105-108;115). This work has shown that 
derivatisation with TFAA-HFIP is unsuitable for analysis of THC and CBD, as it results in identical 
retention time and mass spectra for THC and CBD. This has previously been reported with another 
derivatisation combination, PFPA-PFPOH (35;106) but not with TFAA-HFIP. This calls into 
question publications that have reported on the analysis of THC using perfluorinated anhydrides 
coupled with perfluoroalcohols when the presence of CBD in specimens has not been taken into 
account (22;32;38;40-42;52;53;57;106;108). If these derivatising reagents are used, the presence of 
CBD in a specimen will lead to falsely elevated concentrations of THC. This is of particular 
importance for analysis of hair, because perfluorinated anhydrides coupled with perfluoroalcohols 
are often employed as the derivatising reagents in order to achieve the required sensitivity for the 
concentrations of THC-COOH present in hair. 
The method developed by the work described in this thesis is capable of analysing for THC, CBD, 
CBN and THC-COOH from a single hair specimen. To date there have only been two methods 
published that have analysed for all four compounds together (35;36). The method by Villamor et 
al. used LLE followed by analysis with GC-MS; however the LOD for THC-COOH was 
approximately 25 times higher than this study, and the LOQ approximately 85 times higher (36). 
The method by Baptista et al. involved analysing underivatised hair specimens on two GC-MS 
systems and then subsequently derivatising and analysing them again on two GC-MS systems. The 
LOD for THC-COOH was approximately eight times higher than this study (35). This study had 
better LOD and LOQ for THC-COOH than either of these methods.  
 
6.4 Contribution to knowledge for analysis of post-mortem blood 
specimens 
The method developed for analysis of blood is the first to combine LLE and 2D GC-MS for THC, 
CBD, CBN, 11-OH-THC and THC-COOH. During the development of this method, more papers 
have been published documenting the analysis of various combinations of cannabinoids by 2D GC-
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MS (96;97;110;119;120). However, this is the first method that has been validated specifically for 
and applied to post-mortem blood specimens. This analysis has established the range of 
concentrations of cannabinoids observed in routine HM Coroners’ cases and in fatal RTCs.  
It has also been possible to distinguish particularly high concentrations of THC that may indicate 
possible impairment in the RTC group. 
Initially, it was anticipated that it would be possible to analyse paired post-mortem blood and hair 
samples from fatal RTCs. This would have allowed more detailed interpretation of the blood 
concentrations if it could be established whether the deceased was a regular user of cannabis or not. 
Unfortunately, this was not possible due to the difficulties described in section 6.2.2.  
 
6.5 Wider consequences of this work 
This work demonstrates it is possible to cautiously interpret cannabinoid concentrations in post-
mortem cases where the use of cannabis may be implicated in the cause of death. Specifically, it has 
provided a baseline level of THC concentrations that are routinely observed in post-mortem blood 
samples from cases where the cause of death is unlikely to be linked to cannabis use. Prior to the 
start of this study, it was not possible to provide interpretation on the concentration of cannabinoids 
in post-mortem blood, as there had been no publications detailing the baseline levels of 
cannabinoids normally observed in post-mortem specimens. From this work, there is evidence that 
THC concentrations in post-mortem blood are usually lower than 5 ng/mL. Much higher 
concentrations (up to 69.5 ng/mL) were detected in individuals in the fatal RTC group. This work 
has attempted to classify THC concentrations into four categories in order to provide some 
interpretation when cannabinoids are present in post-mortem blood. The four categories cover the 
degrees of interpretation that are required for HM Coroners’ cases where impairment from cannabis 
use may be important (e.g. in fatal RTCs). This is important for fatal RTC cases or deaths where 
impairment due to cannabis use may be suspected. Category 1 included cases where THC was not 
detected indicating that the deceased was not under the influence at the time of death. Category 2 
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included cases where THC concentrations are lower than 3.5 ng/mL, indicating that impairment was 
unlikely. Category 3 included cases where concentrations of THC are between 3.5 and 5.5 ng/mL, 
which may indicate low level impairment for non-frequent users of cannabis. Based on this study, 
concentrations up to 5 ng/mL are observed in routine post-mortem cases, where the finding of 
cannabis is incidental. In addition, given the possibility of post-mortem redistribution, these cases 
must be interpreted with caution, and in most cases it would be unlikely that impairment could be 
concluded for category 3. Category 4 included cases where the THC concentration was greater than 
5.5 ng/mL. For these cases, impairment should be considered as a possibility. For example, for a 
case involving the death of a driver in a single vehicle crash with a THC concentration detected 
greater than above the range normally associated with post-mortem blood specimens (greater than 5 
ng/mL), it may be possible to make the following statement:- 
  
“The concentration of THC detected was greater than those normally associated with post-mortem 
blood concentrations. This may indicate that the deceased was under the effects of cannabis at the 
time of death.” 
 
Of course, this is only applicable when put into context with all the available facts relating to a 
death. The final decision on the involvement of cannabis in a fatal RTC would be made by HM 
Coroner in view of all other evidence relating to the death. In terms of the toxicologist’s role, it is 
possible to provide the above statement based on the evidence that post-mortem blood 
concentrations in deaths unrelated to cannabis are generally lower than 5 ng/mL. 
The conclusion that post-mortem blood concentrations are generally lower than 5 ng/mL also 
correlates with a very recent government report published in February 2013, that attempts to 
establish specified limits for driving under the influence of drugs (61). Although this represents 
concentrations detected in impaired drivers rather than fatally injured drivers, it concluded that a 
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cut-off concentration of 5 ng/mL was appropriate. This means that any driver with a concentration 
of THC greater than 5 ng/mL may be deemed to be driving under the influence of cannabis.  
The relevance of measuring the concentrations of other cannabinoids is still unclear. It has been 
proposed that the presence of CBD and CBN indicates recent ingestion (24) and this study has 
shown that these compounds were present when the THC concentration was in the higher range, 
although the data is limited because they were only detected in six control cases and five RTC 
cases. The metabolite 11-OH-THC also possesses pharmacological activity, so the presence of this 
in high concentrations in addition to a high THC concentration would increase the likelihood of 
impairment at the time of death. However there are no reports in the literature that correlate 
concentrations of 11-OH-THC with impairment. The concentrations of THC and THC-COOH have 
been used previously to estimate the time of last use of cannabis in ante-mortem specimens. This 
study did not show a significant difference in the estimated times between the control group and 
RTC groups with either model.  It has previously been suggested that the models are not suitable for 
post-mortem specimens (33) and the current study supports this conclusion. 
 
6.6 Summary 
To summarise, this work involved the development of two methods for the analysis of 
cannabinoids:- one in blood and the other in hair.  
The method for analysis of cannabinoids in hair has been used to analyse authentic hair specimens 
from regular cannabis users. It showed that it is possible to detect daily cannabis users with the 
developed method, but further work would be required for detection of less frequent use.  
The method for analysis of post-mortem blood has been used to analyse post-mortem blood 
specimens from routine cases and fatal RTC cases from HM Coroners. The analysis of post-mortem 
blood specimens has shown that fatal RTCs are associated with higher concentrations of 
cannabinoids compared to other routine HM Coroners’ cases. This shows there is merit in analysing 
for cannabinoids in post-mortem blood and that it is feasible to indicate the possibility of 
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impairment due to cannabis use in fatal RTCs when the concentration of THC detected is higher 
than those usually observed in post-mortem blood samples. This work thus makes a novel and 
relevant contribution to the field of post-mortem toxicology.  
In the wider context, the fact that cannabis was the most prevalent compound detected (including 
alcohol) and as the presence of other drugs (both legal and illicit drugs) was uncommon in fatal 
RTCs suggests that cannabis poses a significant problem with impaired driving in the UK. Given 
the proposed changes to legislation with regards to drug driving, this report is timely. Further 
research and publication of recent toxicology findings for the rest of the UK are required to 
understand the true incidence of drugs and alcohol in fatal RTC’s in the UK. 
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Appendix I: Suppliers 
 
All drugs and internal standards were purchased from LGC Standards, Teddington, UK. 
 
All solvents, chemicals and derivatising reagents were purchased from Sigma-Aldrich (Poole, UK), 
VWR (Lutterworth, UK) and Fisher Scientific (Loughborough, UK). 
 
Bond Elut Certify II solid phase cartridges were purchased from Agilent Technologies 
(Stockport,UK) previously Varian Inc. (Oxford, UK). 
 
The standard GC-MS and 2D GC-MS equipment used were purchased from Agilent Technologies 
(Stockport, UK). 
 
The Restek RTX-5MS analytical column was purchased from Thames Restek (Saunderton, UK). 
The HP-5MS and DB-17 analytical columns were purchased from Agilent Technologies (Stockport, 
UK). 
 
Ammonia 99.98% (for NCI GC-MS analysis) was purchased from Argo International (Basildon, 
UK). 
 
The Jun-Air compressor used to operate the cryotrap was purchased from VWR (Lutterworth, UK). 
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Appendix II: Compounds tested for selectivity 
 
 
3,4-methylenedioxyamphetamine (MDA)     Haloperidol 
3,4-methylenedioxyethylamphetamine (MDE)   Ibuprofen   
3,4-methylenedioxymethamphetamine (MDMA)   Imipramine 
6-acetylcodeine         Ketamine   
6-monoacetylmorphine       Lamotrigine 
Amitriptyline         Mephedrone 
Benzylpiperizine         Methadone 
Carbamazepine         Methamphetamine 
Chlordiazepoxide         Metoclopramide 
Chlormethiazole         Mirtazapine 
Chlorpheniramine         Morphine   
Chlorpromazine         Olanzapine 
Citalopram         Orphenadrine 
Clozapine         Oxycodone 
Cocaethylene         Papaverine 
Cocaine           Paracetamol 
Codeine           Paroxetine 
Cyclizine           Pethidine   
Desipramine         Phenytoin   
Desmethyldiazepam         Procyclidine 
Dextromethorphan         Promethazine 
Diazepam         Propoxyphene 
Diclofenac         Quetiapine 
Dihydrocodeine         Sertraline   
Diltiazem           Thioridazine 
Diphenhydramine         Tramadol   
Dipipanone         Trazodone 
Dothiepin           Venlafaxine 
Fentanyl           Zaleplon   
Fluoxetine         Zopiclone 
Gamma-hydroxybutyrate (GHB)         
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Appendix III: Summary of methods of analyses for HM 
Coroners’ cases 
 
            All analyses were dependent on the types of samples submitted. Alcohol (ethanol) was measured by 
dual column headspace gas chromatography with flame ionisation detection (HS-GC-FID) in post-
mortem blood (ante-mortem blood/serum if available), urine and/or vitreous humor. Other volatiles 
including acetone and methanol would also be detected during this analysis. A general screen of 
blood was conducted for chemically basic drugs (including unknowns) by gas chromatography-
mass spectrometry (GC-MS). Drugs which are commonly encountered in HM Coroners’ cases were 
semi-quantitated (i.e reported as low therapeutic, therapeutic or high therapeutic (146).  Drugs 
which required more accurate quantification were measured by GC-MS or high performance liquid 
chromatography with diode array detection (HPLC-DAD). The drugs screened for included 
common prescription medications, over the counter medications and illicit drugs. Illict drugs 
detected in the general screen include cocaine, amphetamine, methamphetamine, 
methylenedioxymethamphetamine (MDMA), methylenedioxyamphetamine (MDA), 
benzylpiperazine (BZP), mephedrone, para-methoxymethamphetamine (PMMA) and para-
methoxyamphetamine (PMA), methadone, street heroin markers and benzodiazepines. Morphine 
was screened for in blood by immunoassay and any positives confirmed and quantitated by GC-MS. 
This included the detection of 6-monoacetylmorphine (6-MAM).  A screen for drugs of abuse in 
urine by GC-MS was carried out if urine was available and requested or indicated by the case 
history. This screened for the common classes of illicit drugs including opiates, street heroin 
markers, methadone and its metabolites, cocaine and its metabolites, amphetamines, THC-COOH 
and benzodiazepines. This screen also detected some common prescription and over the counter 
medications (134). 
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Appendix IV: Models for the prediction of time of last 
ingestion of cannabis 
 
Calculations in section 3.8 were carried out based on the formulae described in the article 
 “Blood Cannabinoids. II. Models for the Prediciton of Time of Marijuana Exposure from 
Plasma Concentrations of 9-tetrahydrocannabinol (THC) and 11-nor-9-tetrahydrocannabinol-
9-carboxylic acid (THC-COOH)” by Huestis et al. (26).  
The calculations are based on plasma concentrations of THC and THC-COOH. As the blood:plasma 
ratio is approximately 0.5, in order to use the whole blood concentrations reported in this thesis, 
concentrations were multiplied by two to estimate the plasma concentration prior to being inserted 
into the formulae as described by Huestis et al. (18). 
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Appendix V: Calculation of cannabis consumption 
 
The following pages detail (a) the questionnaire that was given to cannabis users to describe their 
cannabis use, (b) the answers given to each question listed by specimen number and (c) the 
information regarding how cannabis consumption was calculated from the cannabis user’s answers. 
This information was provided by Professor Matthew Hickman and Rosie Lees from Bristol 
University. 

(a) Cannabis use questionnaire 
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(b) Answers given to each question listed by specimen number (S01 – S26 and CA1 – CA5) 
 
1 2 3a 3b 4a 4b 5a 5b 6 7 8 9 10 11 12 13a 13b 14 15 16a 16b 16c 16d 16e 16f 
S01 Y 6 6 2.5 6 3.0 6 3 32 5 1 1 3 1 2.5 2 2 1 2 3 3 1 1 1 1 
S02 Y 6 5 5.5 5 5.5 6 6 14 5 1 1 6 2 0 2 3 1 1 1 5 3 1 3 1 
S03 Y 6 6 1.5 6 1.5 6 2 17 5 1 1 2 1 1.5 2 3 4 3 2 4 2 1 3 1 
S04 Y 6 6 5.0 6 5.0 6 5 30 5 1 1 5 1 1 2 2 1 3 2 3 3 1 1 1 
S05 Y 6 6 1.0 6 1.0 6 1 14 5 1 1 1 2 0 2 3 1 2 2 5 3 1 1 1 
S06 Y 6 6 4.0 6 4.0 6 4 18 5 1 1 4 2 0 1 
 
1 2 4 4 2 1 1 1 
S07 Y 6 6 4.0 6 4.0 6 4 13 5 1 1 4 1 3 1 
 
2 6 5 5 3 3 3 2 
S08 Y 6 4 3.0 5 4.0 5 4 14 5 1 1 3 2 0 2 3 1 5 3 5 4 5 3 2 
S09 Y 5 2 2.0 2 2.0 2 2 11 5 1 1 2 1 3 1 
 
2 6 4 5 3 2 2 2 
S10 Y 5 2 
 
2 
 
2 
 
15 5 1 1 1 1 2 1 
 
2 3 3 2 1 1 2 1 
S11 Y 6 6 4.5 6 4.5 6 5 17 5 1 1 5 1 3.5 2 2 1 3 2 3 1 1 1 1 
S12 Y 6 6 4.5 6 4.5 6 5 15 5 1 1 5 2 0 2 5 4 3 3 5 3 1 2 1 
S13 Y 6 6 4.0 6 4.0 6 4 18 5 1 1 4 2 0 2 3 
 
3 4 4 3 3 5 1 
S14 Y 5 3 2.0 3 2.0 3 2 16 5 1 1 2 1 1.5 3 2 4 1 1 4 3 1 1 1 
S15 Y 6 6 2.0 6 2.0 6 2 15 5 1 1 2 1 2 2 3 
 
2 2 3 2 3 1 1 
S16 Y 5 4 2.0 4 2.0 4 2 15 5 1 1 2 2 0 3 1 3 3 2 4 4 2 1 1 
S17 Y 6 6 8.0 6 6.0 4 4 13 5 1 1 8 1 2 1 
 
4 6 3 3 1 3 1 2 
S18 Y 6 4 3.0 5 4.0 5 4 14 5 1 1 4 1 2 2 4 1 1 2 4 3 3 1 1 
S19 Y 5 4 5.0 3 5.0 3 5 14 5 1 1 4 1 6 3 1 4 3 3 2 3 1 1 1 
S20 Y 6 5 
 
6 
 
6 
 
16 5 1 3 0 2 0 3 2 1 1 3 4 
 
1 1 1 
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1 2 3a 3b 4a 4b 5a 5b 6 7 8 9 10 11 12 13a 13b 14 15 16a 16b 16c 16d 16e 16f 
S20 Y 6 5 
 
6 
 
6 
 
16 5 1 3 0 2 0 3 2 1 1 3 4 
 
1 1 1 
S21 Y 6 6 10.0 6 10.0 6 10 14 5 1 1 10 2 0 2 1 2 3 5 5 5 4 3 4 
S22 Y 6 6 1.0 6 1.0 6 1 17 5 1 1 1 2 0 4 1 1 1 2 5 5 1 1 1 
S23 Y 6 6 1.0 6 1.0 6 1 13 5 1 1 2 1 1 3 2 1 1 3 4 2 1 2 1 
S24 Y 5 3 6.0 3 6.0 3 6 40 6 1 1 6 1 2 2 3 2 1 3 3 4 5 1 1 
S25 Y 5 4 2.0 4 2.0 4 2 17 5 1 1 2 1 1 3 1 1 2 3 2 2 1 1 1 
S26 Y 5 4 3.0 4 3.0 3 4 14 5 1 1 3 1 1 3 2 3 4 2 3 4 2 1 1 
CA1 Y 5 4 2.0 3 2.0 5 4 13 5 1 1 2 1 3 3 3 2 4 2 2 2 2 1 2 
CA2 Y 5 3 1.0 3 1.0 4 2 18 5 1 1 1 1 2 3 1.5 4 1 1 4 3 3 1 1 
CA3 Y 5 3 2.0 2 2.5 3 3 17 5 2 1 2 1 1.5 2 4 2 3 2 2 3 1 1 1 
CA4 Y 5 3 2.5 1 0.0 4 4 15 5 1 1 2 1 2.5 3 1.5 3 3 3 4 1 2 1 2 
CA5 Y 5 4 4.0 5 4.0 5 4 15 5 2 1 5 1 3.5 2 2 4 3 3 3 2 2 1 1 






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(c) How cannabis consumption was worked out from cannabis user’s scores 
 
Analysis to work out a cannabis consumption score 
To work out a cannabis consumption score we used question 3a/4a/5a coupled with 3b/4b/5b.  
 
3a/4a/5a:  
Less than once a week    Score 1  0x week- 0x month 
  
About once a week    Score 2  1x week- 4x month 
  
Between one and three times a week  Score 3  2x week- 8x month 
 
Between three and six times a week  Score 4  4.5x week- 18x month 
  
I use cannabis daily or almost daily  Score 5  6.5x week- 26x month 
 
I usually use or take cannabis every day Score 6  7x week- 28x month 
 
Worked out an average monthly score for how many days an individual smoked cannabis. 
 
3b/4b/5b: 
On a day when in the LAST MONTH when you smoked approximately how many joints/spliffs do you have:  
Here a number is entered. If a range was entered, for example; 2-4, then the average was used, ie- 3 times.  
 
Calculation 
Per month value from part a x number from part b = number of cannabis joints/spliffs per month. 
 
Can then be correlated/compared with actual cannabis detected in hair.  

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Appendix VI: Publications and Presentations 
 
Publications 
1. Andrews R, Paterson S. Production of Identical Retention Times and Mass Spectra for 
Delta(9)-Tetrahydrocannabinol and Cannabidiol Following Derivatization with 
Trifluoracetic Anhydride with 1,1,1,3,3,3-Hexafluoroisopropanol. J Anal Toxicol 
2012;36(1):61-5. 
 
2.   Andrews R, Paterson S. A validated method for the analysis of cannabinoids in post-mortem 
blood using liquid-liquid extraction and two-dimensional gas chromatography-mass 
spectrometry. Forensic Sci Int 2012 Oct 10;222(2012):111-7. 
 
Oral Presentation 
1. The application of 2D GC-MS for the analysis of cannabinoids in forensic toxicology. 
Presented at London Biological Mass Spectrometry Discussion Group (LBMSDG), 30th 
September 2010. Awarded “Most Valued Student Talk, 2010” by LBMSDG. 
 
Poster Presentations 
1. Production of Identical Retention Times and Mass Spectra for Delta(9)-
Tetrahydrocannabinol (THC) and Cannabidiol (CBD) Following Derivatization with 
Trifluoracetic Anhydride (TFAA). Presented at  
a. United Kingdom and Ireland Association of Forensic Toxicologists (UKIAFT) 2nd 
AGM, Glasgow, September 2010. 
b. The London Toxicology Group (LTG),  London, December 2010. 
c. The  Joint 41st/49th Meeting of the Society of Forensic Toxicologists (SOFT) and 
The International Association of Forensic Toxicologists (TIAFT), San Francisco, 
September 2011. 
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